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Abstract 
 
Meningiomas account for 20% of all brain tumours. They are usually benign and around 35% will 
develop epilepsy. Despite surgery or anti-epileptic drug (AED) use, intermittent seizures can remain. 
This may be significant as AED use and continued seizures can lead to reduced quality of life. 
The aim of this study was to evaluate the impact of epilepsy on the quality of life of patients with 
benign WHO grade 1 meningiomas. Quality of life questionnaires were posted to meningioma 
patients with and without epilepsy, and the scores were compared between the two groups. An 
epilepsy control group (without meningioma) was also included so that the role of meningioma 
could be evaluated. This is the first study to directly compare quality of life between meningioma 
patients and meningioma patients with epilepsy. 
The study hypothesis is that the QoL of meningioma patients with epilepsy will be more impaired 
than the scores of meningioma patients without epilepsy. It is additionally hypothesised that 
meningioma patients with epilepsy will have QoL scores that are more impaired than the scores of 
epilepsy patients without meningioma. In total 229 patients participated in this study: 109 had a 
meningioma, 56 had meningioma and epilepsy, and 64 had epilepsy without a meningioma. Each 
group was sent three questionnaires: the Short Form 36 (SF-36), the Functional Assessment of 
Cancer Therapy with brain subscales (FACT-BR) and the Liverpool Adverse Events Profile (AEP). The 
demographics and comorbidities of all patients were reviewed, as were the tumour and epilepsy 
characteristics. 
Quality of life scores were impaired in the meningioma with epilepsy group but only the FACT-BR 
detected a significant difference. Quality of life was more impaired in the epilepsy without 
meningioma group when compared to the meningioma with epilepsy group, but this difference was 
not significant in any of the questionnaires. In a multiple regression analysis of the meningioma and 
meningioma with epilepsy groups, unemployment, depression, the number of meningioma 
symptoms, and the use of AEDs were repeatedly shown to predict impaired quality of life scores. In a 
regression model containing epilepsy patients and meningioma patients with epilepsy, meningioma 
symptoms did not significantly predict impaired quality of life.  
It was concluded that epilepsy does have a negative impact on the quality of life of meningioma 
patients. However, as epilepsy severity in meningioma patients is mild, so is the impact on quality of 
life. The effect of the meningioma in epilepsy patients was not as strong as the effect of epilepsy in 
meningioma patients.   
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Chapter 1: Meningioma 
1.1. Introduction 
Meningiomas are a group of tumours that arise from the fibrous arachnoid meninges of the 
brain and spinal cord1,2. Due to their proximity to sensitive and crucial structures, it is 
fortunate that meningiomas are rare and in the great majority of cases benign2,3.  
Over the centuries meningiomas have attracted the attention of anatomists, pathologists 
and surgeons because of the varied symptoms and great mass they can present with4. The 
earliest known meningioma description is thought to be written by Felix Plater in 15364. His 
patient presented with a 3 year history of gradual mental and physical decline after 
sustaining a head injury4.  
Since this early description our understanding of meningioma has gradually evolved. This is 
especially evident within histopathology where advances have influenced numerous 
nomenclature and systems of classification. It was in 1922 that the term meningioma was 
coined by Harvey Cushing replacing previous and frequently changing names, such as 
Epithelial Cancer (1858) and Sarkome Der Dura Mater (1863)4,5. He decided that basing the 
tumours name on tissue, as opposed to histology or location, would be most appropriate 
and this idea has persisted since4. 
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1.2. Histopathology and Pathology  
Debate regarding the exact cellular origins of meningioma exists but it is widely accepted 
that meningiomas emerge from the cap cells of the arachnoidal granulations and villi due to 
histological and ultrastructural similarities*6,7,8. These cells have a heterogeneous 
ontogenesis, display mesenchymal and epithelial functions, and are morphologically diverse 
which is in keeping with the complexity and heterogeneity of meningioma 
histopathology7,9,10. There is no recent interest in ascertaining the true cellular origin of 
meningiomas. 
There are many histological subtypes of meningioma and some tumours contain many 
subtypes of cell6,11. There are fifteen subtypes in total and they are summarised in the 
World Health Organisation (WHO) grading system below (Table 2)6. The precise distinction 
between these subtypes serves little clinical importance as all but six types, which correlate 
to higher grades, display  similar clinical behaviours and are less likely to display aggressive 
characteristics or recur6,11,12.  
Meningiomas are closely related to the inner dural layer and their blood supply is usually 
incorporated from the dura11,13. If the dura is penetrated a characteristic reactive 
hyperostosis may be found in the adjacent inner table6,11. When the outer table is involved a 
palpable lump can be felt11.  
Some meningiomas grow en-plaque across the dural surface instead of spherically11. 
Tumour texture varies from firm and fibrous, to soft and gritty5.  Calcified deposits called 
psammoma bodies can often be found in the tumours6,11,14. 
Oedema can develop in the surrounding brain, the mechanism of which is unclear but 
venous obstruction, pial–meningeal anastomoses, capillary permeability and tumour 
secretion have been implicated11. The arachnoid mater appends to cerebral arteries and 
meningiomas in such locations can attach to or encase these vessels6,15.  
 
                                                     
*
Similarities between meningiomas and cap cells include: formation of whorls by cells, complex intertwining 
cell processes, intracellular junctions and intracellular intermediate filaments which stain positive for 
vimentin
5
. 
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1.3. Location  
The anatomical location of meningiomas has great bearing on symptoms and extent of 
resection16,17. It is useful to describe meningiomas in terms of location instead of precise 
histology18. Growth can occur anywhere arachnoidal cells are located which is usually the 
venous sinuses, possibly due to the concentration of cap cell clusters7,10. The usual sites for 
meningioma are listed in Table 116,19.  
Table 1: Distribution of Intracranial Meningiomas19 
Location Proportion (%) 
Parasagittal and falx 25 
Convexity 19 
Sphenoidal wing  17 
Suprasellar 9 
Olfactory groove 8 
Posterior fossa  8 
Ventricle 1-2 
Optic sheath 1-2 
Foramen magnum 1-2 
 
Meningiomas of the spine account for 10% of tumours and very rarely meningiomas are 
found outside the craniospinal axis6,10,12. The latter occurs when arachnoid tissue is trapped 
in ectopic locations during development, and these sites include: the frontal and occipital 
areas in the scalp, the ear and temporal bone, the sinuses, the mandible, the mediastinum, 
the lungs, the muscles, and the feet11,18. 
1.4. Grading 
A universal system to grade meningiomas was developed by the WHO in 200014. This 
superseded the 1993 criteria, which was heavily criticised for being vague and subjective14. 
It was the incorporation of histopathological findings from two Mayo Clinic studies that 
resulted in the creation of an accurate and reproducible meningioma grading 
framework14,17,20. Despite being retrospective, these studies are powerful on account of 
their large sample size, reasonable follow up period and most importantly, their transparent 
and objectified criteria for histological analysis. The 2000 criteria remained unchanged until 
2007 where some minor additions were made for the consideration of brain invasion (Table 
2)21.  
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Table 2: World Health Organisation (WHO) Meningioma Grading System 2007 
 
A strong, blinded and dual observer Scottish re-grading study retrospectively analysed 201 
meningioma resections from before 2001 according to the 2000 criteria, finding a 39% 
increase in the proportion of atypical tumours22. A more recent retrospective Norwegian re-
grading study found a similar 30% increase in the proportion of atypical tumours as a result 
of the 2000 criteria10.   
Additionally, one study has found a 13% increase when taking the 2007 criteria into 
account10. This study of 196 samples re-graded on account of the 2000 and 2007 criteria but 
lacked blinding and dual observer analysis. The latter point is important as despite its 
improvements, the 2007 WHO criteria still suffers from a degree of subjectivity and inter-
observer bias10,14,22.  
 
 
WHO 
grade 
Frequency Pathological features Histologies 
Recurrence 
Rate 
Grade I 80%–90% Pleomorphic; occasional 
mitotic figures; lacks 
criteria of anaplastic or 
atypical meningiomas. 
Meningothelial, 
psammomatous, 
secretory, 
fibroblastic, 
angiomatous, 
lymphoplasmacyte 
rich, transitional, 
microcystic, 
metaplastic 
7%–20% 
Grade II 
(Atypical) 
5%–15% 4 mitotic figures per 10 
high-power fields and 
three of the following: 
(a) increased 
cellularity, 
(b) small cells with 
high N:C ratio, 
(c) prominent nucleoli, 
(d) sheet-like growth, 
(e) necrosis or brain 
invasion 
Clear cell, chordoid, 
atypical. 
30%–40% 
Grade III 
(Anaplastic) 
1%–3% 20 mitotic figures per 10 
high-power fields or frank 
anaplastic features. 
Papillary, rhabdoid, 
anaplastic . 
50%–80% 
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1.5. Epidemiology 
Meningiomas account for at least 20% of all intracranial tumours and are the most common 
benign brain tumour10,23. After puberty, they are twice as common in females, and for both 
genders the incidence increases with age19,23,25. The incidence of meningioma has been 
quoted at 6 per 100,000 persons per year12. This does not take into account incidental 
meningiomas, which are a common autopsy finding and could be found in 2.3% of the 
population24.  
In their most recent statistical report of over 300,000 patients, the Central Brain Tumor 
Registry of the United States organisation (CBTRUS) concluded that meningiomas are the 
most frequently reported central nervous system (CNS) tumour with an annual incidence 
rate of 7.22 per 100,000 persons in the population25. CBTRUS obtains pathology, histology 
and demographic data from two national tumour registries: the Centers for Disease Control 
and Prevention National Program of Cancer Registries, and the National Cancer Institute 
Surveillance Epidemiology and End Results program (SEER)25.  The results from CBTRUS are 
not entirely representative of intracranial meningiomas. Firstly there is no distinction 
between meningiomas of the spine and the cranium and secondly, 49% of the meningiomas 
accounted for in the analysis were included on the basis of radiological confirmation.  
In the United Kingdom (UK), a study utilising the health improvement network (THIN) 
database found the incidence rate of meningioma to be 5.3 per 100,000 persons per year26. 
The THIN database prospectively collects electronic medical records from over 450 general 
practice surgeries across the UK27. One study has validated THIN for epidemiological 
research by finding comparable data on four common diseases in the validated General 
Practice Research Database27. The THIN meningioma study made no distinction between 
cerebral and spinal meningiomas.  
 The differences in incidence between CBTRUS and the THIN study could be explained by the 
methodical differences in sampling, but geographical and genetic differences could also be 
implicated, as suggested by the increased incidence of meningioma in black and Hispanic 
populations and the relatively large incidence rate of 13 per 100,000 persons per year in 
Italian populations6,25.  
Overall the results from CBTRUS are more accurate on account of the large population 
covered and the use of dedicated registries for brain cancer. Both studies were weakened in 
not distinguishing between spinal and cranial meningioma. In either case, meningiomas 
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would be considered rare by the European Commission for Public Health rare disease 
incidence threshold of 1 per 2000 individuals per year28. 
  
1.6. Aetiology and Risk Factors 
1.6.1. Genetics 
The most common genetic abnormalities found in meningioma are monosomy deletions of 
chromosome 22 which is thought to occur in 50-80% of sporadic tumours16,29. This mutation 
can produce most histological types of meningioma, with 70-80% of transitional, 
fibroblastic, atypical and anaplastic meningiomas carrying this mutation30. In meningothelial 
meningiomas this mutation is only responsible for 25% of cases30. Neurofibromatosis type 2 
(NF2), which can lead to multiple en-plaque meningiomas is associated with a deletion on 
chromosome 22 (q12.2)12,29. This gene codes for the merlin and schwannomin proteins12,29.  
There is a gene on chromosome 18 (p11.3) that codes for proteins homologous with merlin,  
the deletion of which has been implicated in familial meningiomas and meningioma 
progression12. Many other chromosomal alterations are implicated albeit to a lesser extent 
and these involve chromosomes 1, 6, 9, 10, 11, 13, 14, 18 and 1916.  
The importance of genetic susceptibility in patients with a meningioma is demonstrated by a 
large Swedish study, which observed a standardized incidence rate of 3 per 100,000 persons 
per year if a parent had meningioma and a rate of 4 per 100,000 persons per year if a sibling 
was affected31. A similar Israeli study suggests that inherited susceptibilities to ionizing 
radiation increases meningioma risk32.  
1.6.2. Radiation 
Ionizing radiation exposure is the strongest modifiable risk factor described for 
meningioma19. The link has been reported for many years and suggestive case reports have 
been published as early as 196933. This link is reinforced by the increased incidence of 
meningioma in the survivors of the Hiroshima and Nagasaki atomic bomb blasts, the 
incidence of which increases as the distance to the epicentre decreases19,34.  Other 
examples of radiation exposure leading to meningioma include radiation therapy for 
intracranial tumours and paediatric leukemia12,35,36.  
Larger studies have associated radiation therapy for tinea capitis of the scalp and dental 
radiographs with meningioma (both result in an approximated exposure of 1-2 Grays (Gy) to 
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the head)37,38. These interventions however, have not been in mainstream use since the 
1960s and the impact of new radiation sources, such as X-ray computed tomography (CT) 
scanners remains to be examined35,39. There is a paucity of recent large scale studies of 
radiation and its influence on meningioma35,39 but one study, the largest of its kind, has 
linked meningioma with leukaemia and thyroid cancer40.   
Radiation associated meningiomas can be multiple, have a long latency period of 17-36 
years, are associated with a higher grade and have a high recurrence 19,41. There is a dose 
response relationship with higher doses resulting in worse outcomes37.  
1.6.3. Hormones 
The increased incidence of meningioma in females (particularly before menopause), the 
presence of sex hormone receptors in some tumours, the change in size of meningioma 
during the luteal phase and pregnancy, the association with exogenous sex hormones and 
the in-vitro proliferation of meningioma cells after oestrogen exposure are collectively 
indicative of a significant hormonal influence in meningioma risk35,37,40.  
The majority of meningiomas have a type ii oestrogen receptor subtype, which has a 
relatively low affinity and specificity to oestrogen16,42. Oestrogen will bind to less than 30% 
of meningiomas16,43. Conversely, progesterone receptors are found in 50-100% of 
meningiomas16,43. Receptor status however does not seem to be influenced by gender43.  
The significance of receptor expression is not yet fully appreciated due to a variation of 
results from limited in-vitro studies, but due to its inverse correlation to mitotic index and 
grade, it is thought that progesterone plays a more essential role in the formation of benign 
meningiomas19,45. Absence of progesterone receptors is correlated to higher grades of 
meningioma, but poor specificity means that other histological parameters must be relied 
upon6.  
The clinical importance of reproductive hormones is harder to define. While case control 
studies show little evidence of increased risk due to hormonal replacement therapy, cohort 
studies find significant associations44,45. A recent case control study and review of the 
literature by Claus et al found that meningioma risk was associated with current exogenous 
hormone use, a finding that is supported by other concordant results in the literature45. 
With regards to endogenous hormone production, a significant association with 
meningioma risk has generally not been found40. It is interesting that current as opposed to 
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previous sex-hormone use is related to meningioma risk, implicating a promoting and not an 
initiating influence on meningiomas40. The study by Claus et al was powerful on account of 
its large sample size, transparent report and comprehensive literature search, but the case 
control study itself was limited by a higher socio-economic status in controls and the small 
number of patients who reported current contraceptive use.  
1.6.4. Natural History 
Advances in imaging technology have resulted in the increased identification of people with 
asymptomatic meningioma46,47. The majority of these tumours are slow growing and 
surgical intervention in this cohort is not necessary unless specifically warranted for a 
reason other than presence of tumour46,47. In the majority of cases, the growth rate of 
asymptomatic meningiomas is less than 1cm per year47. Tumour doubling time is another 
measure of growth and the average tumour doubling time is calculated to be 21.6 years47. 
Younger patients have shorter doubling times and higher growth rates47. 
1.6.5. Presentation 
Symptomatic meningiomas are usually brought to the attention of patients in the form of 
headaches and seizures6, but presentation will usually occur in three ways: 
1. Focal neurological signs: these depend on the meningioma location and occur due to 
local brain or cranial nerve compression12,16. Meningiomas can also mimic transient 
neurological deficits, such as TIA48.  
2. Epilepsy is a presenting feature in 27-67% of cases of which secondary generalised 
seizures are the most prevalent12. 
3.  Raised intracranial pressure; which can manifest with: headache, nausea, vomiting, 
papilloedema and reduced conscious level12. 
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1.7. Investigations 
When meningioma is suspected, radiological investigations are instrumental in establishing 
diagnosis and tumour location. Intracranial radiology for meningioma has been utilised for 
over 100 years but since then, imaging techniques have become increasingly sophisticated4.  
1.7.1. CT 
Plain CT scans will detect and display meningiomas as a slightly hyperdense (or less 
commonly isodense) mass relative to surrounding brain tissue12,13,16,49. Following the 
administration of intravenous iodinated contrast, meningiomas are homogenously 
enhancing and easily identifiable16,49.  CT is also useful for identifying hyperostosis and 
tumour calcification, the latter of which is visible in 50% of tumours16,49.  
1.7.2. MRI 
Magnetic resonance imaging (MRI) is the gold standard neuroimaging method for 
meningioma and is usually performed as the initial scan18. It is a versatile technique that has 
reduced in price, increased in availability and can clearly show features specific to 
meningiomas12,18. It should be noted that the characteristics of the scan can vary due to 
haemorrhage, cysts and calcification, but not by histology49. 
1.7.2.1. T1 
On T1 weighted images, meningiomas are usually isointense or slightly hypointense11,49. 
Following gadolinium contrast meningiomas will enhance intensely and homogenously and 
this technique is particularly useful for delineating en-plaque lesions and vital neurovascular 
structures, especially in skull base meningiomas11,12,18,41.  T1 weighted images can identify 
dural thickening due to the meningioma, known as the dural tail. The criteria adopted for 
identifying a true tail are as follows18,49: 
1. The tail should be seen in 2 consecutive 5-mm sections or 3 consecutive sections on 
thinner slices. 
2. There should be smooth tapering of the tail away from the tumour. 
3. Enhancement of the tail should be more than that of the tumour itself. 
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1.7.2.2. T2 
In T2 weighted images, 50% of meningiomas are hyperintense and the other half are 
isointense relative to grey matter18,49.  Such images are useful for identifying blood vessels 
and peritumoral oedema, the latter of which is more often associated with atypical and 
anaplastic meningiomas as opposed to typical lesions18,49.  MRI venography and angiography 
are helpful in identifying encasement and patency of dural sinuses and major arteries12,18.    
1.7.3. Future of imaging 
MRI lacks specificity for meningioma and the following conditions can mimic its appearance:  
sarcoidosis, lymphoma, plasmocytoma, bony metastases and particularly, dural based 
metastases5,12,49. There is scope for the use of advanced imaging techniques, such as 
diffusion weighted MRI, magnetic resonance spectroscopy (MRS), photon emission 
tomography (PET) and PET CT5,41. Of particular interest is the use of MRS which can detect 
levels of alanine, choline, phosphate and N-acetyl compounds and PET which measures 
levels of radio-labelled glucose metabolism5,13,41. The significance of an alanine peak 
(1.5mm) on MRS is unclear due to varied results in the literature. This variation may be due 
to insufficient MRI field strength, voxel size or tumour size50.  
1.7.4. Angiography 
Catheter angiography was the investigation of choice before CT and MRI12. It could 
distinguish between vertebral or carotid supply and meningiomas would appear as a 
characteristic blush12,16. Now it is indicated to clarify diagnosis in the presence of ambiguous 
CT/MRI findings, to determine blood supply and to prepare for pre-operative 
embolisation12.  
1.7.5. Confirmation of Diagnosis 
Histopathology diagnosis of meningioma is necessary to confirm meningioma type and most 
importantly grade. Current imaging techniques cannot reliably differentiate between 
tumour grades5. 
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1.8. Treatment 
Meningioma management is tailored to the individual patient and this is due to their 
heterogeneity12,19. The decision to proceed with observation, surgery or radiotherapy is 
influenced by retrospective data as currently there are no randomized controlled trials 
comparing such options51.  
For all patients, a course of steroids or anti-epileptic medications may be warranted in the 
presence of oedema and seizures respectively12. Steroids are useful pre and post-
operatively to aid surgery and promote recovery5,16.  The role of anti-epileptic drugs is less 
clear and this will be explained thoroughly in the next chapter.  
1.8.1. Observation  
For asymptomatic and benign meningiomas the management focus is directed at 
monitoring for symptom and or disease progression19. In certain cases, particularly those 
with minimal symptoms, the threshold for performing surgery is less obvious and decisions 
are made on balance of risk5. Important factors include: 
 Advanced patient age; meningiomas are slow growing and surgery might not be 
necessary in older patients18. The healthy aging population makes this harder to 
ascertain52.   
 Tumour location; skull base tumours are rarely completely resected and are 
associated with significant risk of neurovascular damage and mortality53.  
 Future tumour growth; small parasagittal tumours are easier to resect prior to 
sagittal sinus invasion5.  
 Patient choice; some patients decide against surgery5.  
 Imaging features; calcified lesions on CT and hypointense lesions on MRI are more 
likely to remain asymptomatic12.  
 Tumour size and patient health status are also taken into account19.  
Interestingly a recent analysis from the SEER database in the USA stated that survival is 
significantly improved for patients who undergo surgical resection of their meningioma54. 
Unfortunately the reasons for rejecting surgery were not available. This is significant as 
patients may have limited access to healthcare as a result of low socioeconomic status, or 
may have tumours with difficult surgical access, both of which could feasibly influence 
outcomes.  
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1.8.2. Surgery 
In the majority of symptomatic cases, surgical removal is warranted12. Surgical aims are 
largely dependent on tumour position, but five basic principles for all locations apply5,52: 
1. Optimal patient positioning, incision and exposure. 
2. Early tumour devascularisation. 
3. Internal decompression and extracapsular dissection. 
4. Early localization and preservation of adherent or adjacent neurovasculature. 
5. Removal of involved dura and bone. 
There is a catalogue of surgical techniques standardised for each tumour location and it is 
outside of the scope of this thesis to delve into each. The general aim of surgery is to 
remove the entire tumour12,52. The Simpson’s grade, published in 1957, provided an 
objective scale to the completeness of tumour removal in order to predict risk of tumour 
recurrence55. The significance of exctricating the dural attachment and bony infiltration, and 
the correlation of Simpson’s grade to prognosis, was highlighted in Simpson’s and 
subsequent studies5. 
1.8.3. Pre-operative Embolisation 
Meningiomas are vascular lesions which when resected can lead to significant and 
sometimes catastrophic intra-operative haemorrhage52. In some patients this can be 
prevented by delivering adhesives such as polyvinyl alcohol (PVA) and n-butyl cyanoacrylate 
(NBCA) to tumour feeding vessels via femorally inserted microcatheters52.  
The efficacy of pre-operative embolisation is debatable and many studies are limited by 
small sample size, lack of a comparison group, retrospective analysis and selection 
bias56,57,58,59. The strongest study on this topic prospectively compared the short term 
outcomes of a centre performing pre-operative embolisation to a centre which did not60. 
The authors concluded that completely de-vascularised tumours had a significant effect on 
operative blood loss60. Embolisation made no difference to transfusion requirements, 
duration of surgery, Simpson’s Grade and length of hospitalisation60.  
Embolisation is indicated in the minority of cases; usually when the tumour is large, 
hypervascular, basal, or supplied by vessels with difficult surgical access52. There is scope for 
a large prospective RCT (randomised controlled trial) to test these indications as to date 
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none currently exists and the decision to embolise must be balanced against costs and 
potential complications.  
Effective embolisation permanently obstructs vascular supply. This is also the mechanism 
for their complications, which can occur when normal structures share vascular supply with 
the tumour or when embosilate reflux occurs52. While these risks are reduced in procedures 
involving denominations of the external carotid artery (ECA), damage may occur in the 
presence of extracranial-intracranial anastomoses or patent foramen ovale52. Careful pre-
intervention planning is crucial to identify and manage these risks52.  
There is concern that embolization may influence tumour grading12. Perry et al assessed the 
grading and clinicopatholigical features of 64 embolised meningiomas concluding that 
morphological changes were rarely sufficient to result in over-grading61. Importantly, it was 
concluded that the meningiomas graded as atypical in Perry’s study behaved more 
aggressively, a factor ignored in the more recent studies of Matsuda et al62 and Jiménez-
Heffernan JA et al63.  
Embolisation has been attempted as the primary treatment for meningiomas unsuitable for 
surgery. The largest series is of 7 patients by Bendszus et al64 which resulted in 6 patients 
demonstrating tumour shrinkage and symptomatic relief.  
 
1.8.4. Post-Operative Management 
This involves the routine care of patients following a craniotomy, with particular attention 
to minimising cerebral oedema16. Steroid therapy is continued initially and gradually 
tapered. Care is taken to avoid excessive hydration and the patient is nursed with the head 
elevated to promote venous return16. Neurological deterioration may indicate post-
operative haemorrhage or cerebral oedema warranting a CT scan16.  
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1.8.5. Radiotherapy 
Radiotherapy is a diverse and evolving field which utilises sophisticated equipment and 
techniques to deliver ionizing radiation. Radiation damages cells through direct cytotoxic 
injury, DNA damage and vascular or stromal obliteration65. Radiotherapy plays an important 
part in the management of meningiomas.  
1.8.5.1. Conventional Radiation Therapy  
Conventional radiation is efficacious in treating meningioma, particularly after subtotal 
resection or tumour recurrence51. Several studies agree that 10-20 years of tumour control 
is achieved in 70-80% of patients51. These studies are small and retrospective, but 
collectively they cover many variables, such as meningioma grade, location and timing of 
radiotherapy51.  Since conventional radiation therapy targets the tumour and a margin of 
normal parenchyma, there is concern that damage to healthy tissue and radiation induced 
tumours may occur5. In practice the rates of these and other complications are low which 
could be due to insufficient follow up, or the minimisation of parenchymal damage through 
the use of computerised planning systems and fractionation51,66. Computerised planning 
systems use imaging data from CT or MRI scans to contour radiation to the outline of the 
tumour improving progression free survival67.  
Fractionation is reliant upon the α/β ratio of target tissues68. In this context, α and β are 
parameters that quantify the susceptibility of tissues to radiation damage whereby a high 
α/β ratio indicates greater sensitivity to lower but fractionated doses of radiation69,70. 
Tissues that exhibit high α/β ratios of around 10Gy include the skin, intestinal epithelium 
and malignant tumours70. Tumour sensitivity to fractionation as a concept is not fully 
understood, but several theories exist68:  
1. Hypoxic cells are resistant to radiation related killing and tumours contain hypoxic cells. 
A single fraction of high dose radiation will fail to kill all cells, but multiple fractions will 
allow for re-oxygenation and further cell destruction during subsequent fractions. 
2. Cells are more resistant to radiation at certain points of the cell cycle and fractionation 
will allow for cells to pass into vulnerable stages in-between doses.  
3. Cycling cells, such as tumour cells, are more susceptible to radiation than non-cycling 
cells, such as normal cells, thus increasing the safety of fractionation.  
The α/β ratio for meningiomas is approximately 3.76Gy, only slightly greater than the 
surrounding neuroparenchyma which has a ratio of 2.5Gy68. For meningiomas 
15 
 
hypofractionated regimes are theoretically recommended as fractionation has no benefit 
when α/β ratios are equivalent, but in practice fully fractionated regimes are adopted68. 
1.8.5.2. IMRT 
Intensity-modulated radiation therapy (IMRT) boosts the efficacy of conventional 
radiotherapy and planning techniques through the use of multileaf collimators, which 
actively manipulate the radiation field5. In doing this radiation exposure is optimised to 
tumour and minimised to neuroparenchyma, which is particularly useful when 
radiosensitive neural structures are in close proximity71. In one 40 patient strong study of 
skull base meningioma, IMRT resulted in a 5 year progression free survival for 88% of 
participants71. IMRT was the sole treatment in 27% of recruits71. The results of two large 
RCT’s are anticipated71. 
1.8.5.3. Stereotactic Radiosurgery 
Stereotactic radiosurgery (SRS) utilises stereotactic imaging, sophisticated dose planning 
and radiation sources to deliver mutli-source radiation towards a common focus point with 
sub-millimetre precision5,72. As a result, higher doses can be specifically delivered to target 
tissues reducing the need for fractionation5.  
Despite contradicting fractionation radiobiology, single shots of radiation delivered through 
this method can produce excellent results. One retrospective study compared SRS with 
surgical resection for small to medium sized benign meningiomas and observed progression 
free survival rates of 95% at seven years; which was comparable to their patients who had 
Simpson’s grade 1 surgical resection73. This study was weakened by selection bias and a 
relatively short observation period. After larger long term observation and RCT evidence is 
available, it is likely that SRS will be recommended as primary treatment for certain 
meningiomas.  
It is important to note that SRS is only appropriate for targets less than 3.5cm in diameter 
with a sharply defined border and regular shape that is not enveloping eloquent 
structures74. This is due to dose spill into surrounding areas which can lead to post radiation 
reactions such as oedema and radiation necrosis74. This could be prevented with 
fractionation72. Fractionated stereotactic radiotherapy looks promising with minimal 
complications and local control rates of 90-100%74.   
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1.8.5.4. Indications 
Currently, definitive radiotherapy is indicated for inoperable meningiomas and adjuvant 
radiotherapy is indicated for incompletely resected meningiomas or meningiomas of high 
grade16. The number of indications will increase with the production of long term follow up 
data and RCT evidence. 
1.9. Prognosis 
1.9.1. Survival 
Compared to other intracranial tumours, patients with a meningioma fare well in terms of 
survival, but this is not the case when comparing patients with the general population19. 
Several large† observational studies calculated the survival rate of patients at 10 years post 
diagnosis to fall to 80% of that observed in the general population75,76,77,78,79. They were 
completed before the creation of the WHO grading criteria in 1993 and so may include 
tumours which would now be regarded as atypical or malignant. Some studies did not 
attempt to differentiate between grades in their analyses.  
One recently published study by Alkemade et al retrospectively observed the post-surgical 
outcomes of 233 benign meningiomas for a maximum of 23 years80. While the authors have 
stated that only WHO grade 1 tumours were analysed, patients were included from 1985-
2003 and there is no mention of revisiting slides or re-grading cases to account for up to 
date guidelines.  Despite this, the survival rates of this study are higher than stated 
previously at 91% of the general population80.  
Several studies agree that age, tumour grade and surgical resection are strong predictors of 
survival19. There are varied results on the age ranges that predict survival. Some studies 
suggest that short term and long term survival is significantly reduced with progressively 
increasing age75,79. Alkemade et al found that survival in patients under 45 and over 65 is as 
predicted but significantly worse in the 45-65 year group80. This was thought to be a result 
of recurrent tumour and stroke in the 45-65 group, and sampling bias in the over 65s, as 
only those who were fit underwent aggressive resection80.  
The varied results between these studies could be a product of the differences in study and 
comparison group population, or differences in the methods used to predict survival. 
                                                     
†
 Sample sizes ranged from 225 to 1986 patients in the large meningioma survival studies. 
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It is unsurprising that histological grade is inversely proportional to survival, with one study 
quoting 5 year survival rates of 70% and 55% for benign and malignant meningiomas 
respectively79. It is interesting that the atypical meningiomas in this study had a 75% survival 
and while the authors make no comment on this, it appears that this result could be due to 
the relative younger age of the atypical cohort. Furthermore, it is unclear on which criteria 
these tumours were graded and future studies using the current 2007 criteria are 
warranted.  
A link between extent of resection and survival has been postulated since 1959, when 
Donald Simpson published a paper on the recurrence of meningiomas after surgical 
treatment55. His criteria of surgical resection is presented below55: 
 “Grade I.-This is a macroscopically complete removal of the tumour, with excision of its 
dural attachment and of any abnormal bone. Where the tumour arises from the wall of 
a dural venous sinus, such an operation necessarily entails resection of the sinus. 
 Grade II.-This denotes a macroscopically complete removal of the tumour and of its 
visible extensions, with endothermy coagulation (usually to the point of charring) of its 
dural attachment. 
 Grade III.-This denotes a macroscopically complete removal of the intradural tumour, 
without resection or coagulation of its dural attachment, or alternatively, of its 
extradural extensions, e.g., an invaded sinus or hyperostotic bone. 
 Grade IV.-This denotes a partial removal, leaving intradural tumour in situ. 
 Grade V.-This is a simple decompression, with or without biopsy (pages 24 and 25)”. 
Simpson’s study illustrated that the completeness of surgical excision is a key factor 
influencing survival. Despite his series being retrospective; and before the use of CT, MRI or 
microsurgery; subsequent modern studies have mostly agreed with these results12. Kalio et 
al analysed the outcomes of 935 postsurgical meningiomas and found that after 15 years 
the relative survival ratio (RSR) was 78% of what was observed in a non-meningioma 
group81. It was concluded that survival was largely dependent on the extent of resection 
with an RSR of 84% following complete resection (Simpson grades 1 and 2) and 50% 
following incomplete resection (Simpson grades 3-5)81.  
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1.9.2. Recurrence 
Tumour recurrence is a significant endpoint in its own right, but its influence on survival has 
not been focused upon in the literature. In isolation is a comment by Alkemede et al, who 
found an association between poor survival and tumour recurrence80. This notion remains 
unexplored.   
Simpson’s grade of resection is strongly associated with tumour recurrence. Table 3 
summarises the findings of three studies that demonstrate this. 
Table 3: Summary of Three Studies examining Simpson’s Grade of Resection and 
Meningioma Recurrence Rate 
 Simpson
55
 Melamed
82
 Chan
83
 
Simpson’s 
Grade 
Recurrence % Recurrence % Recurrence % 
1 9 8 11 
2 19 15 22 
3 29 29 - 
4 44 33 33 
5 - - 100 
Follow Up 
Period 
Up to 28 Years 7-17 Years Average 9 Years 
 
Seemingly in opposition is a retrospective study by Oya et al, which finds a significant 
difference in recurrence free survival (RFS) between Simpson grades 1-3 and 4, but not 
between grades 1, 2, or 384. The reduced distinction between grades 1-3 could be a result of 
shorter follow up or lead time bias due to advances in scanning equipment and follow up 
regimes. 
Tumour location influences outcomes indirectly as meningiomas with difficult access are 
more likely to be incompletely resected5. This is represented in a post-surgical outcomes 
study by Mirimanoff et al76. It was found that convexity tumours were completely excised in 
96% of cases leading to a 5 year progression free survival rate of 97%. In comparison, 
parasellar meningiomas were completely excised in 57% leading to a progression free 
survival rate of only 81%. This study included spinal meningiomas which have the best 
recurrence free survival rates.  
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1.9.3. Neurological Outcome 
Symptomatic relief or progression is an important outcome for patients. In addition to 
observing survival and recurrence, Alkemade et al monitored patients for symptom 
outcomes in the short and long term80. After a year of follow up, 61%, 13% and 22% of 
patients experienced some resolution, no change, or worsening of symptoms respectively. 
Long term symptomatic observation was obtained for a minimum of 5 years; of the 
responders, 33% experienced no symptoms, 67% of patients experienced at least one 
symptom and 27% of patients experienced severe symptoms that interfered with quality of 
life80. Cerebellar symptoms were most likely resolved after 5 years, while cognitive and 
motor symptoms were most likely to persist in mild and severe forms respectively in the 
same time frame80.  
 
 
1.9.4. Quality of Life 
The literature on Quality of Life (QoL) and meningioma has covered many topics, namely: 
 QoL after surgery, radiotherapy or surgery and radiotherapy83,85,86,87,88,89,90,91,92 and 93. 
 Analysis of the factors affecting QoL and their predictive power (not including seizure 
frequency) by Miao94. 
 Patient satisfaction after surgery by Akagami95.  
 The development of internet-based, self-reporting outcome instruments by Zlotnik96. 
Findings from these studies are not entirely consistent due to variations in sample 
population and questionnaire used. The most commonly used QoL measure was the 
Karnofsky Performance Score (KPS), a questionnaire that rates the ability of a person to 
undertake daily activities on a scale of 0 – 100. This questionnaire is particularly effective at 
identifying problems with physical function.  
Studies using the KPS have found that the presence of symptoms due to the meningioma, 
such as cranial nerve dysfunction and hemiparesis score significantly85. Other influencing 
factors include tumour size, extent of resection and tumour grade94.  
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Chapter 2: Epilepsy 
2.1.  Introduction 
Epilepsy is a disorder of the cerebral cortex where a tendency to “an excessive and 
disorderly discharge of cerebral neurones‡ (page 3109)”97 can manifest as recurrent seizures 
of numerous form that are stereotyped to the individual7,98. It can exist as a primary 
disorder of the CNS or secondary to other pathological processes11. Like meningioma, 
epilepsy is a heterogenous condition which produces some difficulty in definition and 
classification.  
2.2. Definition 
The word Epilepsy is derived from the Greek epilambánein which means to seize upon.  
Rather confusingly, epilepsy can be incorrectly used as a colloquial term for fit, seizure or 
convulsion by a lay member of the public99.  
Modern definitions agree that a patient is said to have epilepsy when two or more 
unprovoked seizures occur7,11. This clinical definition targets those that are likely to have 
further seizures and thus may benefit from counsel and anti-epileptic drug (AED) 
prophylaxis as proven by observation studies7. 
2.3. Classification 
Patients are currently classified on the basis of two schemata: seizure type and epilepsy 
syndrome. In 1982 The International League Against Epilepsy (ILAE) released the 
International Classification of epileptic seizures; a refined product of Gastaut’s 1970 
classification system7,11. It identifies seizures by their clinical form and 
electroencephalographic (EEG) features, which separates seizures into two main categories 
of partial and generalised attacks depending on whether seizure activity originated in one 
hemisphere or both hemispheres simultaneously; this separation is useful for prognosis to a 
certain extent100. In 1989 the ILAE introduced the classification of the epilepsies, which 
consists of three groups100: 
 Idiopathic  
 Symptomatic 
 Cryptogenic 
                                                     
‡
This quote originates from the writings of Hughlings Jackson (1870).  
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The understanding in 1989 was that idiopathic, symptomatic and cryptogenic epilepsies 
usually correlated with primarly generalised epilepsies with a genetic basis, partial 
epilepsies due to a structural lesion and partial seizures with no apparent cause 
respectively11. Advances in genetic understanding, neuroimaging and neurophysiological 
techniques have led to the realisation that epilepsy is more complex than originally 
presumed and certain cases do not fit neatly into these groups100.  
The ILAE have thus recently updated both classification systems to simplify classification and 
allow for future alterations100. This classification of seizures differs from the 1981 
classification in concept and content in the following ways101: 
1. The omission of the concept that focal and generalised seizures represent a 
dichotomous pair (although this is still implicit).  
2. The inclusion of neonatal seizures. 
3. Absence seizures have been categorised in a simpler manner and myoclonic absence 
seizures and eyelid myoclonia have been included.  
4. The inclusion of spasms. There was some debate as to whether these represented 
focal or generalised seizures, but ultimately they were categorised separately.  
5. Myoclonic atonic seizures are included. 
 
One major change is omission of distinction between simple and complex partial seizures. 
This distinction is poorly understood and the seizures inconsistently categorised101. 
Description of seizures based on their ictal phenomenology is still recommended but in the 
following form and under certain circumstances101: 
 Simple partial seizures:  Without impairment of consciousness or awareness with 
observable motor or autonomic components. 
 Complex partial seizures: With impairment of consciousness or awareness 
The classification of epilepsies has been simplified to pragmatically represent aetiologies as 
follows101: 
 Genetic 
 Structural 
 Unknown Cause 
 
22 
 
They replace the terms idiopathic, symptomatic and cryptogenic which had a significant 
degree of overlap100. Additional concepts of epilepsy were also offered; to rename the 
concept of idiopathic epilepsy to self-limiting or pharmacoresponsive epilepsy and to add 
the concept of epileptic encephalopathy to describe the observation of epilepsy specific 
cognitive impairment101.  
The previous ILAE classification systems have been highly influential on a global scale. The 
WHO, in constructing the current International Classification of Diseases manual (ICD-10), 
based their epilepsy section on the previous ILAE systems102. The ICD-10 is utilised by a 
range of disciplines worldwide and so changing the epilepsy classification schema is 
significant. The WHO are drafting the ICD-11 head of its release in 2015, the epilepsy section 
of which is based on the current ILAE classification systems102.  
2.4. Epidemiology 
Epilepsy is a relatively common neurological condition that is thought to affect at least 50 
million people worldwide103. There is difficulty in obtaining accurate figures for the 
incidence and prevalence of epilepsy and this is a product of difficulty in case definition 
across studies, clinical misdiagnosis and failure to seek medical attention due to fear of 
stigmatisation or ignorance of symptoms104.  
The prevalence of epilepsy in the UK is uncertain. The National Institute of Clinical 
Excellence (NICE), which uses prospectively collected primary care Quality and Outcomes 
Framework data, estimated the prevalence of epilepsy to be between 362,000 and 
415,000105. The Joint Epilepsy Council (JEC) used prospectively collected primary care data 
(read and Pegasus coding systems), estimating the prevalence of epilepsy to be 600,000 in 
the UK (0.97% of population)106. The data from both organisations is limited due to reliance 
on GP coding systems and lack of validation, which will include many patients who are 
misdiagnosed. Compounding this issue is the belief that 25% of epilepsy diagnoses are 
incorrect in the UK107.  Furthermore, the JEC estimates are based on patients with a 
diagnosis of epilepsy and a prescription for AED, which is not representative of all persons 
with epilepsy. 
Both NICE and the JEC are in agreement that the incidence of epilepsy is likely to amount to 
50 cases per 100,000 of the population per year118,119. A systematic review and meta-
analysis of 167 studies before 1999 quoted a similar incidence rate at 50.7 per 100 000 for 
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males and 46.2 per 100 000 for females108. It is generally shown (not always significantly) 
that epilepsy is more common in males due to a higher incidence of cerebral injury leading 
to symptomatic/structural epilepsy104.  
The Rochester Minnesota study examined the prevalence of epilepsy between 1940 and 
1980; epilepsy was classified as idiopathic or cryptogenic in 75% of cases and symptomatic 
in the rest109. No distinction was made between idiopathic or cryptogenic epilepsy, but it 
was stated that with thorough investigation the majority of cases would be cryptogenic109. 
In an almost identical population to the above, 65% of incident cases were classified as 
idiopathic or cryptogenic110.  The relatively increased proportion of symptomatic patients in 
the incidence study is explained by the high mortality associated with these epilepsies and 
thus reduced prevalence.  
Overall, focal seizures are more incident than generalised seizures with one large UK study 
finding 59% of seizures to be focal111. In developed countries, there is a 59% majority in the 
prevalence of focal seizures and the opposite is observed in developing countries104. The 
proportions of seizure types seen also varies by age. Absences and myoclonic seizures are 
highly incident in children, while complex partial seizures are the most incident type of 
seizure in adults: at least 40% of adult seizures are complex partial. Age is significantly 
associated with incidence rates: bimodal peaks are frequently demonstrated in studies104. 
This is a product of the various aetiologies for epilepsy and the ages at which they are likely 
to present. In the very young, recurrent seizures are likely to be secondary to congenital 
structural or metabolic conditions7. Up to early adulthood, the proportion of seizures due to 
acquired disorders or recognised genetic generalised epilepsy increases7,112. After 
adolescence the role of acquired disease becomes more influential, with infections, tumours 
and cerebrovascular disease being found responsible for the majority of epilepsy7.  
Symptomatic seizures in late adulthood lead to an overall increase in the incidence of 
epilepsy7.  
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2.5. Pathophysiology 
A precise pathological understanding of seizure generation is currently non-existent, but in 
broad terms, a seizure is said to occur when electrical discharges of high voltage and 
paroxysmal high frequency, or synchronous low frequency, propagate to surrounding 
neurones and structures7. The concept of excessive discharges leading to seizures was 
famously theorised by Hughlings Jackson in the 19th century and reinforced with the advent 
of the EEG in the 20th centrury11.   
Numerous observations on a smaller scale are continuously increasing our understanding of 
epilepsy. Studies focussing on hereditary epilepsies have revealed a polygenic mode of 
inheritance and unsurprisingly numerous genes involved with neuronal discharge are 
implicated113. Abnormalities pertaining to code and epigenetic modulation have been found 
for sodium and potassium channels, receptors for acetylcholine (ACH) and gamma-
Aminobutyric acid (GABA)7,11. Such mutations are implicated in the primary generalised 
epilepsies: they have a strong familial inheritance and genetic mutations that influence 
neuronal excitation are increasingly being found7. Spontaneous bilateral spike or polyspike 
and slow wave discharges can be seen on the EEG, the frequency of which varies by seizure 
type and phase7. It is clear that subcortical structures play a significant role in producing 
generalised seizures, but whether this is in producing or modulating seizure activity is not 
known7. 
Studies on seizure foci have revealed biochemical abnormalities such as increased levels of 
extracellular potassium around glial scars and increased sensitivity of foci to ACH7,114. Levels 
of GABA, taurine, glycine and glutamic acid are altered in excised seizure foci7. Furthermore, 
there is growing evidence that abnormal glial cells can manipulate seizure activity through 
the modulation of ions, neurotransmitters and inflammation115: seizure threshold is reduced 
in Knock out mouse models of glial neurotransmitter transporters116. 
Animal models with penicillin induced lesions have shown that epileptogenic foci 
spontaneously depolarise and are suppressed by surrounding hyperpolarised inhibitory 
GABA neurones117. How much of this applies to humans is unclear, but when electrical 
activity manages to spread beyond the focus, that is when a seizure is believed to occur7.  
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For this to happen, the following is thought to be required7: 
1. Population of pathologically excitable neurons 
2. Increased excitatory glutaminergic activity 
3. Decreased inhibitory gabanergic activity  
It is not understood how focal lesions can lead to the spontaneous and synchronous 
discharge of neurons, but one theory is that the offending neurones have been de-
afferented7. This is known to occur after CNS injury and has been implicated in epilepsy, 
complex regional pain syndrome and spasticity118. De-afferented neurones remain in a state 
of partial depolarisation, which makes them hyper-excitable7. The mechanism underpinning 
this is not fully understood, but potential factors could include alterations of neuronal 
networks due to the malfunction of inhibitory afferent neurones or the sprouting of new 
excitatory collaterals119.  Additionally, or alternatively, intrinsic hyper-excitability may be a 
factor, a manifestation of physiological GABA receptor up-regulation or alterations in the 
function of ion channels118.  
Modern EEG techniques have led researchers to discover that trace abnormalities may be 
found several minutes and even days before the onset of a seizure, suggesting that the 
influence of subcortical rhythms or a cascade of electrical events may be influential in 
initiation or modulation7,120. 
Precisely how isolated areas of cortical activity lead to seizures is not understood7.  
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2.6. Investigations 
In most cases, the diagnosis of epilepsy can be made on clinical grounds and investigations 
are important for supporting the diagnosis, seeking an underlying cause and classifying the 
epilepsy. 
2.6.1. EEG 
When there is clinical suspicion of epilepsy after a seizure, most patients will receive an EEG. 
During the basic 30 minute trace of an awake patient with epilepsy, abnormalities can be 
found in 50% of recordings121. This was first observed in a study of 308 persons with 
epilepsy, in whom 55.5% demonstrated an identifiable paroxysmal discharge on their first 
EEG122. These were definite cases of epilepsy which perhaps is not representative of the 
clinically indiscernible cases a clinician sees. Other studies have found abnormalities in 30-
50% of inter-ictal traces and this variation could be explained by variances in age, seizure 
proximity, seizure frequency and epilepsy syndrome7,122.  
When an EEG is recorded in close proximity to a seizure or if seizure frequency is high this 
will increase the chance of recording an abnormality122. An increased yield is also found in 
younger patients: patients over 60 have a decreased yield with abnormalities found in 35% 
of patients with previous epilepsy and 26% of patients with seizure onset after 60 years123. 
As is expected, the majority of these patients had focal epilepsy. The reduced yield in these 
patients seems to be a result of age and epilepsy syndrome; non idiopathic epilepsy had a 
reduced yield123. Sample size was small in this regard and comment on this was not 
entertained.  
In idiopathic epilepsy, characteristic inter-ictal epileptiform discharges can be found in 50% 
of grand mal seizures and 30% of absence seizures7. Of the focal epilepsies, temporal lobe 
epilepsy will produce characteristic abnormality in 70-90% of cases124. In extra-temporal 
focal epilepsies, aberrations of normal EEG patterns are sought, the sensitivity of which 
varies by the localisation of the epilepsy: 
 In frontal lobe epilepsies, 40% of cases will demonstrate abnormal inter-ictal 
patterns125. 
 Parietal lobe epilepsy will infrequently demonstrate EEG abnormalities and when 
they do they are poorly localised125.  
 Epilepsies of the occipital lobe frequently produce localised abnormalities125. 
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In most epilepsy patients, the yield of abnormalities can be increased with activation 
procedures (hyperventilation and photic stimulation), multiple recordings, sleep deprivation 
and sleep EEG121,124. When a combination of repeated awake and sleep EEG recordings is 
used, the yield can be as high as 92%121.  
The EEG is more specific than it is sensitive. In the general population, only 1% of people will 
demonstrate activity121,126. When focusing on populations of patients with cerebral injury 
and yet no seizures, abnormalities can be found in 17% of patients with congenital or 
perinatal brain injuries: 11% of patients after cranial surgery and  8% of patients with brain 
tumours127. In psychiatric patients, one study of 3000 psychiatric inpatients suggests that 
abnormalities can be seen in 2.6%: a consequence of medications and probable metabolic 
disturbance, drug abuse or cerebral injury128. Furthermore, there are normal sharp wave 
phenomena that look similar to epileptiform activity, but they occur in healthy people and 
sleep or drowsiness may precipitate them126.  
In the fortunate circumstance that a seizure is captured by EEG, the sensitivity and 
specificity of this is far superior to inter-ictal EEG129. This is the basis of video EEG which 
monitors patient movement, EEG activity and electrocardiogram (ECG) activity and proves a 
useful tool for establishing a seizure diagnosis, seizure frequency and localization of foci for 
clinical or surgical management129. During prolonged recordings, a seizure can be captured 
in around 50-70% of cases and in 20% of cases previously unrecognized seizures may be 
identified129,130.  It should be noted that absence of abnormal activity during ictal EEG can 
occur in simple partial seizures and auras and rarely occur in the context of complex partial 
seizures130. Contrary to this, almost all types of generalized seizure will produce ictal EEG 
abnormalities7.  
Scalp electrodes can be relatively poor at identifying seizure activity. Synchronous 
epileptiform activity over a 6cm2 area of cortex is required for scalp electrode recognition, 
which can be the case in simple partial seizures124. Furthermore, the signal travelling to 
scalp electrodes is altered by parenchyma, meninges, skull and scalp; electrical activity 
arising in deeper structures may not be identified124. These issues can be resolved with the 
use of surface or depth electrodes which can identify electrical activity with millimeter 
precision; albeit at a risk of infection, haemorrhage and cortical damage131. Such measures 
are usually reserved in cases of refractory epilepsy, where surgery may be indicated and 
great precision in localising foci is required131.  
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2.6.2. Neuroimaging 
Structural imaging techniques are required to rule out a structural cause for epilepsy11. NICE 
recommend that neuroimaging be used in all patients105. X-ray computed tomography (CT) 
scans are relatively insensitive and can miss lesions such as small tumours, cortical dysplasia 
or hippocampal sclerosis11. MRI is the preferred investigation, it is recommended by NICE 
and the ILAE105,132. In patients with a first seizure or newly diagnosed epilepsy, 13-14% of 
patients will have an identifiable lesion on magnetic resonance imaging (MRI)133. Of note is 
the study by Griffith et al who found abnormalities in 26% of patients with epilepsy if 3-
Tesla scanners are used and localisation related epilepsy is suspected134. These results are 
particularly applicable to a UK population, as NICE guidelines were followed in the study 
design and method. The images of 120 patients were analysed by two reporters with 100% 
agreement and the most common abnormality was mesial temporal lobe sclerosis, which 
was found in 8% of all scans134. Other abnormalities included134: 
 4 brain tumours: 2 glioma, 1 dysembryoplastic neuroepithelial tumour and 1 
epidermoid tumour 
 Brain malformations 
 Vascular malformations 
 Encephalomalacia due to  infarction 
Lesions of the temporal lobe predominated this series: they were found in 69% of 
patients134. In some series, sensitivity of MRI can be 50%, so a standard protocol of T2 
weighted, 3-5mm sliced scans are recommended for screening132. Griffiths et al utilised 
fluid-attenuated inversion recovery imaging (FLAIR) which allows for detection of more 
subtle grey matter changes132,134. Abnormalities can be found in up tp 83% of patients134. In 
a pre-surgical series of 385 patients with epilepsy, this high yield was obtained by using a 
combination of 3D T1, T2, FLAIR and contrast techniques135.  
In the immediate period after a seizure, MRI with FLAIR or contrast techniques focal can 
identify cortical swelling and other signal changes7. They are thought to be associated more 
with focal seizures and increased seizure severity; these changes be seen for around two 
days7.  
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2.6.3. Other Investigations 
In addition to imaging changes after a seizure, biochemical abnormalities associated with a 
seizure may include7,136: 
 Cerebrospinal fluid (CSF) pleocytosis  
 Lactic acidosis 
 Raised Creatinine Kinase (CK) 
 Raised prolactin (after generalised or complex partial seizures, but not absence or 
myoclonic) 
These abnormalities are not specific to seizures; syncopal episodes can lead to raised CK and 
raised prolactin7.The following investigations are usually performed to identify the cause of 
the seizure, rule out alternative diagnoses, and screen for any potential contra-indications 
for commencing AED therapy7,105,136: 
 Complete blood count 
 Blood biochemistry 
 Liver Function test 
 Thyroid Function test 
There are numerous conditions which need to be ruled out when investigating patients with 
possible epilepsy. If cardiovascular events, such as vasovagal syncope and cardiac 
arrhythmias, are not ruled out by the history, EEG, prolonged ECG, tilt table testing, holter 
monitors, cardiac stress tests and CK levels may help7,11. Hypoglycaemia can be excluded 
through the use of blood sugar estimation when patients are symptomatic11. Transient 
ischaemic attacks could be indicated by the presence of abnormalities from carotid doppler, 
echocardiograms and biochemistry studies137. Serum CK levels are usually normal after 
attacks due to non-epileptic attack disorder7.  
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2.7. Management 
Epilepsy has a significant impact and this is especially evident when observing epilepsy in 
under-developed countries138. One study from Cameroon with matched controls found that 
persons with epilepsy had a 6-fold increase in mortality139.  The most common causes of 
death in the epilepsy group were seizure related; i.e: status epilepticus, sudden unexpected 
death in epilepsy (SUDEP) and drowning139. As will be highlighted later, the mortality 
associated with epilepsy in developed countries is lower138. This disparity can be partly 
explained by a lack of treatment with anti-epileptic medication, which is a testament to 
their effectiveness140. 
2.7.1. Anti-epileptic drugs 
Approximately 65% of newly diagnosed patients will eventually experience a degree of 
seizure freedom after commencement on an AED141. This is shown in SANAD (Standard and 
New Antiepileptic Drugs), the largest RCT performed in epilepsy, where in focal epilepsy AED 
treatment led to a remission of at least 24 months in 64% of cases after 6 years across all 
treatment groups142. For generalised epilepsy, AED treatment led to a 24 month remission 
after 6 years in 82% of cases143.There are currently 23 AEDs available for use in the United 
kingdom (UK) and for the most part they are each unique in their use and mechanism of 
action144,145. 
2.7.1.1. Mechanisms of action 
AEDs prevent seizures and no conclusive evidence exists to suggest that they exhibit anti-
epileptogenic properties in humans146,147. Hopeful areas of anti-epileptogenesis research 
involve immunosuppressant’s, anti-inflammatory drugs, plasticity modulatory drugs and 
proconvulssants147.   
The anti-seizure properties of most AED were discovered after the screening of drugs in 
animal models and it is only after this that their mechanism of action has been elucidated145. 
The anti-seizure properties of phenobarbital, the first known AED, was being tested for 
hypnotic efficacy at the time of discovery146.  
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Current AEDs utilise numerous modes of action, but each AED can be broadly assigned to a 
category of anti-seizure action146:  
1. Modulation of voltage dependent sodium, calcium or potassium channels.  
2. Modulation of neurotransmitter release via presynaptic mechanisms, with an action on 
glutamate release being most relevant. 
3. Alterations in GABAergic inhibition via actions on GABAA receptors or on GABA 
synthesis, reuptake, or degradation. 
4. Decreased synaptic excitation via actions on ionotropic glutamate receptors.  
Voltage gated sodium channels are responsible for sodium flux and thus neuronal 
depolarisation during the action potential145. They can rapidly cycle through active and 
inactive states which is important in normal neuronal function and also epileptic activity145. 
High frequency repetitive firing is thought to be essential in spreading partial and 
generalised seizure activity and AEDs dampen this by targeting sodium channels in the 
inactivated (depolarised) state145. This means that AED preferentially target neurones that 
are over-active, sparing their action on neurones displaying normal physiological activity145. 
Drugs that predominantly target sodium channels include phenytoin, lamotrigine, 
carbamazepine, oxcarbazepine and zonisamide145. While these drugs do not directly alter 
synaptic activity, their effect on presynaptic action potentials can inhibit synaptic output, 
and this is especially true for glutamate145.   
High voltage activated calcium ion channels are a key component of presynaptic 
neurotransmitter release145. Specific calcium channels are thought to be targeted by 
gabapentin, but exactly how this leads to reduced seizure activity has not been proven145,146. 
Other proposed secondary mechanisms for gabapentin include the synthesis of GABA 
transporters and the induction of increased sensitivity to GABA on receptors148. Other AEDs 
are found to mediate high voltage activated calcium channels, but it is not felt that this is 
their main mode of action. They include: phenobarbital, lamotrigine and leviteracetam145.   
Low voltage calcium channels regulate neuronal firing and are strongly associated with 
oscillatory thalamic activity during generalised absences145. Ethosuximide has a low affinity 
for these channels, but is very effective in reducing generalised absences145. This drug does 
not act on sodium channels or high voltage calcium channels and this in part explains its 
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ineffectiveness for partial and generalised seizures145. Interestingly, lamotrigine is also 
effective against generalised absences, but does not share this mechanism of action145.  
GABA mediated neurones are sparse in areas associated with epilepsy, for example the 
neocortex, hippocampus and the amygdala, which contain a higher number of excitatory 
synapses145. Despite this, they are crucial in dampening epileptic activity by preventing 
synchronisation and are a mode of action for some AED145. Phenobarbital was the first 
recognised anti-epileptic substance and it works by increasing receptor sensitivity to GABA 
and potentiating resultant signal propagation145. There are other drugs in which the main 
anti-epileptic mechanism is GABA modulation and they include the benzodiazepines, 
vigabatrin and tiagabine. Furthermore, drugs such as valproate, utilise GABA mechanisms 
secondarily145. These drugs work by targeting receptors, enzymes or transporters and are 
effective against most seizure types, with the exception of absences145. 
Glutamate is an important excitatory neurotransmitter that influences stimulation at the 
majority of CNS synapses149. There numerous glutamate receptor ion channels of which 
there are four families: AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), 
kainate, NMDA (N-Methyl-D-aspartic acid) and delta receptors149. While no AED is solely 
associated with glutamate receptors, several mediate their effects at least in part through 
this method145. Felbamate exhibits action on GABA and NMDA glutaminergic synapses and 
is the only drug that is proven to clinically ameliorate seizures through NMDA146. 
Topiramate is effective against partial and generalised seizures and its mechanism is 
thought to include AMPA/kainate receptors: in addition to voltage-gated sodium channels, 
high-voltage activated calcium channels, GABAA receptors and carbonic anhydrase 
isoenzymes146. AMPA receptors are key mediators of seizure spread145.  
2.7.1.2. Non Seizure Effects 
The CNS and AEDs are both complex and it is unsurprising that some AEDs do not solely 
prevent seizures. They can be used to treat migraine and neuropathic pain, probably as a 
result of overlapping pathophysiological mechanisms150. Furthermore, they have benefit for 
psychiatric disorders such as bipolar disorder, depression and schizophrenia, perhaps 
through influences on neuronal structural integrity and synaptic plasticity151. These are but a 
few of their non-epilepsy indications. Unfortunately, this varied benefit also  relates to a risk 
of widespread adverse events. 
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2.7.1.3. Adverse Events 
Choice of AED and dose is a compromise between seizure reduction and tolerability of side 
effects141. Data from SANAD highlights the importance of this; 50% of patients with focal 
epilepsy (arm A) reported adverse events at least once during the 6 year period of study142. 
This was the sole reason for treatment failure in 34% of patients, which was 17% of all 
patients142. It was the superior tolerability and side effect profile of lamotrigine over 
carbamazepine that made it the best drug of the trial, despite similar seizure preventing 
efficacy142. This finding has subsequently influenced clinical guidance, with lamotrigine and 
carbamazepine being considered first line treatment in focal epilepsy95. While SANAD 
reported that most clinicians would have prescribed modified release versions of 
carbamazepine, which has an improved side effect profile, critics argue that such 
preparations may not have been used and thus, carbamazepine was disadvantaged142,152. 
While this is unlikely to have altered the results in SANAD, special mention of 
carbamazepine and the use of modified release preparations has been included in the most 
recent NICE guidance105.  
Dose dependent adverse events include sedation, drowsiness, incoordination, nausea and 
fatigue153. They can be prevented with dose titration153. Other common side effects include 
headache, slurred speech and cognitive effects (including sedation)153. Organ systems other 
than the CNS are also adversely affected by AED. Such adverse events include liver failure, 
hypersensitivity reactions and aplastic anaemia to name a few141.  
It is important to note that different AEDs have different side effect profiles and that some 
side effects occur at different times after commencement of therapy (Table 4)154. Some of 
the newer anti-epileptic drugs do not induce hypersensitivity reactions, weight problems 
and do not require routine laboratory monitoring; unlike carbamazepine and valproate, 
where white cell counts and liver function tests respectively are routinely performed147.  
The most common idiosyncratic reactions are skin eruptions7. They vary in severity from a 
maculopaular rash to toxic epidermal necrolysis7. Such reactions are more strongly 
associated with the aromatic compounds in phenytoin, carbamazepine, phenobarbital and 
lamotrigine7. The milder rashes usually develop within the first month of treatment and will 
resolve in a matter of days after AED discontinuation7.  
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Table 4: Early Onset and Late Onset Adverse Events after Commencing AEDs154 
Early-onset adverse events 
Late-onset adverse 
events 
Somnolence Sedation 
Dizziness Encephalopathy 
Seizure aggravation Depression 
Gastrointestinal Behavioral problems 
Liver failure Psychotic episodes 
Hypersensitivity Rash Leukopenia 
 Aplastic anemia 
 Thrombopenia 
 Megaloblastic anemia 
 Pancreatitis 
 Nephrolithiasis 
 Osteoporosis 
 Hyponatremia 
 Weight gain 
 Weight loss 
 Impaired Cognition 
 
Other issues to consider are interactions with medications, worsening of seizures and 
teratogenic effects141. Carbamazepine, phenobarbital and phenytoin alter the hepatic 
cytochrome p450 system and valproate inhibits glucuronidation154. Newer drugs have little 
or no metabolism by the cytochrome p450 system and these drugs include oxcarbazepine,  
gabapentin, levetiracetam, lacosamide, lamotrigine, pregabalin, topiramate and 
zonisamide154. Older AEDs are also more likely to reduce therapeutic levels of drug when 
used in combination, e.g. carbamazepine reducing the plasma concentration of valproate141.  
Seizure worsening after AED is a particular risk for patients with idiopathic generalised 
epilepsy154. Typical absences are aggravated by carbamazepine, vigabatrin, tiagabine and 
gabapentin, and confusingly, idiopathic generalised epilepsies may respond therapeutically 
to these drugs154.  
AED drug monotherapy during pregnancy increases the risk of major congenital 
malformations in the foetus two to threefold when compared to the general population155. 
One Manchester based study took 277 women with epilepsy and compared their pregnancy 
outcomes to controls from the general population155.  Of the epilepsy group, 67% of 
mothers took at least one AED and major congenital malformations were found in 6.6%, 
three times that of the control group155. Valproate was found to be significantly associated 
with abnormalities found in 16.7% of babies exposed with valproate polytherapy and 11.3% 
of those with valproate monotherapy155. Data on the teratogenic effects of AED has grown 
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due to registries in Europe and in the UK156. Topiramate increases the incidence of cleft 
palate by eleven times156. Phenobarbital, carbamazepine and lamotrigine are more loosely 
associated with teratogenic effects156. While monotherapy is preferred, polytherapy with 
carbamazepine or lamotrigine and any drug other than valproate does not seem to increase 
the risk of malformations156.  
2.7.1.4. Indications 
It has already been mentioned that AED are matched to patients on the basis of their 
efficacy in treating different seizure types and while clinician and patient preference also 
influence AED choice it is important that prescribing practice in the UK follows NICE 
guidance105,157. Current NICE guidance for prescribing AEDs is included in appendix I. 
2.7.2. Lifestyle Management 
2.7.2.1. Sleep 
It is clear that sleep deprivation increases the incidence of interictal spike wave discharges 
on the EEG and that sleep deprivation aggravates seizures in patients with generalised 
epilepsy7. For focal seizures, such a relationship is less clear. One survey study found that 
sleep deprivation alone did not account for seizures, but sleep deprivation, stress and 
fatigue in combination did158. Another study observing patients with and without sleep 
deprivation on video telemetry found that seizures were not increased by alternate days of 
sleep deprivation over a period of 6 days159. Possible reasons for these contrasting results 
include: patient difficulty in distinguishing between fatigue, stress and lack of sleep; and an 
observation period that was too short in the EEG study, or insufficient sleep deprivation. 
Either way, it is clear that it is harder to associate sleep deprivation with increased seizures 
in focal than primary generalised epilepsy.  
Other than sleep deprivation, patients should also be aware that the following can trigger 
seizures: emotional stress, infections, fever, the menstrual cycle and more importantly: 
alcohol use, caffeine use, fasting, flashing lights and heat or humidity158,159. After sleep 
deprivation, fatigue andfever or illness are most likely to be reported by patients to 
aggravate seizures158.   
2.7.2.2. Accidents 
In a telephone and interview based cohort study of 1000 epilepsy patients across Europe, it 
was found that epilepsy patients were over two times more likely to have an accident 
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leading to injury or financial loss while at home, at work and in the street160. When 
discounting seizure related injuries, epilepsy patients were still experiencing more accidents 
at a slightly increased rate when compared to controls160. Interestingly, there was no 
increased risk during sporting activities160. The authors believed that epilepsy patients 
undertook less sporting activities than controls, explaining this finding160. 
Moderate amounts of supervised exercise is permissible and with proper supervision 
swimming and boating can be safe, but patients with incompletely controlled seizures 
should avoid unguarded machinery, ladders, baths alone and driving for risk of harm to self 
and others7.  
 
2.7.2.3. Driving 
Most countries ban patients from driving after a seizure, but the duration of the ban and 
deciding who is fit to drive is still debated161. In the UK, any form of seizure will lead to a 
driving ban by law. Patients that do not drive heavy good vehicles are able to re-apply for a 
licence after one year of seizure freedom.  
New guidance states patients with an isolated seizure (defined as seizures occurring within a 
24 hour time period only with no prior seizure history) can re-apply for their licence in 6 
months, provided that there are no further seizures and there are no features in the case 
suggestive of an increased risk of further seizures, such as a cerebral lesion or abnormalities 
on an EEG162. 
Previously, patients with seizures isolated to sleep had to wait 3 years to reapply for their 
licence, but this has now reduced to one year. Patients that have focal seizures and are able 
to fully control a car during a seizure are able to re-apply for a licence after a one year 
period if this established pattern of seizures is maintained. These and patients with isolated 
sleep seizures can drive and continue to have seizures so long as the nature of these 
seizures do not change162.  
If a patient experiences a breakthrough seizure due to a change in medication, they are now 
allowed to re-apply for a licence after a seizure free period of 6 months with their previous 
medication162.  
These recent changes in driving legislation reflect an improvement in our understanding of 
seizure recurrence, which is a result of data from large studies, like the Multicentre study of 
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early Epilepsy and Single Seizures (MESS)163. This RCT randomised 637 patients who had a 
single unprovoked seizure to groups of immediate and delayed treatment. In patients like 
these, the decision to commence pharmacological management is difficult and MESS only 
recruited patients where the clinician was unsure whether to start treatment or not163. 
There were some concerns surrounding the external validity of the study as a result of this, 
but nonetheless, this study has influenced guidance. 
The main findings of MESS can be summarised as follows163: 
 “Six months after an index seizure the overall risk of recurrence in the following 12 
months was significantly below 20% for people who started anti-epileptic drug 
treatment (page 7).” 
 “Seizure while asleep and abnormal electroencephalogram results significantly 
increase the risk of a seizure recurrence in the next 12 months according to a 
multivariable analysis (page 7).” 
For the first time, individualised risk is being calculated to inform decisions surrounding 
driving and this poses interesting questions about the availability of service provisions to 
match our knowledge.  
 
2.7.3. Surgery  
In 20-40% of patients, AED treatment is ineffective at controlling seizures164. It is estimated 
that surgery should be considered in 25% of all patients and that half of these would benefit 
from surgery7,164. However, delays in the identification of suitable patients, and hesitancy in 
referral, mean that surgery is underutilised165. Some authors argue that surgery should be 
considered earlier in the course of disease, as this may improve seizure freedom and quality 
of life7,164. Whilst this concept may seem implied, there is no supporting evidence from 
observational or RCT studies166.  
Before surgery can occur, a thorough pre-surgical workup including MRI, EEG, video 
telemetry, neuropsychological assessment and the Wada test may be performed to identify 
and confirm the site of the epileptogenic lesion and the areas of the cortex that are 
essential for function167.In cases where the lesion is difficult to identify, for example mesial 
temporal lobe epilepsy with bilateral interictal spikes or extra-temporal epilepsy with non-
correlating MRI and EEG findings, invasive EEG monitoring may be indicated168. An 
arrangement of subdural strips, subdural grids or intracerebral electrodes is tailored to each 
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patient’s presumed epileptogenic zone168. Subdural strips and grids or strips and 
intracerebral electrodes are often used in combination168. Complications are infrequent, as 
infection and haematoma occur in 2.5% and 3% respectively with subdural electrodes and 
1.8% and 0.8% respectively with intracerebral electrodes168. 
Refractory patients with mesial temporal lobe epilepsy associated with hippocampal 
sclerosis are particularly favourable for surgery164. In these patients, class I RCT evidence 
suggests that temporal resection will lead to seizure freedom in around 60% after one 
year169. Numerous RCTs have been performed, all quoting significant seizure improvement 
in 60-80% of patients164. Unfortunately only half of these patients will remain seizure free 
after 10 years, even with commencement of AED treatment7.  
Excision of extra-temporal foci is not as commonly performed and results generally are not 
as good as temporal cases170. One observational study by Kral et al found that 72% of 39 
patients with refractory extra-temporal epilepsy experienced a significant seizure 
improvement, were patients had at worst only 2 seizures per year, after a 50 month average 
follow up period171.  In the same study, 79% of temporal cases had a significant 
improvement of their seizures171.  
2.7.3.1. Neurostimulation 
When drugs and surgery are not successful, or when respective surgery is not indicated, 
neurostimulation may be attempted as an alternative172. Neurostimulation for epilepsy is 
delivered in the following forms: vagal nerve stimulation (VNS), trigeminal nerve 
stimulation, transcranial magnetic stimulation, transcranial direct current stimulation, deep 
brain stimulation (DBS) and cortical stimulation172. The evidence level of these methods 
varies from RCT to experimental pilot studies172. Strong RCT evidence exists for VNS, DBS of 
the anterior thalamus and closed loop stimulation173. In the UK, VNS is recommended by 
NICE guidance for use in adults and children with refractory epilepsy105. NICE suggest that 
when DBS is used, further actions such as informing clinical governance and auditing 
outcomes be performed due to the relative limitations in DBS understanding174.  
Vagus nerve stimulation has proven efficacy and safety172. Seizure improvement, in terms of 
seizure frequency, duration and intensity, seems to start 6-8 weeks after initiation of 
treatment and the effect of seizures will continue to improve after a plateau is reached, 
where in 44% of patients experience a reduction in seizure frequency after 2 years172. A long 
term study from Sweden found that after 5 years, 44% of patients experienced seizure 
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reduction175. A recent series of 90 patients found seizure improvement after 5 years in up to 
64% of patients176. Seizure reduction was complete or over 90% improved in 21% of cases 
and complications were present in 13%176. In vagal nerve stimulation, complications 
include172: 
 Tingling of the throat and hoarseness of the voice 
 Vocal cord paresis 
 Left anterior neck muscle movement 
 Hiccup  
 Cough 
 Shortness of breath of exertion 
 Bradycardia 
 Ventricular asystole 
Despite these potential complications, VNS is well tolerated and stimulation is discontinued 
most often as a result of lack of seizure reduction172.  
2.7.4. Ketogenic Diet 
The ketogenic diet can be used in all refractory epilepsy patients to reduce seizures177. The 
effectiveness of the diet varies in different patient populations177. The diet is usually 
prescribed to children177. In one series of 150 children with frequent generalised seizures 
despite polytherapy on AEDs, 7% were seizure free, 20% had a greater than 90% reduction 
in seizure frequency and 23% had a 50-90% seizure reduction178. Follow up studies 
demonstrate that the effectiveness in reducing seizures is maintained 3-6 years after 
initiation of treatment and that seizure freedom can occur in patients with only a partial 
response to the diet initially177.  Most studies are aimed at generalised epilepsies in children, 
but one study comparing the efficacy of the ketogenic in focal and generalised epilepsy 
demonstrated that the seizure reduction between the two groups was not significant179. 
NICE guidelines recommend that the ketogenic be considered in children and young adults 
with epilepsy that have not responded to AED105.  
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2.8. Prognosis 
2.8.1. Quality of Life  
Epilepsy is a lifelong condition that can impact on most domains of a person’s life; the right 
to drive and the risk of accident has already been mentioned161. QoL is representative of 
overall life satisfaction and both are influenced by all life domains180. It is not surprising 
therefore that patients with epilepsy have a reduced QoL138.  
It is widely quoted that the quality of life of children with epilepsy is poorer than that of 
children in the healthy population, but this statement may not be generalizable to all 
children with epilepsy181,182. Studies that have shown significant differences in QoL between 
patients and controls recruited patients that either had refractory epilepsy or a significant 
proportion of severe neurological comorbidities183,184. One study compared the quality of 
life of 31 children with well controlled epilepsy and healthy controls185.  Apart from 6, all of 
the epilepsy children were seizure free and off medication185. There was no significant 
difference found in the quality of life of either groups and this could be due to the genuine 
wellness of the epilepsy cohort, or due to reduced sensitivity to poor quality of life because 
of low sample size or the use of an inappropriate tool; the QoL questionnaire used was 
designed for children with short stature172.  Predictors of poor QoL in children include181: 
 Older age 
 Lower socioeconomic status 
 Increased seizure severity 
 Multiple AED use 
 AED neurotoxicity and 
 Co-morbid neurological impairment  
While still complex, the quality of life of adults is far easier to establish and there is a large 
amount of research on the topic. Data from two large population based studies in the USA 
and Canada demonstrate that the quality of life of people with seizures or epilepsy is 
significantly poorer than healthy people and people with other chronic diseases in the 
general population186,187. There was a high proportion of comorbid conditions in the USA 
epilepsy population when compared to the general population and these were: stroke, 
cancer, arthritis, lower neck pain, lower back pain and asthma186. Comorbid medical and 
psychiatric conditions combined can explain 14% of the variance in QoL scores in Epilepsy188.  
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Both studies demonstrated that people with seizures or epilepsy were more likely to report 
lower levels of education, unemployment and physical activity, and increased levels of 
psychological distress and recurrent pain186,187. A study looking at predictive factors for poor 
quality of life in outpatient attendees with epilepsy identified the following as negatively 
predictive189: 
 Increased seizure frequency 
 Lack of Seizure freedom 
 Depressive state 
 Short duration of epilepsy in older persons 
 Temporal lobe epilepsy (through mood and cognition) 
 Young females due to AED adverse effect concerns 
Extending on the point of epilepsy duration, Jacoby and Baker performed a thorough 
literature search to estimate quality of life trajectories for patients with epilepsy at different 
stages of management188. They found that patients with isolated or very few seizures had an 
initial dip in QoL around the time of the event which eventually normalised to that of the 
general population188. Active epilepsy, defined by varying degrees of seizure frequency 
ranging from 1 in 2 years to 1 in 3 months, significantly depresses QoL and the resultant 
trajectory varies by the clinical trajectory that follows188. For example, patients with 
intractable epilepsy were suggested to have peaks and troughs in QoL depending on seizure 
frequency and patients that eventually are seizure free will gradually improve in QoL until 
normalisation188. After epilepsy surgery, QoL will improve towards normal, unless clinical 
outcome is poor188.  Another finding from this review was that the time taken for QoL to 
improve seemed to be 1-2 years for patients with single seizures and 2 years for patients 
with remission after epilepsy treated medically or with surgery188.  
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2.8.2. Epilepsy outcomes 
2.8.2.1. Seizure Reduction 
One of the primary aims in epilepsy management is to reduce the number of seizures a 
patient has. As patients with epilepsy are usually commenced on an AED, the long term 
likelihood of the condition entering remission without intervention is not certain138.  It is 
unethical to withhold medication during prospective studies and retrospective studies are 
hampered by inaccurate data138. One prospective study in Kenya recruited 249 patients with 
epilepsy; for inclusion they needed to have at least 2 witnessed generalised tonic clonic 
seizures and to be started on either carbamazepine or phenobarbitone190. After 6 months, a 
quarter of patients had a significant (50%) reduction of seizures and after a year, 50% of 
patients were seizure free190.  
The minority of patients will develop epilepsy after one seizure, but after a second seizure, 
the risk of further seizures is 75%138. Studies that monitor the effects of delayed treatment, 
like the aforementioned MESS study, help to ascertain the risk of seizures after an AED is 
started163. There is a 20% chance of seizure in the 12 months following commencement of 
AED treatment163. Studies with a longer follow up or observation period demonstrate that 
approximately 65% of patients will eventually enter remission138. After remission, 
approximately 24% of patients in remission will relapse138. The following are found to be 
negative predictors of long term seizure prognosis138: 
 Symptomatic epilepsy 
 Epilepsy associated with Cerebral Palsy and Learning Difficulties 
 Partial Seizures, particularly complex partial 
 Status Epilepticus in childhood 
 Focal slowing of the EEG in childhood 
According to the ILAE, patients with refractory epilepsy should be defined as “failure of 
adequate trials of two tolerated and appropriately chosen and used AEDs to achieve 
sustained seizure freedom for a sufficiently long period of time (page 1076)”191. In this 
definition, a sufficiently long period of time is either three times the longest seizure-free 
period, or one year, whichever is longer191.  
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2.8.2.2. Adverse Effects of AEDs 
Approximately 50% of patients will report adverse effects when started on an AED142. 
Overall adverse effects are unpredictable, but certain drugs have different side effect 
profiles, increased doses are more likely to lead to side effects and pharmacogenetics can 
predict who is at risk; for example, Stevens-Johnson syndrome in an Asian patients with 
HLAB* HLA allele141.  
2.8.2.3. Drug resistance 
Long term observational studies show that 7% of newly diagnosed patients will prove to be 
extensively drug resistant, never achieving one year remission192. A further 15-20% will 
relapse and remit194. It has been observed that a high frequency of seizures before the onset 
of therapy suggests an increased risk of having refractory epilepsy141.  
2.8.2.4. Tolerance 
AED can lose their anti-seizure properties after long periods of administration due to 
pharmacodynamic tolerance193. It is difficult to identify the effect of tolerance on efficacy of 
medication, but studies looking at outcome shifts from responder to non-responder may be 
suggestive193. In Loscher et al.’s review of the literature on tolerance, it was stated that for 
older generation drugs, the transition from responder to non-responder occurs in 7-58%193. 
It is lower for drugs that act predominantly on sodium channels193. For second and third 
generation drugs this same effect occurs in around 25%193. These figures vary by drug193.    
2.8.2.5. Mortality 
When compared to the general population, the standardised mortality ratio (SMR) for 
epilepsy has ranged between 1.6 and 4.1 in hospital and community based studies125. The 
SMR is high in symptomatic epilepsy, ranging between 2-6; and for patients with 
neurodevelopmental problems, it ranges from 11-25138. Predictors of higher SMR include138: 
 Male gender 
 Age: childhood or the elderly 
 Duration of epilepsy (being within few years of diagnosis) 
 Generalised tonic clonic seizures 
 Myoclonic seizures 
The increased mortality in epilepsy can be accounted by the co-morbid condition leading to 
epilepsy, for example stroke, neoplasia and pneumonia, but also by epilepsy related causes, 
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such as SUDEP. According to a 40 year follow up population based study, the overall risk of 
SUDEP was 7% for patients not in 5 year remission and 12% for those who were 
unmedicated194.  
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Chapter 3: Quality of Life 
3.1. Introduction 
It is not difficult to understand the concept of quality of life (QoL). Most people will know 
what QoL represents and can predict the factors that are relevant in its overall assessment. 
Defining QoL and measuring it however, is difficult due to variable opinions on definition, 
the significance of many factors on quality of life and the variability of QoL between subjects 
and indeed within subjects.  
3.1.1. What is Quality of life? 
The constituents required for a good life have been debated and there is a range of 
overlapping models to help describe this concept195,196. Frequently proposed themes 
include, happiness, a sense of purpose, wisdom, creativity, a philosophy of life, achievement 
and the experience of love195. Aristotle argued that all of these components ultimately lead 
to happiness195. Large cross cultural surveys on the perceived importance of life goals 
conclude that happiness is considered to be most important goal, more important than 
good health, a high income, high intelligence, being attractive, experiencing love and finding 
meaning and purpose in life197.  
According to Daniel Haybron, a modern professor in philosophy, there are three parts to 
happiness197: 
 Psychological Happiness; a state of mind involving feelings of joy, serenity and 
affection as a result of hedonic experiences (sensory thrill).   
 Prudential Happiness; a state of mental and physical wellbeing. Life satisfaction (a 
cognitive assessment of happiness or wellbeing) is important in this regard.  
 Perfectionist Happiness; a moral life that is good in all aspects. This is similar to the 
association of virtue as described by the Greek philosophers, Plato, Socrates and 
Aristotle. 
Despite the existence of such theories and concepts, a pragmatic and broad approach is 
adopted in QoL research on account of a lack of clarity, overlap and inconsistency in 
theories196. Reinforcing this point is a systematic review by Bakas et al, which found that out 
of 1,552 articles reviewed on the topic of QoL research in healthcare, only 100 articles 
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mentioned a QoL model180. Furthermore, there was little consensus between studies for the 
model used when one was mentioned180.  
QoL can be defined as “An essentially subjective judgment of the way people perceive 
themselves as contented and happy or otherwise and able to function physically, 
emotionally and socially (page 1)”198. It is important to note that there is no consensus on 
the definition of QoL, which differs especially by field of study199. Most would agree that 
QoL “is a multidimensional construct, encompassing aspects of psychological, social and 
physical well-being (page 24)”199. 
3.1.2. Utilisation of Quality of Life  
The concept of Quality of Life was first mentioned in 1953 by the economist Samuel to 
describe concerns surrounding unlimited economical growth and its negative ecological 
effect200. In the subsequent decades, understanding of QoL grew and its application utilised 
in medicine for identifying patient needs and as an outcome measure for treatment199.  
 
3.1.3. Health Related Quality of Life 
Within the field of medicine, interest in QoL increased in the early 1970’s: possibly as a 
result of the improvement in medical technology; and the need to evaluate quality of life 
when quantity of life increases201. Health related quality of life can be defined as: 
“a concept encompassing a broad range of physical and psychological characteristics and 
limitations, which describe an individual's ability to function and to derive satisfaction from 
doing so (page 24)”199. 
In 1980, the World Health Organisation released an International Classification of 
Functioning, Disability and Health (WHO ICF)180. It has evolved since to the current 2007 
version and lists factors that are important in evaluating wellbeing, health and disability on a 
physical, mental, social and environmental level202. The ICF has since been used for policy 
development, economic assessment and in research203.  
QoL research interest has increased particularly since 1974 as shown in Figure 1 when 
“quality of life” was inserted into pubmed204.  
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3.2. Questionnaires 
QoL is usually ascertained by a questionnaire that is completed by the subject or by an 
examiner196. Numerous health related QoL tools exist and most have numerical values for 
answers where scores can be totalled up and compared between subjects196. Items in 
questionnaires can be split into indicator and causal variables. Indicator variables do not 
necessarily alter QoL but reflect it, while causal variables in theory influence QoL205. 
Recognising the presence, absence and proportion of indicator or causal variables is 
important to establish as both act differently205. In questionnaires with separate domains, 
e.g. physical wellbeing, social wellbeing etc, subscale scores can be calculated207.   
Some questionnaires provide a generalised overview of quality of life and others are more 
specific in teasing out factors specific to a pathology and the complex impairments on 
wellbeing that can result196. General QoL questionnaires have the advantage of producing 
data that can be compared between different patient disease groups196. This also means 
that they may not be sensitive enough to recognise factors that are important in a particular 
patient group196. Disease specific questionnaires are tailored so that particular issues within 
a disease are recognised and reflected by the resultant scores196. These scores are usually 
more sensitive to changes in disease196.  
The choice of using a general or specific questionnaire should largely depends on the group 
of patients studied. In one study comparing general to disease specific questionnaires in 
Figure 1: Pubmed Search; Quality of Life Articles per Year 
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patients with Rheumatoid Arthritis (RA), all questionnaires were able to differentiate 
between severities of RA206. In another comparison study, a general questionnaire was a 
more valid measure of QoL than a disease specific tool in Asthma and was better at 
discriminating between different QoL domains207. On the other hand, a disease specific QoL 
score for Atrial Fibrillation was found to be more sensitive in detecting lower QoL than a 
generic tool208.   
It is advantageous for a questionnaire study to contain aspects of both a general and a 
disease specific questionnaire196. Some questionnaires have been designed with this in mind 
and alternatively some studies use both a general and a disease specific questionnaire196.  
3.2.1. Questionnaire Development 
The creation of a questionnaire is a complex and time consuming process205. The European 
Organisation for Research and Treatment of Cancer’s (EORTC) QoL group have developed 
many QoL questionnaires and have published guidelines for questionnaire development209. 
Below is a summary of the main points in the process209:  
 The questions must be chosen after a thorough knowledge and understanding of the 
target population has been obtained: which can be achieved by reviewing past 
literature; and interviews with patients and clinicians.  
 Once a series of questions have been chosen, the questionnaire will begin a testing 
procedure.    
 A pre-test will be performed, testing the design of the questionnaire and questions. 
A review process with structured interviews will then follow. Preliminary scale 
structures can be hypothesised.  
  A field test will be performed to assess the validity, reliability, acceptability and 
cross cultural application. For this a large multinational cohort of patients must be 
used.   
3.2.1.1. Validity  
The EORTC propose that the sample size needed for the validation of questionnaires is 10 
subjects per question209. Questionnaires need to be valid in terms of the following199: 
 Content: is the questionnaire sensitive to the relevant QoL domains of the tested 
population? 
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 Convergence: does the questionnaire correlate with other similar outcomes? While 
there is no gold standard of life quality in which to validate questionnaires, general 
questionnaires or a single global scale question are used for comparison196,199. In 
disease specific questionnaires, another specific questionnaire may be used, or new 
validation studies using general scales may need to be carried out196.  
 Discriminance: does the questionnaire distinguish between dissimilar constructs?  
 
3.2.1.2. Reliability, Appropriateness and Responsiveness 
Tests of reliability are also important. Can the questionnaire produce the same results when 
repeated? The inter-rater (observer) and test-retest reliability scores for questionnaires 
need to be considered196. While precise levels of reliability required are controversial, the 
EORTC state that a test-retest reliability of 0.70 is regarded as acceptable, while a reliability 
of 0.80 is regarded as good209.  If the tool is required for patient monitoring, the reliability 
needs to be higher than this209.  
 Also, how appropriate is the questionnaire to the study population? Is the time scale, 
format and wording of questions applicable to the study population?196. Furthermore, can 
the tool recognise clinically meaningful changes in QoL when they are present?196. 
3.2.1.3. Other Psychometric Issues 
The ceiling effect may occur when the response to a question has a tendency to skew 
towards an extreme, this can be prevented by adapting the available responses to create 
more variability within the extremes199.  
It is recognised that patients adapt to changes in their physical wellbeing199.  One study 
demonstrating this is of 160 breast cancer patients at least 5 years post-diagnosis210. Their 
QoL was compared to the QoL of a control group, in which no differences of QoL were 
found210.   
In studies using a pre and post-test design, subjects may initially over-estimate their 
wellbeing (response shift)199. This phenomena can be reduced by adding a retrospective 
pre-test after the post-test response has been created, thus ensuring that subjects complete 
both tests with the same internal cognitive standards199. This technique was tested by 
Howard et al, who applied the technique to 33 psychology students and their perceived 
knowledge on a particular class211. He found that there were significant differences between 
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the retrospective pre-test and the prospective pre-test, in which subjects over-estimated 
their knowledge in the prospective pretest211. The same findings were found in a similar 
study by Pohl212.    
 
3.3. Factors Influencing QoL   
It is beyond the scope of this thesis to review the literature on the factors that generally 
influence QoL. Instead, the important influential factors will be mentioned. It is important to 
note that the research presented refers to life satisfaction, happiness or overall wellbeing, 
which influences QoL, but does not necessarily dictate it.  
3.3.1. Population Factors 
On a macroscopic level, economic and political factors are known to effect the general 
wellbeing of a population.  
3.3.2. Economy 
Examples of factors that are important in the wellbeing of a population are economic 
fluctuations, income inequality and unemployment213.  
Between 1991 and 2004, Ireland experienced an economic boom with a 70% increase in 
GNP and reduction in unemployment214. A study using population representative data from 
the Living in Ireland Survey looked at the responses to questions in different domains, 
finding a substantial increase in financial satisfaction and modest increases in work 
satisfaction and mental health as measured by the general health questionnaire (GHQ)214. 
Satisfaction related to housing, leisure activities and most importantly overall health were 
not affected214. 
After a review of the topic, one author concludes that income inequality will reduce the QoL 
of a population overall, particularly for the poor215. Subjects that are employed, over 40, 
with below average incomes and have a recent wage increase tend to have the highest life 
satisfaction ratings215.  
Unemployment is repeatedly shown to reduce the QoL of persons in countries with a higher 
GDP213. A longitudinal population based study asking people to rate their overall life 
satisfaction found that people who are eventually unemployed do not initially have poor life 
satisfaction before the unemployment event, but develop poor life satisfaction which is 
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maintained even if re-employment occurs216. This relationship is complex, with many factors 
such as health influencing unemployment and QoL213.  
3.3.2.1. Political and Cultural Factors 
Studies monitoring the levels of life satisfaction comparing countries with and without 
political unrest have found that life satisfaction tends to increase in countries with low levels 
of corruption and high levels of law and order213. Furthermore, economic freedom is found 
to correlate with increased satisfaction in poor countries, while political freedom correlates 
more strongly in wealthier countries213. But both economic freedom and political freedom 
are thought to be associated with good life satisfaction in the population213.  
3.3.3. Individual Factors Influencing QoL 
3.3.3.1.  Wealth 
Cross-sectional survey studies generally conclude that increasing wealth improves subjective 
wellbeing, but the very wealthy (selected from the Forbes list of most wealthy Americans) 
are not much happier than a control group of wealthy people in a similar area213. This effect 
is mediated by ones perception of comparative wealth213.  
Long term studies demonstrate that as income steadily increases however, this does not 
lead to an increase in satisfaction213. This is explained by an increase in material 
aspirations213.  
 
3.3.3.2. Age 
Long term population based studies suggest that wellbeing follows a U shaped curve relative 
to age, with satisfaction bottoming out in middle age and increasing to the age of 65213. 
After the age of 65 life satisfaction steadily declines, mirroring the perceived reduction in 
health213.  
3.3.3.3. Gender 
Females are usually reported to have higher life satisfaction ratings than males in population 
based surveys, but this finding is not consistent215. Age is an important moderator as middle 
age women report reduced overall happiness than males213. A meta-analysis of 300 studies 
concludes that older females have worse subjective wellbeing than males217.   
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3.3.3.4. Marriage and Family Life 
A literature review of cross-sectional studies concludes that wellbeing is higher in persons 
that are married than not married218. Longitudinal studies however suggest that while 
happiness is increased after marriage, this effect is not long lasting219.  
Subjects that become widowed demonstrate long term reduced life satisfaction ratings. A 
longitudinal study of 15 years suggests that widows have reduced life satisfaction ratings 
that never return to that of their pre-widowed state220. Divorce leads to a more temporary 
reduction in life satisfaction205,213.  
 
3.3.3.5. Health Factors 
Physical health is an important factor in determining quality of life, from a patient or 
population perspective. In a population based survey study, physical health was deemed the 
most important factor that determined happiness221. 
The relationship between health and wellbeing is complex; an individual condition can 
effect varying and numerous QoL domains, but compounding this may be the presence of 
numerous conditions within the individual222. QoL after a cardiac event for example is 
impaired in domains of mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression, while domains affected due to peripheral arterial disease are mobility 
and pain223. In a recent multicentre study of 3000 primary care patients between the ages of 
65 and 85 with multimorbid conditions, it was found that QoL was negatively correlated 
with increased disease severity and disease count222. This study took into account a large 
number of conditions, 45 in total, where previous literature only analysed 29 conditions222. 
Of these 45 conditions, 21 were found to impair quality of life222. Table 5 shows the top 16 
conditions that impacted QoL, ranked by their effect on the EQ-VAS (a 100 point overall 
wellbeing visual analogue scale)222. 
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Table 5: Medical Conditions that Significantly Reduce QoL According to 
Reductions in EQ-VAS Score222 
Disease Drop in EQ-VAS (total score 
100) 
Parkinson’s disease (-12.29) 
Rheumatism/CPA (-5.56) 
Depression (-5.33) 
Obesity (-4.33) 
Cardiac insufficiency (-4.19) 
Neuropathies, asthma/COPD, 
osteoporosis, chronic low back pain, 
coronary heart disease, insomnia and 
urinary incontinence. 
significant negative effects on 
HRQL 
 
An inverse link between disease count and QoL has been shown in studies with younger 
populations222. Meta-analyses find moderate but consistent correlations between physical 
health and overall wellbeing; this finding is stronger in females than males213.  
3.3.3.6. Sleep 
Lack of sleep is known to negatively influence the body and mind. In a study of 502 
community residents, those with poor sleep were found to be impaired in various domains 
of wellbeing224. The relationship between sleep duration and health follows a U shaped 
curve224. One large scale epidemiological study associated low mood and social isolation to 
persons who on average achieved less than 7 hours and more than 9 hours of sleep in a 24 
hour period225. This U shaped relationship between sleep duration and impaired health has 
been reproduced in many epidemiological studies224. A causal direction has not been 
established, but it is likely that the association between sleep and wellbeing is bi-
directional225.   
3.3.3.7. Summary 
Quality of life is a multidimensional concept with complex interrelationships between 
physical, psychological and social factors. In order to appreciate a person’s quality of life in 
the context of epilepsy and meningioma, an understanding of these two conditions and the 
combination of these conditions is required.  
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Chapter 4: Epilepsy and Meningioma 
4.1. Introduction 
The epileptogenic potential of meningioma is well recognised. In 1935, Robert Groff 
published his series of 291 resected meningioma patients describing their association with 
epilepsy226. Of these patients, 114 experienced seizures of various type, frequency and 
prognosis226. Among his observations, he found that epilepsy often predated neurological 
impairment, that meningiomas of the parietal, frontal and temporal lobes were particularly 
epileptogenic, that seizures can develop after surgery, that surgery can relieve seizures and 
that seizures can recur after a long period of remission with no evidence of tumour 
recurrence226. Of those experiencing seizures, 50 died prematurely within the average 
follow up period of 4 years226. While the causes of death in these patients may not be 
seizure related, it is important to note that epilepsy has a significant effect on the outcome 
of meningioma226.  
 
4.2. Epidemiology 
4.2.1. Epilepsy in Meningioma 
Not many studies have focused on the incidence of epilepsy in meningioma227. In the 
literature, the proportion of patients with seizures as the first symptom ranges between 20 
and 50%227. In Lieu et al.’s retrospective analysis of 222 surgically treated meningiomas, 59 
(26.6%) presented with epilepsy and 30 (13%) presented postoperatively227. This data 
suggests that at least 40% of meningioma patients will develop seizures around the time of 
diagnosis and within a relatively short follow up period§227. Similar percentages of pre and 
postsurgical epilepsy have been found in other recent studies228,229. The majority of studies 
conducted between 1930 and 1980 find that the proportion of patients with epilepsy pre-
operatively is greater than 60%230,231.  The proportion of patients developing epilepsy post-
operatively however, is comparable to that of recent studies230,231. One explanation for this 
is the increased availability of advanced imaging techniques after 1980, leading to an earlier 
diagnosis of meningioma and thus a reduced risk of developing seizures. 
                                                     
§
 Maximum follow up period for patients with epilepsy was 12 years and the minimum was 1 year in this study 
looking at the prognosis of meningioma patients
227
.   
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4.2.2. Meningioma in Epilepsy 
Brain tumours are responsible for 6-10% of all epilepsy cases and 12% of acquired epilepsy 
cases232. Meningiomas receive little mention in the epilepsy literature, whereas gliomas are 
frequently reported104,109,110,233. In one prospective population based study of epilepsy, 
brain tumours were found in 11% of cases: 71% of brain tumours were primary and at least 
71% of the primary tumours were glioma234. Perhaps the reason meningiomas are not 
mentioned is they account for one fifth of intracranial tumours and are less epileptogenic 
than benign gliomas235. In one study of parietal tumours and epilepsy, meningiomas were 
found accountable for seizures in 14% of cases236.   
4.3. Associated Factors with Epilepsy 
There are no gender differences associated with the occurrence of epilepsy in 
meningioma227. Preoperative epilepsy is more common in meningioma patients who are 
aged between 50 and 60, but this finding was not statistically significant in Lieu et al.’s 
study227.  
Location of the meningioma is important in the development of epilepsy, with an increased 
incidence associated with supratentorial tumours and more specifically the convexity, 
sphenoid wing parasagittal and falx regions227,237. The parietal lobe is most often quoted as 
the lobe most associated with epilepsy in meningiomas, but there is variation in the 
literature227,237. A recent 3D magnetic resonance imaging (MRI) study of 44 pre-surgical 
supra-tentorial meningioma patients found the premotor cortex of the frontal lobe to be 
associated with the highest incidence of epilepsy238.  
The histological type of meningioma  is usually not associated with significant differences in 
epilepsy incidence227,237. Peri-tumour oedema is significantly associated with the 
development of epilepsy in Lieu et al.’s study227. Around 40% of patients with oedema 
developed epilepsy, as opposed to 20% of patients without oedema227. The MRI study by 
Hamasaki et al found that the absence of oedema was a significant finding for their non-
epilepsy group238. Patients experiencing seizure freedom after surgery varies between 19% 
and 64%227.  
Factors associated with the development of seizures postoperatively include: pre-operative 
seizures, peritumoural and cerebral oedema, brain retraction, interruption of cortical veins, 
arterial damage and Simpson’s grade of resection227.  
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While informative, studies looking at the associated factors leading to epilepsy are limited. 
One recent retrospective study observed the seizure outcomes of 626 surgically resected 
supratentorial meningiomas and summarised the limitations of the literature in the 
following way239: 
 Studies lacked a uniform population (infratentorial, paediatric, different grades) 
 Lack of multivariate analysis 
Their study had a uniform population and a multivariate analysis was performed. The 
factors significantly associated with preoperative seizures after multivariate analysis were 
Karnofsky Performance Score (KPS) <80, absence of headaches and vasogenic oedema. Less 
significant factors associated with pre-operative seizures were male gender and larger 
tumours. Significant factors for the continuation of post-operative seizures were 
uncontrolled pre-operative seizures, parasagittal and sphenoid wing tumours. 
4.4. Pathophysiology 
4.4.1. Epilepsy in Brain Tumours 
The following are thought to influence the development of epilepsy in brain tumours232,237: 
 disruption of neuronal connections and inhibition of local network regulation 
 Neuronal, axonal and synaptic plasticity, i.e. neuronal generation, axon collateral 
sprouting and neosynaptogenesis 
 impaired glial cell activity 
 increased vascular permeability 
 abnormal function of the blood brain barrier  
 peritumoral oedema  
 inflammation 
 necrosis  
 hemosiderin deposition 
 disequilibrium of neurotransmitters, ions and amino acids  
Some tumours vary in their basic epileptogenic actions232. Glioma for example are 
infiltrative, while meningiomas disturb the cortical surface232. The development of epilepsy 
in brain tumours is multifactorial232.  
4.4.2. Meningioma Specific Factors 
Peritumoural brain iscahemia is one factor thought to be important in meningiomas and this 
would partly explain the correlation between oedma and the development of epilepsy232,237. 
It would also be expected that size of the tumour, degree of mass effect and necrosis and 
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the location of the tumour would correlate with the development and location of the 
epileptogenic foci237. As this is not always the case, it is clear that other factors are 
significant237.  
While denervation of surrounding cortex is a significant epileptogenic factor, meningiomas 
usually distort the surrounding cortex and influence an increase in connectivity237. 
Dysequilibrium of ions, neurotransmitters and amino acids is also thought to be influencial 
in meningioma and epileptogeneis237.  
Histological studies of peritumoural cortex provide further evidence to the epileptogenesis 
of meningiomas237. Significant differences in the levels of size, distribution and number of 
presynaptic neurones could lead to increased release of excitatory neurotransmitters237. 
4.5. Treatment 
There is a desire to prevent seizures, they can lead to aspiration, brain injury, trauma and 
brain oedema240. In meningioma, anti-epileptic drugs (AEDs) are widely used in this regard 
but the evidence base behind this is poor.  
4.5.1. Prophylaxis 
Neurosurgery is known to promote seizures as a result of brain retraction, cortical irritation, 
hydrocephalus, oedema, or infection241. But despite this there is no data to suggest that all 
meningiomas should receive seizure prophylaxis around the time of surgery. In a recent 
systematic analysis of 698 supratentorial meningioma patients from 19 studies containing 
AED prophylaxis outcomes, no early or late seizure benefit was found between treated and 
non-treated populations241. This does not mean that patients should not receive 
prophylactic treatment. The analysis excluded patients with pre-operative seizures, a strong 
risk factor for developing post-operative seizures. Therefore, the use of prophylactic AEDs 
may be considered in cases where there is a high seizure risk241. 
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4.5.2. Long Term Pharmacotherapy 
Studies of seizure control and characteristics are few and limited239. One recently published 
study observed the seizure outcomes of 626 surgically resected supratentorial 
meningiomas239. Patients with seizures were treated with the following AEDs: 
 Phenytoin 52% 
 Levetiracetam 26%,  
 Divalproex sodium 11% 
 Carbamazepine 11% 
 Lamotrigine 2% 
 Phenobarbital 2% 
 
Patients were followed up and their seizure frequency recorded with the Engel242 
classification: 
 class I: seizure-free. 
 class II: rare seizures. 
 class III: meaningful seizures. 
 class IV: no seizure improvement or worsening 
The majority of patients were seizure free with AED treatment. The distribution of patients 
across Engel scores after 12 and 48 months is included in Table 6.  
Table 6: Seizure Outcome Classified by Engel Score 12 and 24 Months Post 
Meningioma Resection239 
 
 
 
 
As mentioned previously, adverse post-operative seizure prognosis is associated with 
uncontrolled pre-operative seizures, parasagittal and sphenoid wing tumours239. Choice of 
AED was not found to influence seizure outcomes239. 
Another retrospective study has observed that AED withdrawal in meningioma results in 
seizure recurrence for 9% of patients, which is less than that observed in non-tumour 
patients with epilepsy243.  
Engel Score 12 Month (%) 48 Month(%) 
1 82 90 
2 5 3 
3 7 0 
4 5 7 
59 
 
4.6. Prognosis 
While mortality is not increased when epilepsy and meningioma occur concurrently, 
morbidity may be synergistically affected80. A recent study comparing neuro-cognitive 
function of meningioma patients to healthy controls, found that meningioma patients 
experienced significant deficits in all domains tested after an average follow up period of 3.4 
years; domains tested were: executive functioning, verbal memory, information processing 
capacity, attention, psychomotor speed and working memory244. Patients that also had 
epilepsy, had significantly worse executive functioning and psychomotor functioning and 
this was attributed to higher epilepsy burden and the use of AED244. Another study also 
found that quality of life (QoL) was impaired in patients with meningioma and epilepsy, this 
will be discussed in the next section.  
 
4.7. Epilepsy Meningioma and Quality of Life 
Minimal research has been conducted on the quality of life of those with epilepsy due to 
meningioma245. To demonstrate this, a literature search was performed.  
4.7.1. Literature Search 
The following search terms were entered into PubMed (MEDLINE): 
“(epilep* OR seizure*) AND (quality of life OR qol OR wellbeing OR health) AND 
(meningioma)” 
This generated 11 results. Only three articles were relevant to the topic of QoL in 
meningioma due to epilepsy and written in English: 
1. Seizure Control for Patients Undergoing Meningioma Surgery239.  
2. Long-term impact of cognitive deficits and epilepsy on quality of life in patients with 
low-grade meningiomas245. 
3. Factors influencing morbidity and mortality after cranial meningioma surgery-a 
multivariate analysis85.   
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4.7.2. Literature Review 
Seizure Control for Patients Undergoing Meningioma Surgery239 
This is a retrospective analysis of 626 post surgery meningioma patients, 84 of which 
presented with seizures. The authours found that patients with epilepsy were three times 
more likely to have a reduced KPS (<80). KPS is a 100 point measure of physical functioning. 
While physical functioning is an important element of quality of life, it does not correspond 
to overall QoL246. 
Long-term impact of cognitive deficits and epilepsy on quality of life in patients 
with low-grade meningiomas245 
Waagemans et al looked at the effect of cognitive defects and epilepsy on long term QoL in 
89 low grade meningioma patients after neurosurgery. They found that QoL as measured by 
the SF-36 (an overall QoL instrument) was significantly impaired by cognitive dysfunction or 
AED use. The authours concluded that epilepsy reduced quality of life as a result of cognitive 
deficits via AEDs. This study was limited by a small sample size; AED use was found in only 
23 patients and only 11 patients had seizures in year prior to participation. In addition to 
this, epilepsy’s effect on QoL was not the primary outcome of the study.  
Factors influencing morbidity and mortality after cranial meningioma surgery-a 
multivariate analysis85 
This study performed a multivariate analysis on 385 post-surgical meningioma patients. 
Seizures were found to influence the post-operative KPS score, but had no bearing on QoL, 
which was only significantly impaired by cranial nerve disturbances.  
4.7.3. Discussion 
There is a lack of literature focussing on the impact of epilepsy and meningioma on QoL. 
Studies that mention both factors have a low sample size of participants with epilepsy, do 
not use an appropriate QoL tool, or look at too few epilepsy related variables. Within 
research establishing quality of life factors and meningioma, the main focus has been to 
establish quality of life after surgery and or radiotherapy by using a variety of self-reported 
and operator dependent questionnaires. These studies either do not measure seizure 
outcomes or use a tool that measures functioning, such as the KPS.  
In summary, the role that epilepsy may have in influencing the QoL of meningioma patients 
is poorly understood and understudied. Clinically this is significant as many patients with 
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meningioma will develop epilepsy and QoL is an important factor when considering how to 
manage seizures. More specifically, it is important to know: whether or not AEDs should be 
commenced; what the treatment aims are; how aggressively should treatment be 
administered; and their impact on QoL. In addition to this, it is important that clinicians are 
able to counsel patients about the effects of meningioma and epilepsy on life. When 
considering the wider population a disease specific understanding of QoL is important so 
that inter-disease comparisons can be made for resource allocation.  
An understanding of meningioma, epilepsy and QoL is also important for guiding research, 
particularly by identifying factors that are influential with QoL. Future studies will benefit by 
focusing on factors that are important to QoL in patients with meningioma or epilepsy.  
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Chapter 5: Methods 
5.1. Aims  
The overall aim of this thesis is to conduct an observational pilot study that examines the 
relationships between meningioma, epilepsy and quality of life (QoL). The aims of this study 
are: 
1. To assess the impact of epilepsy on QoL in meningioma patients by comparing 
meningioma patients with epilepsy to those without. 
2. To assess the additional impact of meningioma in patients with epilepsy by 
comparing meningioma patients with epilepsy to matched epilepsy patients without 
meningioma. 
3. To assess the influence of patient characteristics on QoL in these groups.  
5.2. Hypothesis 
The primary hypothesis is that meningioma patients with epilepsy will have QoL scores that 
are more impaired than the scores of meningioma patients without epilepsy. 
The secondary hypothesis is that meningioma patients with epilepsy will have QoL scores 
that are more impaired than the scores of epilepsy patients without meningioma.  
5.3. Overview 
This study was conducted at the Walton Centre NHS Foundation Trust between November 
2012 and August 2013. Patients with meningioma and epilepsy were identified and assessed 
for study eligibility. Eligible patients were invited to participate by post and those that 
responded were included in the study. Study participants were then posted QoL 
questionnaires. Once a completed questionnaire was obtained, the case-notes of that 
participant were reviewed and when all a full dataset was obtained, the data analysis began. 
5.4. Permissions and Ethical Approval 
Approval from the Walton Centre NHS Foundation Trust Research and Development 
department was requested and obtained in October 2012. Full ethical approval was 
obtained from the NHS National Research Ethics Service (NRES) North West committee in 
November 2012 after completion of requested amendments to the patient information 
leaflets. Approval letters are included in appendix II.  
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5.5. Participants 
5.5.1. Meningioma Patients With and Without Epilepsy 
5.5.1.1. Selection 
When selecting meningioma participants for inclusion, tumour grade, tumour location, time 
since surgery, aetiology of meningioma, diseases of cognition and the presence of other 
intracranial tumours were considered with the aim of reducing heterogeneity.   
High grade meningiomas are rare and are more likely to impair QoL. Extracranial 
meningiomas were not of interest in this study and meningiomas of the posterior fossa are 
not likely to produce seizures. Surgery is known to impair quality of life and this is 
particularly true for intracranial surgery.  In the vast majority of patients there is no known 
trigger or aetiological factor in the development of a meningioma. For a small proportion of 
patients, meningiomas are secondary to neurofibromatosis type 2 (NF2), which renders 
patients susceptible to multiple lesions. Finally, patients with severe cognitive difficulty may 
find it difficult to comprehend and answer questions accurately about QoL and patients with 
other intracranial tumours will also have a significantly impaired quality of life. 
The following selection criteria were applied when constructing the meningioma sample.  
Inclusion Criteria: 
 Benign World Health Organisation (WHO) grade 1 meningioma 
 Supratentorial meningioma 
 Minimum 6 months post-op 
Exclusion criteria 
 WHO grade 2 or 3 meningioma 
 Infratentorial meningioma 
 Intracranial surgery occurring within 6 months of participation date 
 Formally diagnosed NF2 
 Formally diagnosed dementia or learning difficulties 
 Other intracranial tumours that are not meningioma 
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Meningioma patients were separated into two groups by the presence of epilepsy: 
meningioma with epilepsy and meningioma without epilepsy. Patients were placed into the 
meningioma with epilepsy group if they experienced at least two seizure episodes, or one 
seizure episode for which anti-epileptic drug (AED) therapy was commenced. One seizure 
episode is defined as the occurrence of any number of seizures within a 24 hour period7. 
5.5.1.2. Recruitment 
Meningioma patients who underwent surgical resection after January 2002 were identified 
by searching the hospital’s pathology department’s histopathology database. This resulted 
in the identification of 590 meningioma patients. The case notes of each patient were 
reviewed to ensure that the selection criteria were met. The histology records were also 
reviewed to ensure that patients diagnosed before the recent revisions of the WHO grading 
criteria would still be classified as grade I after the revision. Furthermore, patient details 
were checked against a central NHS database to obtain the most up to date postal details 
and alive/dead status.  
At the end of this process 350 patients were suitable for inclusion. These patients were 
invited to participate.  
5.5.2. Epilepsy without Meningioma 
5.5.2.1. Selection 
The epilepsy without meningioma group was matched to the meningioma group by sex, age 
(±5 years) and duration of disease (±3 years). The bracketed cut offs were deemed 
appropriate for balancing practicalities with robustness of matching.  
With regards to patient selection: epilepsy classification, disorders of cognition, presence of 
tumours and intracranial surgery were considered.  
Structural epilepsies as opposed to genetic or unknown causes of epilepsy are most 
comparable to epilepsy in meningioma.  Disorders of cognition, the presence of intracranial 
tumours (including meningioma) and intracranial surgery were excluded. Lesions that are 
known to be benign, such as angiomas, were not excluded.  
 
The definition for epilepsy was the same as that used in the meningioma group. The 
selection criteria for the epilepsy group were as follows.  
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Inclusion: 
 Focal epilepsy   
 Epilepsy of symptomatic and cryptogenic aetiology 
 Matched by age, sex and duration of disease 
 Meets requirements for epilepsy definition 
Exclusion: 
 Primary generalised seizures 
 Known idiopathic epilepsy  
 Intracranial surgery occurring within 6 months of screening for study 
 Formally diagnosed dementia or learning difficulties 
 Non-benign Intracranial tumours  
 
5.5.2.2. Recruitment 
To identify patients for the epilepsy without meningioma group, a bank of epilepsy patients 
was created by filtering the hospitals electronic clinic database for clinic codes and disease 
codes specific to epilepsy. These codes are based on the International Classification of 
Diseases (ICD)10. Meningioma patients from the meningioma with epilepsy and 
meningioma without epilepsy groups were then matched to several age, sex and disease 
duration epilepsy patients by filtering the epilepsy bank by these three characteristics. This 
process generated a list of possible matches, in which the case notes were reviewed until a 
suitable epilepsy participant that met the selection criteria was found.  
When this process failed to identify a suitable participant, the bank was filtered again but 
for similar as opposed to equal ages (±5 years) and disease durations (±3 years). Difference 
in disease duration was considered to be more significant for influencing QoL and so the 
repetition of the filtering process was performed with a particular rank in mind. This rank is 
tabulated below (Table 7).  
Some members of the epilepsy without meningioma group previously experienced a period 
of remission in which they had no seizures for a significant period of time (>10 years). For 
these patients, disease duration was taken from the year that epilepsy recurred. 
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Table 7: Match Ranking Guide for the Selection of Epilepsy without Meningioma 
Patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When the list of matched epilepsy without meningioma patients was created, their details 
were also cross checked against the central NHS database for recent addresses and 
live/dead status.  
 
 
 
 
 
 
 
Rank Age (± years) 
Disease 
Duration 
(± years) 
Sex 
1 0 0 Exact 
2 1 0 Exact 
3 2 0 Exact 
4 3 0 Exact 
5 4 0 Exact 
6 5 0 Exact 
7 0 1 Exact 
8 1 1 Exact 
9 2 1 Exact 
10 3 1 Exact 
11 4 1 Exact 
12 5 1 Exact 
13 0 2 Exact 
14 1 2 Exact 
15 2 2 Exact 
16 3 2 Exact 
17 4 2 Exact 
18 5 2 Exact 
19 0 3 Exact 
20 1 3 Exact 
21 2 3 Exact 
22 3 3 Exact 
23 4 3 Exact 
24 5 3 Exact 
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5.6. Outcome Measures 
5.6.1. QoL Questionnaires 
Three questionnaires provided the quality of life data for this study. It was decided that a 
mixture of general and disease specific measures were used. Many questionnaires were 
considered, but the following three were chosen for their ease of application and scoring, 
their widespread use and their use in meningioma and epilepsy studies. All questionnaires 
are included in appendix IV.  
5.6.1.1. SF-36 
The short form 36 (SF-36) is a 36 item general QoL measure that has been widely used in 
numerous disease populations, including that of meningioma and epilepsy245. It has 
undergone numerous validation studies and has been validated for use as a self-
administrated postal questionnaire in the United Kingdom (UK)247. The SF-36 can be 
administered in 5-10 minutes248. The output of the SF-36 is organised into 8 subscales which 
are summarised by two general scores, one for physical health and another for mental 
health. This is shown in Table 8. 
Table 8: SF-36 Subscale Categories and Summary Scores 
Subscales Summary Score 
Physical 
Functioning 
(PF) 
Role Physical 
(RP) 
Bodily Pain 
(BP) 
General 
Health 
(GH) 
Physical  Health 
Summary (PCS) 
Vitality (VT) 
Social 
Functioning 
(SF) 
Role 
Emotional 
(RE) 
Mental 
Health 
(MH) 
Mental Health 
Summary 
(MCS) 
 
The SF-36 provides scoring software that transforms subscale and summary scores so that a 
mean of 50 and standard deviation of 10 is representative of normal QoL248. The algorithm 
behind these transformations uses data from a healthy US population to define normal QoL.  
For this study, minimally important changes have been defined as a difference of 3.0 points 
in PCS and 4.6 points in MCS249. These figures are based on mean QoL changes seen within 
epilepsy patients over a period of time249. Minimally important changes in other conditions 
can range from 0.5 to 5.0 in PCS and 2.5 to 6.6 for MCS, with more severe conditions 
requiring larger changes250.   
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5.6.1.2. FACT-BR 
The Functional Assessment of Cancer Therapy-Brain questionnaire (FACT-BR) is a disease 
specific questionnaire. It can be considered in two parts: the FACT-G, which is a general tool 
within the context of cancer and the FACT-BR which is specific to brain cancer patients. The 
only difference in these forms is the addition of a brain cancer subscale (BRCS) to the FACT-
BR. The FACT-BR is split into 5 subscales that lead to one summary score. The FACT-G is split 
into 4 subscales that form one summary score. This is demonstrated in Table 9.  
Table 9: FACT-BR Subscale Categories and Summary Scores 
Subscales 
Summary 
Scores 
Physical 
Wellbeing 
(PWB) 
Social/Family 
Wellbeing 
(SWB) 
Emotional 
Wellbeing 
(EWB) 
Functional 
Wellbeing 
(FWB) 
NA
a FACT-G 
Total 
Physical 
Wellbeing 
(PWB) 
Social/Family 
Wellbeing 
(SWB) 
Emotional 
Wellbeing 
(EWB) 
Functional 
Wellbeing 
(FWB) 
Brain 
Cancer 
(BRCS) 
FACT-BR 
Total 
a
BRCS not used for FACT-G  
 
Both versions of the form can be completed in 10-15 minutes. The FACT-BR and FACT-G 
have been used in meningioma previously and both are validated as self-administered 
tools88,251.  
On the FACT-BR, no healthy normal scores are available, but in patients with primary brain 
cancer the mean FACT-BR score is 136 (SD = 26). In this study, a meaningful difference for 
the FACT-BR total score has been defined as a minimum of 9.2 in the total score252. 
Recommended minimal changes specific to the FACT-BR are not available, so this value was 
created on the information provided by Ringash J et al on estimating important differences 
in brain cancer patients252.  Recommended changes for subscales have been estimated in 
brain cancer patients as 5-7 for BRCS and 2-3 for all other subscales253.  
The normal score of the FACT-G has been defined as 80.1 (SD = 18.1) with reference to a 
healthy US population254. A minimally important change on FACT-G has been defined as 3 to 
7 points in patients with a primary brain tumour251.  
5.6.1.3. AEP 
The Liverpool Adverse Events Profile (AEP) is designed to detect common central nervous 
system side effects related to anti-epileptic medications255. Anti-epileptic drugs are known 
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to influence the QoL of patients and studies in meningioma suggest that this also may be the 
case for meningioma patients245. Each individual item on the AEP can be considered as an 
output, or the scores can be summated into one summary score. The AEP is a validated tool 
that is suitable for self-administration256.  
The mean total AEP score in epilepsy patients is usually between 37 to 39257,258. In this 
study, an overall change of 11 points on the AEP is defined as clinically significant245. This 
figure is based on clinical change in patients with temporal lobe epilepsy.    
 
5.6.2. Missing Data  
The FACT-BR categorises items into subscale scores by adding each item within the subscale. 
If less than 50% of items within a subscale are missing, the following formula can be used to 
create a prorated subscale score: 
Prorated subscale score = ([Sum of item scores] x [N of items in subscale])   [N of items answered] 
If more than 50% of items within a subscale are missing, the subscale and thus the total 
scores cannot be calculated. 
The SF-36 is more sophisticated in the handling of missing data. The physical functioning 
subscale score is estimated by a model that utilises item response theory when missing data 
are present248. This IRT based model did not improve the missing data estimation for the 
remaining subscales. Instead, a subscale score is estimated by taking the mean of the 
subscale scores and inserting this into the missing item. If a subscale score cannot be 
estimated, a total summary score can still be calculated with the use of a regression model 
and the remaining scales. To calculate PCS, the PF subscale and a total of 7 subscales must 
be present. For MCS, the MH subscale and a total of 7 subscales must be present.  
Participants with computed total scores on the SF-36 and FACT-BR will be put forward for 
analysis.  
The AEP is a simple questionnaire with no subscales. When an item is missing on the AEP, 
simple mean imputation on a group by group basis was used to replace the missing item. 
For example, missing items from cases within the meningioma with epilepsy group are 
replaced by the average score of an item within the meningioma with epilepsy group. A 
maximum of three missing items per case was tolerated for inclusion into the analysis.  
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5.6.3. Clinical characteristics 
Patient demographics and clinical factors potentially influence quality of life. Details related 
to demographics, comorbidities, the meningioma and epilepsy were collected in this study 
to account for confounding factors and to provide insight into their factors that have 
influence on QoL. These variables and the intended collection style are tabulated in Table 10 
below. 
Table 10: Variables Considered for Data Collection and Data Input Style 
Category Independent Variable Data Input 
Demographics 
Age Years 
Sex Male or Female 
Employment Status As Employment Questionnaire 
Comorbidities 
# Comorbidities Number 
Named Comorbidity Free-text 
Meningioma 
Time since Surgery Number 
Tumour Location Free-text 
Lobe Affected Free-text 
Tumour Recurrence Yes or No 
Simpson Resection Grade 1-5 
Radiotherapy Yes or No 
# Meningioma Symptoms Number 
Named Meningioma Symptoms Free-text 
Epilepsy 
Time since first Seizure Years 
Time since first AED Years 
First AED Free-text 
Current AEDs Free-text 
# AEDs Number 
Seizure Frequency As Epilepsy Questionnaire 
Seizure Type Focal / Dyscognitive / Bilateral 
Cause of Epilepsy Free-text 
 
Seizure frequency, AED use and employment status was obtained from patients directly via 
supplementary questions placed on the end of the AEP. These are included in appendix IV. 
All other variables were collected from the patient notes.  
 
 
 
71 
 
5.7. Points of Contact  
Three documents were posted to eligible patients as a first contact: 
 A cover sheet summarising the study and the purpose of the postal contact 
 A detailed patient information sheet explaining the study in simple terms (specific to 
each patient group) 
 Consent form 
These forms are included in appendix III. Patients were given a pre-paid envelope and 3 
weeks to return their consent form. In the case of non-responders, a telephone call was 
made to ensure the correct address had been used so that further effort can be made in 
maximising participation numbers. 
Once a consent form was received, the three questionnaires and a supplementary sheet 
were sent to participants and a prepaid envelope was provided.  
 
5.8. Data Analysis 
All questionnaire data and data relating to patient characteristics were inserted into excel 
spread sheets. When data collection was complete the questionnaires were scored and all 
data were transferred to a statistical software package. SPSS version 20 was used to 
perform all statistical analyses.  
The analysis was split into three parts: descriptive statistics; quality of life mean score 
comparisons; and quality of life regression analysis. The dependent variables in this study 
were the total scores and subscale scores of the questionnaires. Independent variables were 
all the clinical characteristics stated previously.  
Students t-tests were used to compare means and chi squared and Fisher’s exact t-tests 
were used to compare frequencies. Significance was set at the p = 0.05 level for all analyses. 
Levenes test for equal variances was used where appropriate.  
5.8.1. Descriptive Statistics 
The differences in patient characteristics and response rates were identified and 
appropriate statistical tests applied to look for significant differences between the three 
patient groups. The null hypothesis for each of these tests is that there is no difference in 
characteristic between groups.  
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Patient groups were compared in the following manner: 
1. Meningioma with epilepsy versus meningioma without epilepsy 
2. Meningioma with epilepsy versus epilepsy without meningioma 
Only the statistical details of significant results are fully reported.  
5.8.2. QoL Mean Score Comparisons 
The SF-36, FACT-BR and AEP measure QoL on ranked Likert scales. This is ordinal data but it 
was assumed to be continuous and each ordered point was assumed to be equidistant. 
These assumptions are believed to be robust in the presence of large sample size259.   
A preliminary data analysis was performed to identify cases with missing data, to assess the 
reliability of the questionnaires and to decide if parametric techniques can be applied to the 
dataset for the comparison of means.  
After this, the mean scores of each subscale and summary measure were compared 
between groups in the same pairsspecified for the descriptive statistics analysis. Only the 
significant statistical results are reported. 
5.8.3. Regression Analysis 
Univariate regression analysis were performed between all independent variables and all 
the questionnaire summary scores as an exploratory analysis. Multiple hierarchical linear 
regression models were created for two pooled groups and for each dependent variable, as 
demonstrated in Table 11. Eight regression models were created in total. The dependent 
variables were assumed to be continuous.  
 Table 11: Group and Questionnaire Plan for Regression Analysis 
 Groups 
Meningioma without Epilepsy 
and Meningioma with Epilepsy 
Meningioma with Epilepsy and 
Epilepsy without Meningioma  
Dependent 
variables 
PCS PCS 
MCS MCS 
FACT-BR TOTAL FACT-G 
AEP AEP 
 
Independent variables inserted into the multiple regression models were chosen on the 
basis of the univariate analysis, Pearson correlations and theoretical considerations.  More 
details are included in the results chapter.  
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Chapter 6: Results 
6.1. Descriptive Statistics 
 
6.1.1. Responders 
The first patients were identified for inclusion in March 2013 and the last questionnaire was 
received by July of the same year. Table 12 summarises the response rates in the study. The 
epilepsy without meningiomagroup was significantly worse at responding than the 
meningioma with epilepsy group (X2 (1, n = 486) = 24.31, p < 0.001) and the meningioma 
with epilepsy group were significantly worse at responding than the meningioma without 
epilepsy group (X2 (1, n = 350) = 3.90, p = 0.048). 
Table 12: Participant Response Rate 
                                      Groups  
Meningioma 
Without 
Epilepsy 
Meningioma 
with Epilepsy 
Epilepsy 
without 
Meningioma 
Total 
Count Percent Count Percent Count Percent Count Percent 
Total 
Eligible 
211 - 139 - 347 - 697 - 
Non-
Responder 
80 37.90% 72 51.80% 260 74.90% 412 59.10% 
Drop Out 
After 
Consent 
22 10.40% 11 7.90% 23 6.60% 56 8.00% 
Study 
Participant 
109 51.70% 56 40.30% 64 18.40% 229 32.90% 
 
6.1.2. Demographics 
Table 13 summarises the demographics of each group.  
6.1.2.1. Age 
The mean age of the study population was 59.9 (± 12.2) years.  For the meningioma without 
epilepsy and meningioma with epilepsy group, the mean age was 60.3 (± 12.0) and 61.2 (± 
11.2) respectively. The mean age in the epilepsy without meningiomagroup was 57.9 (± 
13.2). There is no statistically significant difference between the mean age of the 
meningioma with epilepsy group compared to the meningioma without epilepsy group and 
the epilepsy without meningioma group (p > 0.05).  
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6.1.2.2. Gender 
The majority of participants were female (80.8%). In the meningioma without epilepsy 
group and epilepsy without meningioma group the proportion of female participants was 
85.3% and 81.2% respectively. The proportion of females was lowest in the meningioma 
with epilepsy group (71.4%). The differences in gender between the meningioma with 
epilepsy group and the other groups are not significant (p > 0.05).  
6.1.2.3. Employment 
The majority of participants across all groups were retired (43%). Thirty-two percent of 
participants were employed and 17% of participants were unemployed. There was no 
significant difference in employment status between the meningioma with epilepsy and the 
other groups (p > 0.05).  
Table 13: Group Demographics 
    Meningioma 
without 
Epilepsy 
(n=109) 
Meningioma 
with Epilepsy 
(n=56) 
Epilepsy 
without 
Meningioma 
(n=64) 
Total 
(n=229) 
 Characteristics 
  
Mean Mean Mean Mean 
Age 60.33 61.20 57.92 59.87 
     
Characteristics 
Meningioma 
Meningioma 
with Epilepsy 
Epilepsy 
without 
Meningioma 
Total 
  n % n % n % n % 
Sex Female 93 85.30% 40 71.40% 52 81.20% 185 80.80% 
Male 16 14.70% 16 28.60% 12 18.80% 44 19.20% 
E
m
p
lo
y
m
en
t 
Full Time 21 19.30% 11 19.60% 15 23.40% 47 20.50% 
Part Time 17 15.60% 6 10.70% 4 6.20% 27 11.80% 
Unemployed
a
  3 2.8% 0 0.0% 1 1.6% 4 1.7% 
Unemployed
b 
0 0.0% 1 1.8% 0 0.0% 1 0.4% 
Unemployed
c 
12 11.0% 9 16.1% 13 20.3% 34 14.8% 
Carer
 
3 2.80% 0 0.00% 4 6.20% 7 3.10% 
Retired 49 45.00% 25 44.60% 25 39.10% 99 43.20% 
Student 1 0.90% 2 3.60% 0 0.00% 3 1.30% 
No Answer 3 2.80% 2 3.60% 2 3.10% 7 3.10% 
a
Unemployed and seeking employment 
b
Unemoployed and not seeking employment 
c
Unemployed due to disability 
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6.1.3. Meningioma Variables 
These are summarised in Table 15. 
6.1.3.1. Years since Operation 
The mean number of years between participation and surgery was 4.68 years (±2.71). In the 
meningioma with epilepsy group, the mean number of years was 4.85 (±2.85) and this is 
compared to 4.59 years (± 2.65) in the meningioma without epilepsy group. This difference 
is not significant (p > 0.05). These points are illustrated by the boxplot below (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
6.1.3.2. Simpson’s Grade of Resection 
The meningioma with epilepsy group were more likely to have achieved a grade one 
resection (43.6%), a higher proportion than the meningioma without epilepsy group 
(26.9%). The meningioma without epilepsy group were most likely to have achieved a grade 
2 resection (43.5%), which was achieved in 30.9% patients within the meningioma with 
epilepsy group. These differences are not statistically significant (p > 0.05).  
Figure 2: Boxplot of Years since Surgery for Meningioma Groups 
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6.1.3.3. Current Symptoms Related to Meningioma and the Resection 
In the meningioma without epilepsy group, 45.0% of patients were symptom free whilst 
33.9% experienced just one symptom. Epilepsy was not included as a symptom in this 
analysis. In the meningioma with epilepsy group 42.9.0% of patients were symptom free 
whilst 46.4% experienced just one symptom. This is tabulated in Table 14 and further 
demonstrated in Figure 3. The differences in complication number between groups are not 
statistically significant (p > 0.05).  
 
 
 
The most frequently occurring symptoms in the meningioma without epilepsy group were 
related to vision (26.6%), headaches (11%) and cognitive/emotional difficulties (9.2%). In the 
meningioma with epilepsy group, the most frequent symptoms were motor/sensory (14.3%) 
cognitive/emotional (14.3%) and visual (8.9%). These distributions are tabulated below. The 
differences in the distribution of individual symptoms between groups are non-significant (p 
> 0.05), with exception to visual symptoms (X2 (1, n = 165) = 6.03, p = 0.014). 
Figure 3: Number of Current Symptoms due to Meningioma or Meningioma 
Resection 
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Table 14: Symptoms Secondary to Meningioma or Meningioma Resection 
6.1.3.4. Meningioma Location 
In the meningioma without epilepsy group the most frequent location of the meningioma 
was parafalcine/parasagittal (24.8%) and convexity (22.0%). In the meningioma with 
epilepsy group, the most frequent locations were also parafalcine/parasagittal (30.4%) and 
convexity (28.6%). The difference in tentorial meningiomas between the meningioma with 
epilepsy (0.0%) and meningioma without epilepsy group (9.2%)was significant (X2 (1, n = 
165) = 3.98, p = 0.046).  
6.1.3.5. Lobe Effected 
The lobe most commonly encroached in the meningioma without epilepsy group was the 
frontal lobe (41.3%) followed by the parietal lobe (11.9%). For the meningioma with 
epilepsy group, the lobe most commonly encroached was again the frontal (55.4%) and 
parietal lobes (16.1%). A total of 8 cases had a tumour which abutted two lobes. In these 
    
Meningioma 
without 
Epilepsy 
(n=109) 
Meningioma with 
Epilepsy 
(n=56) 
Total 
(n=165) 
    Count % Count % Count % 
Visual
a
 29 26.60% 5 8.90% 34 20.60% 
Cognitive/Emotional 10 9.20% 8 14.30% 18 10.90% 
Headache 12 11.00% 3 5.40% 15 9.10% 
Motor/Sensory 7 6.40% 8 14.30% 15 9.10% 
Infection 6 5.50% 5 8.90% 11 6.70% 
Cranial Nerve 9 8.30% 1 1.80% 10 6.10% 
CSF problems 5 4.60% 4 7.10% 9 5.50% 
Balance/Co-ordination 5 4.60% 1 1.80% 6 3.60% 
Cosmetic 3 2.80% 2 3.60% 5 3.00% 
Neuroendocrine 3 2.80% 0 0.00% 3 1.80% 
Resus
b
 0 0.00% 2 3.60% 2 1.20% 
Scar Pain 2 1.80% 0 0.00% 2 1.20% 
PE
bc
 0 0.00% 1 1.80% 1 0.60% 
Haemorrhage 1 0.90% 0 0.00% 1 0.60% 
Tinnitus 0 0.00% 1 1.80% 1 0.60% 
Number of Symptoms 
0 49 45.00% 24 42.90% 73 44.20% 
1 37 33.90% 26 46.40% 63 38.20% 
2 15 13.80% 4 7.10% 19 11.50% 
3 7 6.40% 1 1.80% 8 4.80% 
4 1 0.90% 1 1.80% 2 1.20% 
a
Difference is statistically significant   
b
Not current symptom, but deemed significant enough to have potential implications for 
current health. 
c
Pulmonary Embolism 
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cases, each lobe was counted separately. There is no statistical difference in the lobe 
encroached between the meningioma without epilepsy and meningioma with epilepsy 
groups (p > 0.05).  
6.1.3.6. Recurrent Meningioma 
The present tumour was a recurrent meningiomain 8.9% and 7.3% of the meningioma with 
epilepsy group and the meningioma without epilepsy group respectively. This difference is 
not significant (p > 0.05). The mean number of years since the first meningioma resection 
for these patients was 9 (±7) for the meningioma without epilepsy group and 12 (±6) for the 
meningioma with epilepsy group. The difference between these values is not significant (p > 
0.05). 
6.1.3.7. Radiotherapy 
Radiotherapy was delivered in 11.9% of cases in the meningioma without epilepsy group 
and in 8.9% of cases in the meningioma with epilepsy group. The mean number of years 
since the completion of radiotherapy is 5(±3) and 2(±1) in the meningioma with epilepsy and 
meningioma without epilepsy groups respectively. None of these differences are significant 
(p > 0.05).  This is tabulated below in Table 15; as are the remainder of the meningioma 
variables. 
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Table 15: Summary Table of Meningioma related Variables 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Meningioma 
without epilepsy 
(n=109) 
Meningioma with 
Epilepsy 
(n=56) 
Total 
(n=165) 
  
 Characteristics 
Mean SD Mean SD Mean SD 
Years since surgery 4.59 2.65 4.86 2.85 4.68 2.72 
# Meningioma Symptoms 0.84 0.95 0.73 0.82 0.81 0.91 
        
    Count Percent Count Percent Count Percent 
S
im
p
so
n
’s
 
g
ra
d
e 
1 29 26.90% 24 43.60% 53 32.50% 
2 47 43.50% 17 30.90% 64 39.30% 
3 6 5.60% 5 9.10% 11 6.70% 
4 26 24.10% 9 16.40% 35 21.50% 
M
en
in
g
io
m
a 
lo
ca
ti
o
n
 
Convexity 24 22.00% 16 28.60% 40 24.20% 
Intraventricular 1 0.90% 0 0.00% 1 0.60% 
Parafalcine 27 24.80% 17 30.40% 44 26.70% 
Skull base 22 20.20% 11 19.60% 33 20.00% 
Skull base
a 
6 5.50% 0 0.00% 6 3.60% 
Sphenoid Wing 19 17.40% 12 21.40% 31 18.80% 
Tentorial 10 9.20% 0 0.00% 10 6.10% 
L
o
b
e 
Frontal 45 41.30% 31 55.40% 76 46.10% 
Occipital 11 10.10% 2 3.60% 13 7.90% 
parietal 13 11.90% 9 16.10% 22 13.30% 
Temporal 12 11.00% 7 12.50% 19 11.50% 
Not Stated 32 29.40% 11 19.60% 43 26.10% 
Recurrent Meningioma 8 7.30% 5 8.90% 13 7.90% 
Radiotherapy 13 11.90% 5 8.90% 18 10.90% 
a
encroaching towards posterior fossa  
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6.1.4. Epilepsy Variables 
6.1.4.1. Epilepsy Cause 
In the meningioma with epilepsy group, epilepsy can be classified as secondary to 
meningioma (Table 16). For the epilepsy without meningioma group, the aetiology of 
epilepsy varied. In 41 (64%) cases the aetiology was unknown. In 23 (36%) cases however, a 
cause of epilepsy was identified. The most common known aetiology was stroke (20.3% of 
structural cases).  
Table 16: Aetiology of Epilepsy in the Epilepsy without Meningioma Group 
Aetiology Count Percentage % 
Unknown 41 64.1% 
Stroke 13 20.3% 
Mesial Temporal Lobe Sclerosis 2 3.1% 
Hippocampal Sclerosis 1 1.6% 
Arteriovenous Malformation 1 1.6% 
Cavernoma 1 1.6% 
Epidermoid Tumour 1 1.6% 
Acoustic Neuroma 1 1.6% 
Encephalitis 1 1.6% 
Other Structural
a 
2 3.1% 
a
Aetiology not mentioned in notes 
6.1.4.2. Seizure Onset 
The average time between seizure onset and study participation for the 56 meningioma 
patients with epilepsy was 5.59 (± 3.8) years. This is compared to the average of 6.25 (±4.6) 
years in the epilepsy without meningioma group. The range of seizure onset is considerably 
larger in the epilepsy without meningioma group (28.0 years versus 15.5).  The difference in 
means is not statistically significant (p = >0.05).  
6.1.4.3. Years on AED 
The meningioma with epilepsy group have been taking anti-epileptic drugs (AEDs) for an 
average of 5 (±4) years and this is compared to the epilepsy without meningioma group who 
have been taking AEDs for an average of 6 (±6) years.  The difference in means is not 
statistically significant (p = > 0.05).  
6.1.4.4. Seizure Frequency 
Only 7 (12.5%) participants in the meningioma with epilepsy group experienced a seizure in 
the previous 6 months, compared to 39 (60.9%) participants in the control group. The 
distribution of seizure frequencies is summarised in  Table 17.  
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 Table 17: Seizure Frequency of Meningioma with Epilepsy and Epilepsy without 
Meningioma Groups 
 
Meningioma with 
Epilepsy 
(n=56) 
Epilepsy without 
Meningioma 
(n=64) 
Seizure Frequency in 
Previous 6 Months 
Count Percentage Count Percentage 
0 49 87.50% 39 60.90% 
1 2 3.60% 6 9.40% 
2 - 3 4 7.10% 6 9.40% 
4 - 5 0 0.00% 2 3.10% 
6 - 9 0 0.00% 5 7.80% 
10+ 1 1.80% 6 9.40% 
 
When comparing seizure frequencies, the difference in proportion of participants without 
seizures is significant (X2 (1, n = 120) = 9.46, p = 0.02). 
 
6.1.4.5. Seizure Type 
In both groups, bilateral convulsive seizures have occurred in the majority of cases. This is 
shown in Table 18. The “Focal” row is representative of participants in which only focal 
seizures occur. The “Dyscognitive” row is representative of patients that have dyscognitive 
seizures, may have focal seizures, but do not have bilateral convulsive seizures. The 
“Bilateral Convulsive” row is representative of participants in which bilateral convulsive 
seizures occur, and focal or dyscognitive seizures may occur.  
Table 18: Distribution of Seizure Type in the Meningioma with Epilepsy and 
Epilepsy without Meningioma Groups 
When assessing the differences of each individual seizure type, the proportion of 
participants with dyscognitive seizures significantly differed between the groups (X2 (1, n = 
120) = 6.51, p = 0.011). 
Groups 
 Meningioma with 
Epilepsy 
(n=56) 
Epilepsy without 
Meningioma 
(n=64) 
Total 
(n=120) 
Most Severe Seizure
 
Count Percentage Count Percentage Count Percentage 
Focal 9 16.10% 4 6.30% 13 10.80% 
Dyscognitive 4 7.10% 17 26.60% 21 17.50% 
Bilateral Convulsive 33 58.90% 42 65.60% 75 62.50% 
Not Known 10 17.90% 1 1.60% 11 9.20% 
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6.1.4.6. First Drug 
The most frequent first drug prescribed was Phenytoin (50.0%) in the meningioma with 
epilepsy group and lamotrigine in the epilepsy without meningioma group (37.7%). The 
proportions of first drug prescribed between groups is tabulated below (Table 19).  
Table 19: First AED;  Meningioma with Epilepsy and Epilepsy without Meningioma  
  Group  
  Meningioma with 
Epilepsy 
(n=56) 
Epilepsy without 
meningioma 
(n=64) 
Total 
(n=120) 
 First Drug Count Percentage Count Percentage Count Percentage 
Carbamazepine 12 21.4% 16 26.2% 28 23.9% 
Gabapentin 1 1.8% 0 0.0% 1 0.9% 
Lamotrigine 3 5.4% 23 37.7% 26 22.2% 
Levetiracetam 5 8.9% 5 8.2% 10 8.5% 
Oxcarbemazepine 1 1.8% 1 1.6% 2 1.7% 
Phenytoin 28 50.0% 7 11.5% 35 29.9% 
Sodium Valproate 4 7.1% 8 13.1% 12 10.3% 
Phenobarbitone 0 0.0% 1 1.6% 1 0.9% 
Not Stated 2 3.6% 0 0.0% 2 1.7% 
When looking at the difference of proportions between each drug, only lamotrigine  (X2(1, n 
= 120) = 14.70, p < 0.001) and Phenytoin (X2 (1, n = 120) = 20.21, p < 0.001) differed 
significantly.  
6.1.4.7. Number of Current AEDs 
For the meningioma with epilepsy group the average number of AEDs being taken was 0.68 
(±0.69). In the epilepsy without meningioma group, the average number of AEDs being 
taken was 1.20 (±0.60). Despite the apparent similarity in these means, there is a statistical 
difference in the mean number of AEDs for each group (t (118) = 4.47, p < .001). This is 
tabulated below (Table 20). 
Table 20: Number of Current AEDs Meningioma with Epilepsy and Epilepsy 
without Meningioma Groups 
                    Group   
 Meningioma with 
Epilepsy 
(n=56) 
Epilepsy without 
Meningioma 
(n=64) 
Total 
(n=120) 
Number of 
AEDS 
Count Percentage Count Percentage Count Percentage 
0 24 42.90% 5 7.80% 29 29.25% 
1 27 48.20% 42 65.60% 69 89.70% 
2 4 7.10% 16 25.00% 20 28.55% 
3 1 1.80% 1 1.60% 2 2.50% 
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6.1.4.8. Current AED 
In the meningioma with epilepsy group 32 participants took a total of 40 AEDs, the most 
common of which were sodium valproate (15.9%) and phenytoin (15.9%). In the epilepsy 
without meningioma group 59 patients took a total of 77 AEDs and the most commonly 
prescribed drugs were lamotrigine (25.6%) and levetiracetam (25.6%). All the prescribed 
AEDs for each group is summarised in Table 21.  
Table 21: Current AEDs taken by the Meningioma with Epilepsy and Epilepsy 
without Meningioma Groups 
                       Group 
  Meningioma 
with Epilepsy 
(n=56) 
Epilepsy without 
Meningioma 
(n=64) 
Total 
(n=120) 
Current AED Count Percent Count Percent Count Percent 
 Lamotrigine 8 12.7% 21 25.6% 29 20.0% 
  Levetiracetam 4 6.3% 21 25.6% 25 17.2% 
  Sodium Valproate 10 15.9% 9 11.0% 19 13.1% 
  Carbamazepine 5 7.9% 12 14.6% 17 11.7% 
  Phenytoin 10 15.9% 5 6.1% 15 10.3% 
  Gabapentin 1 1.6% 2 2.4% 3 2.1% 
  Zonisamide 0 0.0% 2 2.4% 2 1.4% 
  Oxcarbemazepine 1 1.6% 0 0.0% 1 0.7% 
  Phenobarbitone 0 0.0% 1 1.2% 1 0.7% 
  Lacosamide 0 0.0% 1 1.2% 1 0.7% 
  Pregablin 0 0.0% 1 1.2% 1 0.7% 
  Topiramate 0 0.0% 1 1.2% 1 0.7% 
  Acetozalamide 0 0.0% 1 1.2% 1 0.7% 
  Clobazam 1 1.6% 0 0.0% 1 0.7% 
 
The differences in current AED were only significant for levetiracetam (X2(1, n = 120) = 
10.43, p = 0.001). It is used more often as a second line drug in the epilepsy without 
meningioma group and it is particularly effective in treating drug resistant focal epilepsy260.  
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Figure 4: Proportion of Number of Comorbidities by Participant Group 
6.1.5. Comorbidities 
6.1.5.1. Number of Comorbidities 
The total number of medical and surgical comorbidities was collected for all three 
participant groups. In each group, the mean number of comorbid conditions was 2 (±2). The 
differences between these means are not significant when comparing the meningioma with 
epilepsy to the meningioma without epilepsy group and meningioma with epilepsy to the 
epilepsy without meningioma group (p > 0.05). Below is a bar chart summarising these 
findings (Figure 4).  
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6.1.5.2. Named Comorbidities 
In the meningioma with epilepsy group, there were 58 comorbidities in 56 patients. The 
most prevalent comorbidity with 25% of participants affected was hypertension. This was 
followed by arthritis (12.5%), diabetes (12.5%) and thyroid disorders (12.5%). In the 
meningioma without epilepsy group, there were 209 comorbidities in 109 patients. The 
most prevalent comorbidity was hypertension, which was present in 23.9% of participants. 
Cancers (23.9%), depression (10.1%) arthritis (9.2%) and thyroid disorders (9.2%) most 
frequently occur after hypertension. In the epilepsy without meningioma group there were 
143 comorbidities in 64 participants. Hypertension is again most prevalent with 14 (25%) 
participants exhibiting this comorbidity. Stroke (18.8%), depression (15.6%) and ischaemic 
heart disease (14.1%) were the next most prevalent.  
There was no significant difference with the distribution of any individual medical or surgical 
comorbidity between the meningioma with epilepsy and the meningioma without epilepsy 
group.   
When comparing comorbidity between the meningioma with epilepsy and the epilepsy 
without meningioma group, stroke differed significantly (X2 p = 0.022). All other variables 
were non-significant. (X2(1, n = 120) = 5.29, p = 0.022). 
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6.2. Quality of Life Mean Scores 
6.2.1. Preliminary data analysis 
6.2.1.1. Missing Data Analysis 
In total there were 81 cases (35.4%) with missing items in a questionnaire (Table 22). Only 
14 questionnaires (2%) could not be included in the quality of life (QoL) analysis: 7 from the 
SF-36, 4 from the FACT-BR questionnaire and 3 from the AEP (Table 23).  
Table 22: Cases with Missing Data in All Groups 
 
Table 23: Number of Cases Excluded from Analysis by Questionnaire and Group 
                                 Group     
 
Meningioma 
without Epilepsy 
(n=109) 
Meningioma 
with Epilepsy 
(n=56) 
Epilepsy without 
Meningioma 
(n=64) 
Total 
(n=229) 
Questionnaire n % n % n % n % 
SF-36 2 1.83% 1 1.79% 4 6.25% 7 3.06% 
FACT-BR 2 1.83% 0 0.00% 2 3.13% 4 1.75% 
AEP 2 1.83% 1 1.79% 0 0.00% 3 1.31% 
Total 6 5.50% 2 3.57% 6 9.38% 14 6.11% 
 
There was no significant difference in the number of questionnaires with missing data, or 
the proportion of cases put forward for analysis between the meningioma with epilepsy and 
meningioma without epilepsy group or epilepsy without meningioma group (p > 0.05). 
When looking at patient characteristics, patients with missing data are older than 
responders (Table 24). This difference is highly significant (t (227) = 3.75, p < 0.001). 
 
 
                                    Group     
    Meningioma 
without Epilepsy 
(n=109) 
Meningioma 
with Epilepsy 
(n=56) 
Epilepsy without 
Meningioma 
(n=64) 
Total 
(n=229) 
Questionnaires 
with Missing Data 
n % n % n % n % 
None 69 63.30% 36 64.30% 43 67.20% 148 64.60% 
1 31 28.40% 18 32.10% 12 18.80% 61 26.60% 
2 8 7.30% 2 3.60% 6 9.40% 16 7.00% 
3 1 0.90% 0 0.00% 3 4.70% 4 1.70% 
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Table 24: Demographics of Participants with Missing Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.2.1.2. Reliability 
To determine the reliability of the questionnaires, their internal consistency was assessed 
with the Cronbachs Alpha tool261. This tool produces a coefficient ranging from 0 to 1 
representing the reliability of summated scales within a questionnaire. A coefficient score of 
greater than 0.70 is deemed an acceptable level of reliability. All summated scales in the 
three questionnaires had an α coefficient greater than 0.70, confirming the reliability of 
these questionnaires (tables 25-27). 
Table 25: Cronbachs Alpha Coefficients for SF-36 
  SF-36 
  
Scale 
Cronbachs 
Alpha 
Items in 
Scale 
S
u
b
sc
a
le
s 
GH 0.88 5 
PF 0.96 10 
RP 0.97 4 
BP 0.89 2 
VT 0.87 4 
SF 0.91 2 
RE 0.95 3 
MH 0.77 5 
Total 
Scores 
PCS 0.89 4 
MCS 0.91 4 
 
    Missing Data Present? 
    No Missing Data Missing Data 
Characteristics  Mean SD Mean SD 
AGE 57.7 12.4 63.8 10.7 
              
 No Missing Data Missing Data 
 Characteristics  n % n % 
Gender Female 119 80.40% 66 81.50% 
Male 29 19.60% 15 18.50% 
E
m
p
lo
y
m
en
t 
Full Time 33 22.30% 14 17.30% 
Part Time 24 16.20% 3 3.70% 
Unemployed
a 
4 2.7% 1 1.20% 
Unemployed
b 
20 13.50% 14 17.30% 
Carer 5 3.40% 2 2.50% 
Retired 57 38.50% 42 51.90% 
Student 3 2.00% 0 0.00% 
No Answer 2 1.40% 5 6.20% 
a
Unemployed  
b
Unemployed due to disability
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Table 26: Cronbachs Alpha Coefficients for FACT-BR 
 
 
 
 
 
 
 
Table 27: Cronbachs Alpha Coefficient for AEP 
 
 
 
6.2.1.3. Normality Testing  
T-tests and multiple regression analyses require that the dependent variable is normally 
distributed for inferences to be reliable and accurate.  Normality testing was performed in 
each group and for each dependent variable with q-q plots, histograms and Kolmogorov-
Smirnov and Shapiro-Wilk tests.  
The q-q plots showed that data was normally distributed. Non-normality seems most 
pronounced in the Kolmogorov-Smirnov and Shapiro-Wilk tests. These tests have reduced 
power with smaller sample sizes and are highly sensitive to extreme values. Their results are 
usually a supplement to the visual plots262.  
A log10 transformation was attempted but this did not improve the appearance of the plots, 
nor did it improve the outcomes of the Kolmogorov-Smirnov and Shapiro-Wilk tests. 
According to the central limit theorem, when sample data is taken from a population which 
is approximately normal, the sampling data should be normal also262. Furthermore, when 
sample sizes are greater than 40, a slight violation of normal distribution is not problematic 
and parametric testing can still be used262. All groups have sample sizes that are greater 
than 40. 
While the data for each dependent variable does not follow a perfect normal distribution, it 
could be argued that parametric testing was still appropriate in this dataset.  
  FACT-BR 
  
Scale 
Cronbachs 
Alpha 
Items in Scale 
S
u
b
sc
al
es
 PWB 0.89 7 
SWB 0.88 7 
EWB 0.82 6 
FWB 0.91 7 
BRCS 0.89 20 
Total 
Scores 
FACT-G 0.87 4 
FACT-BR 0.84 5 
AEP 
  
Scale 
Cronbachs 
Alpha 
Items in Scale 
AEP 0.92 19 
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6.2.2. QoL Scores 
6.2.2.1. Meningioma without Epilepsy and Meningioma with Epilepsy 
The mean QoL scores for the meningioma without epilepsy and meningioma with epilepsy 
groups were compared and independent samples t-tests completed. The mean scores from 
each questionnaire are shown in tables 28, 29 and 30, and box plots of the summary scores 
are shown in figures 5, 6 and 7. It is evident that for all outcome measures except general 
health (GH), QoL is worse in the meningioma with epilepsy group when compared to the 
meningioma without epilepsy group. With exception to the AEP, a lower score equates to 
worse QoL.  
The difference in means was significant for the FACT-BR summary score (t (92.9) = -2.55, p = 
0.012) and the BRCS subscale score (t (161) = -3.14, p = 0.002). No other summary or 
subscale score means differed significantly.  
Table 28: SF-36 Summary and Subscale Scores Meningioma Groups 
    
Meningioma  
without Epilepsy 
(n=109) 
Meningioma with 
Epilepsy 
(n=56) 
  
Score Domain Mean SD Mean SD 
Difference 
in Mean 
Subscale 
PF 46.8 11.6 44.5 13.0 -2.4 
RP 46.2 11.5 44.0 12.0 -2.3 
BP 48.6 11.2 48.8 10.7 +0.2 
GH 49.5 11.3 46.3 12.4 -3.2 
VT 49.0 11.3 47.6 10.6 -1.4 
SF 47.9 11.0 44.1 13.7 -3.8 
RE 46.9 11.8 44.0 12.2 -2.9 
MH 49.0 11.2 48.2 11.3 -0.8 
Summary 
PCS 47.5 11.2 45.8 11.2 -1.7 
MCS 48.9 11.4 46.8 11.7 -2.0 
Note: No statistically significant differences in means 
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Table 29: FACT-BR Summary and Subscale Scores Meningioma Groups 
 
 
 
 
 
 
 
 Table 30: AEP Summary Scores of Meningioma Groups 
 
 
 
 
 
Each item of the AEP was compared between groups with students t-tests. Patients in the 
meningioma with epilepsy group were significantly more likely to report the presence of 
shaky hands (t (76.5) = -3.57, p < 0.001). The proportion of patients with scores above 45 in 
the meningioma with epilepsy group (32.1%) and the meningioma without epilepsy group 
(22.0%) did not differ significantly (X2 (1, n = 165) = 2.00, p < 0.221). 
 
 
 
 
 
 
 
 
  
Meningioma  
without epilepsy 
(n=109) 
Meningioma with 
Epilepsy 
(n=56) 
 
Score Domain Mean SD Mean SD 
Difference in 
Mean 
Subscale 
PWB 22.9 5.5 21.2 6.2 -1.8 
SWB 22.4 5.7 20.3 7.0 -2.1 
EWB 19.5 4.5 18.6 5.2 -0.9 
FWB 20.5 6.7 19.1 7.7 -1.4 
BRCS 60.1 14.1 52.6 14.8 -7.4** 
Summary TOTAL 146.1 29.6 131.7 35.9 -14.4* 
* p = < 0.05     **p = <0.01 
  
Meningioma  
without Epilepsy 
(n=109) 
Meningioma 
with Epilepsy 
(n=56) 
 
Questionnaire Mean SD Mean SD 
Difference 
in Mean 
AEP 36.1 10.4 39.4 13.7 +3.3 
Note: Difference in mean is not significant 
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6.2.2.2. Meningioma with Epilepsy and Epilepsy without Meningioma 
The mean QoL scores for the meningioma with epilepsy and epilepsy without meningioma 
group were compared and an independent samples t-test applied to each (Tables 31-33). All 
summary scores indicated worse functioning in the epilepsy without meningioma group, as 
were all subscales scores except PF on the SF-36 (Table 31) and SWB on FACT-BR (Table 32). 
None of these differences were significant at the p = 0.05 level. These scores are presented 
in figures 5, 6 and 7. The differences in item means for the AEP were also not significant. 
The proportion of epilepsy without meningioma patients with a score over 45 was 37.5%, 
which does not significantly differ from the 32% of patients with a score over 45 in the 
meningioma with epilepsy group (X2 (1, n = 120) = 0.178, p < 0.673).  
Table 31: SF-36 Summary and Subscale Scores Epilepsy Groups 
  
Meningioma with 
Epilepsy 
(n=56) 
Epilepsy  without 
Meningioma 
(n=64) 
 
 
Domain Mean 
Std. 
Deviation 
Mean 
Std. 
Deviation 
Difference 
in Mean 
Subscale 
PF 44.5 13.0 44.8 13.3 +0.3 
RP 44.0 12.0 42.7 12.3 -1.3 
BP 48.8 10.7 47.6 11.8 -1.2 
GH 46.3 12.4 44.1 13.9 -2.2 
VT 47.6 10.6 43.7 12.3 -3.8 
SF 44.1 13.7 42.7 13.0 -1.4 
RE 44.0 12.2 41.7 14.3 -2.3 
MH 48.2 11.3 43.9 12.0 -4.3 
Summary 
PCS 45.8 11.2 45.6 11.9 -0.2 
MCS 46.8 11.7 42.8 12.8 -4.1 
Note: No significant differences in means 
 
Table 32: FACT-G Summary and Subscale Scores Epilepsy Groups 
 
 
 
 
 
 
 
 
  
Meningioma 
with Epilepsy 
(n=56) 
Epilepsy without 
Meningioma 
(n=64) 
 
 
Domain Mean SD Mean SD 
Difference 
in Mean 
Subscale 
PWB 21.2 6.2 20.4 6.9 -0.8 
SWB 20.3 7.1 20.6 6.0 +0.3 
EWB 18.6 5.2 16.7 5.7 -1.8 
FWB 19.1 7.7 18.1 7.7 -1.0 
Summary FACTG 79.1 22.9 75.8 23.2 -3.3 
Note: No significant differences in means 
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Figure 5: Boxplots of SF-36 Scores for all Participant Groups 
Table 33: AEP Summary Scores of Epilepsy Groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Meningioma 
with Epilepsy 
(n=56) 
Epilepsy without 
Meningioma 
(n=64) 
 
Score Mean SD Mean SD 
Difference 
in Mean 
AEP 39.4 13.7 40.8 11.3 +1.4 
Note: No statistically significant difference in mean 
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Figure 6: Boxplots of FACT Total and FACT G 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Boxplot of AEP scores for all Participant Groups 
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6.2.3. Outliers 
Box and whisker plots with the dependent variable on the y axis were used to identify 
outliers (figures 5 to 7). Three outliers were found, all in the meningioma without epilepsy 
group. Each case was an outlier for different questionnaires: one physical component 
summary (PCS); one mental component summary (MCS) and FACT-BR Total; and one FACT-
BR Total. All had quality of life scores well below the interquartile range for their respective 
questionnaires.  
No specific reason could be found to explain the low scores of these participants, but two 
were unemployed due to disability; all had comorbidities; and all had significant symptoms 
resulting from their meningioma or resection. Of the three cases, two had visual problems; 
two had problems with their motor or sensory function; and all three had problems with 
either headache, cognition/emotion or cranial nerves (Table 34).   
 
Table 34: Characteristics of Outliers in the Meningioma without Epilepsy Group 
 Outliers 
Outlier Group 
(n=3) 
Meningioma without 
Epilepsy Group 
(n=109) 
Characteristic 1 2 3 Mean or Mode Mean or Mode 
Age 48 66 58 57 60.3 
Gender Male Female Female Female (66.6%) Female (85.3%) 
Employment Unemployed Retired Unemployed 
Unemployed 
(66.6%) 
Retired (45%) 
Years Since 
Surgery 
4 2 9 5 5 
Simpson’s Grade 1 2 1 1 (66.6%) 2 (43.5%) 
Tumour Location Tentorial 
Skull 
Base 
Tentorial Tentorial (66.6%) 
Parafalcine/Parasagittal 
(24.8%) 
# Meningioma 
Symptoms 
2 2 3 2 0.73 
# Comorbidities 2 3 1 2 2 
S
co
re
 PCS 44 15
a 30 30 47 
MCS 10
a 59 20 29 49 
FACT-BR 42
a 146
 
54
a 81 146 
LAEP 49 29
 
64 47 49 
a
Outlying scores 
 
In all cases, QoL was found to be particularly impaired in other subscales and summary 
scores reducing the possibility of an isolated error. Therefore, these scores are felt to 
represent a truly impaired score. The QoL and subscale scores for the three outliers are 
tabulated below.  
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No justification can be made for the removal of these outliers on the basis of erroneous 
data. As these are three cases in a sample of over 100 it is unlikely that their inclusion will 
significantly alter the results or conclusions of this study. It was decided not to remove these 
cases from the analysis.  
To observe the effect of this decision, t-tests of questionnaire scores between the 
meningioma with epilepsy and meningioma without epilepsy group were compared with 
and without the outliers. As would be expected, the meningioma without epilepsy group 
would have improved mean QoL scores after the removal of outliers. However, no 
differences in outcome were observed by removing these cases, with exception to the 
“TOTAL” score of the FACT-BR. When removing outliers, the difference in means between 
the meningioma without epilepsy and meningioma with epilepsy group changes from being 
significant (t (92.9) = -2.55, p = 0.012) to very significant (t (86.4) = -3.09, p = 0.003) (two 
sample t-test p = 0.004).   
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6.3. Regression Analysis 
There are numerous assumptions that should be met for a multiple linear regression 
analysis263. Each regression model was assessed for the following: 
1. Normal distribution of the dependent variable residuals  
2. Homoscedasticity 
3. Multicollinearity 
4. Linearity of dependent and independent variables  
5. Independence of observations  
A histogram and standardised p-p plot of the four dependent variables in each group was 
assessed and found to be normally distributed. Scatter plots of the standardised residual for 
each dependent variable in each group was assessed and found to be homoscedastic.  
Multicollinearity was avoided by producing a Pearson correlation table and by outright 
eliminating any independent variables with a high correlation (> 0.8). No variables had a 
Pearson correlation that was greater than 0.8 but some variables had significant correlations 
greater than 0.6 (Table 35  and Table 36). This influenced the insertion of independent 
variables into the multiple regression analysis.  
Table 35: Variables with Correlations Greater than 0.6 in the Meningioma Groups 
 
 
 
 
Table 36: Variables with Correlations Greater than 0.6 in the Epilepsy Groups 
Meningioma with Epilepsy and Epilepsy without Meningioma 
Correlating Variables Correlation (R) 
Age Retired 0.626* 
Employed Retired -0.616* 
Epilepsy without meningioma Cryptogenic Epilepsy 0.674* 
Year on AED Years Since Seizure Onset 0.732* 
Lamotrigine 2
nd
 and 3
rd
 Generation Drug 0.635* 
Any Seizure Prior 6 Months 1-3 Seizures prior 6 Months -0.697* 
Any Seizure Prior 6 Months > 4 Seizures prior 6 Months -0.603* 
*p < 0.001 
 
 
Meningioma without Epilepsy and Meningioma with Epilepsy 
Correlating Variables Correlation (R) 
Age Retired 0.647* 
Employed Retired -0.689* 
Current AED Use Epilepsy Meningioma  Group 0.698* 
*p < 0.001 
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Scatterplots of each independent variable and each dependent variable showed evidence of 
a linear relationship in all counts. After each multiple regression model was produced, the 
absence of multicollinearity was confirmed by the variance inflation factor (<3) and 
tolerance (>0.3) of the final model.  Independence of observations was assessed and 
confirmed after the production of each model with the Durbin-Watson statistic (>1.5 and < 
2.5). 
6.3.1. Correlating Variables 
Some variables of particular interest were found to significantly correlate with one another, 
but did not have correlations greater than 0.6. They are listed in Table 37 and  
Table 38. 
Table 37: Correlating Variables of Interest Meningioma Groups 
 
 
 
 
 
Table 38: Correlating Variables of Interest Epilepsy Groups 
 
 
 
 
 
 
 
 
 
 
 
 
Meningioma without Epilepsy and Meningioma with Epilepsy 
Correlating Variables Correlation (R) 
Depression Unemployment 0.261*** 
Depression No. Comorbidities 0.177* 
*p < 0.05 
***p < 0.001 
 Meningioma with Epilepsy and Epilepsy without Meningioma 
Correlating Variables Correlation (R) 
Depression Years Since Seizure Onset 0.281** 
Depression Neoplasm 0.177* 
Depression No. Comorbidities 0.184* 
*p < 0.05 
**p < 0.01 
98 
 
6.3.2. Univariate Regression Analysis 
The number of participants should substantially outnumber the number of independent 
variables in a multiple regression analysis. A minimum number of 5 participants per variable 
is usually tolerated but at least 10 participants per variable should be attempted264.  
A selection process was undertaken to select independent variables of interest that 
correlate with the dependent variables but not the independent variables (Table 34 and 
Table 35). Simple linear regression  was performed to identify variables that predict the 
dependent variables in the meningioma (meningioma with epilepsy and meningioma 
without epilepsy) and the epilepsy groups (meningioma with epilepsy and epilepsy without 
meningioma).  
Eight sets of analysis with all dependent and independent variables were performed in the 
format shown in Table 10.  The results of this analysis are presented in appendix V. 
Significantly predictive variables are presented below (Tables 39 to 46). Certain variables 
were recoded for simplification or to account for their low distribution in the dataset: 
 “Employed full time” and “Employed part time” were recoded into “Employed”. 
 “Unemployed and seeking employment”, ”Unemployed and not seeking 
employment” and “Unemployed due to disability” were recoded into one 
“Unemployed” variable. 
  “Number of AEDs” was coded as a binary “current AED use” for the meningioma 
groups. 
 Named current AEDs were also coded into “1st generation” or “2nd-3rd generation” 
AED.  
 Seizure frequency was coded into: “0 Seizures prior 6 month”, “Any Seizure Prior 6 
Months”, “1-3 Seizures Prior 6 Months” and “4+ Seizures Prior 6 Months”. “Any 
Seizure Prior 6 Months” is equal to “No Seizure Prior 6 Months” but the direction of 
the relationship is inverted.   
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Table 39: Univariate Analysis; Significant Predictors of PCS Meningioma Groups 
 
 
 
 
 
 
 
 
Table 40: Univariate Analysis; Significant Predictors of MCS Meningioma Groups 
Independent Variables Adjusted R 
Squared (R
2
) 
Beta (β) 
Significance 
(p) 
Unemployed 0.180 -0.431 0.000
a 
# Meningioma Symptoms 0.094 -0.316 0.000
a 
Age 0.087 0.304 0.000
a 
Depression 0.072 -0.279 0.000
a 
Cranial Nerve 0.051 -0.238 0.002 
Retired 0.049 0.234 0.003 
Resus 0.033 -0.196 0.012 
Student 0.028 -0.186 0.018 
Employed 0.022 0.169 0.032 
Current AED Use 0.021 -0.164 0.037 
Note: Table organised by magnitude of  Beta 
 a
p < 0.001  
Table 41: Univariate Analysis; Significant Predictors of FACT-BR  Meningioma 
Groups 
Independent Variables 
Adjusted R 
Squared (R
2
) 
Beta (β) 
Significance 
(p) 
Unemployed 0.218 -0.472 0.000
a 
# Meningioma Symptoms 0.153 -0.398 0.000
a 
Current AED Use 0.066 -0.268 0.001 
0 Seizures
 
Prior 6 Months 0.060 0.257 0.001 
First Generation 0.054 -0.246 0.002 
Employed 0.051 0.239 0.002 
Resus 0.046 -0.228 0.004 
Depression 0.041 0.217 0.006 
Meningioma Group 0.038 0.210 0.007 
Motor Sensory 0.038 -0.209 0.008 
Current Phenytoin 0.036 -0.206 0.009 
Recurrence (Meningioma) 0.036 -0.205 0.009 
Cranial Nerve 0.032 -0.196 0.013 
Parietal Lobe 0.022 0.169 0.032 
First Phenytoin 0.020 -0.160 0.042 
Note: Table organised by magnitude of  Beta 
 a
p < 0.001 
Independent Variables Adjusted R 
Squared (R
2
) 
Beta (β) 
Significance 
(p) 
Unemployed 0.123 -0.359 0.000
a 
# Comorbidities 0.122 -0.357 0.000
a 
# Meningioma Symptoms 0.114 -0.345 0.000
a 
Employed 0.101 0.327 0.000
a 
Recurrence (Meningioma) 0.043 -0.221 0.005 
Motor Sensory 0.040 -0.216 0.006 
Neuropathy 0.038 -0.210 0.007 
Neoplasm 0.032 -0.195 0.013 
Depression 0.031 -0.193 0.014 
Cognitive/Emotional 0.029 -0.186 0.018 
Hypertension 0.025 -0.175 0.026 
Radiotherapy 0.023 -0.171 0.030 
Arthritis 0.023 -0.170 0.031 
Diabetes M 0.019 -0.160 0.042 
Stroke 0.019 -0.159 0.043 
Age 0.019 -0.157 0.046 
Note: Table organised by magnitude of  Beta 
a
p  < 0.001  
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Table 42: Univariate Analysis; Significant Predictors of AEP Meningioma Groups 
Independent Variables Adjusted R 
Squared (R
2
) 
Beta (β) 
Significance 
(p) 
Unemployed 0.191 0.443 0.000
a 
#  Meningioma Symptoms 0.119 0.353 0.000
a 
0 Seizure
b
  0.093 -0.313 0.000
a 
Depression 0.072 -0.280 0.000
a 
1-3 Seizures
b 0.063 0.262 0.001 
Recurrence (Meningioma) 0.055 0.247 0.001 
Current Levetiracetam 0.053 0.242 0.002 
# Comorbidities 0.041 -0.217 0.006 
Current AED Use 0.039 0.211 0.007 
Age 0.038 -0.209 0.008 
Cranial Nerve 0.036 0.204 0.009 
2
nd 
3
rd
 Generation AED 0.029 0.186 0.018 
Current Clobazam 0.027 0.181 0.021 
4+ Seizures
b 0.027 0.181 0.021 
Headache 0.023 0.169 0.031 
Diabetes M 0.022 -0.168 0.033 
Tinnitus 0.022 0.167 0.033 
1st Generation AED  0.022 0.167 0.034 
Retired 0.021 -0.165 0.036 
Cognitive/Emotional 0.019 0.158 0.044 
Current Phenytoin 0.019 0.157 0.046 
Note: Table organised by magnitude of  Beta 
 a
p < 0.001 
b   
Prior 6 Months 
 
 
Table 43: Univariate Analysis; Significant Predictors of PCS Epilepsy Groups 
 
 
 
 
 
 
 
 
 
 
 
Independent Variables 
Adjusted R Squared 
(R
2
) 
Beta (β) 
Significance 
(p) 
# Comorbidities 0.186 -0.440 0.000
a 
Unemployed 0.123 -0.359 0.000
a 
Employed 0.101 0.327 0.000
a 
Recurrence (Meningioma) 0.062 -0.265 0.004 
Arthritis 0.058 -0.258 0.005 
Age 0.041 -0.222 0.017 
0 Seizure
b
 0.039 0.217 0.020 
Neuropathy 0.039 -0.217 0.020 
Diabetes M 0.036 -0.211 0.023 
Neoplasm 0.034 -0.205 0.028 
Motor Sensory 0.032 -0.201 0.031 
First Lamotrigine 0.030 0.195 0.037 
Hypertension 0.026 -0.187 0.046 
Note: Table organised by magnitude of  Beta 
 a
p < 0.001 
b
Prior 6 Months 
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Table 44: Univariate Analysis; Significant Predictors of MCS Epilepsy Groups 
 
 
 
 
 
 
 
Table 45: Univariate Analysis; Significant Predictors of FACT-G Epilepsy Groups 
Independent Variables 
Adjusted R 
Squared (R
2
) 
Beta (β) 
Significance 
(p) 
Unemployed 0.218 -0.472 0.000
a 
0 Seizures
b
  0.120 0.357 0.000
a 
# AED 0.101 -0.330 0.000
a 
Current Levetiracetam 0.090 -0.313 0.001 
Current AED Use 0.078 -0.293 0.001 
2
nd 
3
rd
 Generation AED 0.074 -0.287 0.002 
Employed 0.051 0.239 0.002 
4+ Seizures
b 0.049 -0.239 0.009 
# Comorbidities 0.048 -0.237 0.009 
1-3 Seizures
b 0.043 -0.227 0.013 
Resus 0.035 -0.209 0.023 
Cranial Nerve 0.028 -0.191 0.037 
Current Pregablin 0.028 -0.191 0.038 
Recurrence (Meningioma) 0.026 -0.185 0.044 
Note: Table organised by magnitude of  Beta 
 a
p < 0.001 
b
Prior 6 Months 
Table 46: Univariate Analysis; Significant Predictors of AEP Epilepsy Groups 
Independent Variables 
Adjusted R 
Squared (R
2
) 
Beta (β) 
Significance 
(p) 
Unemployed 0.191 0.443 0.000
a 
0 Seizure
b
 0.124 -0.363 0.000
a 
# AED 0.114 0.349 0.000
a 
Current Levetiracetam 0.094 0.319 0.000
a 
2
nd 
3
rd
 Generation AED 0.088 0.309 0.001 
# Comorbidities 0.070 0.279 0.002 
Recurrence (Meningioma) 0.057 0.254 0.005 
Parietal Lobe 0.054 -0.249 0.006 
4+ Seizures
b 0.052 0.244 0.007 
1-3 Seizures
b 0.045 0.230 0.012 
Cranial Nerve 0.032 0.199 0.030 
Diabetes M 0.027 0.189 0.040 
Note: Table organised by magnitude of  Beta 
 a
p < 0.01 
b
Prior 6 Months 
Independent Variables 
Adjusted R 
Squared (R
2
) 
Beta (β) 
Significance 
(p) 
Unemployed 0.180 -0.431 0.000
a 
# AED 0.094 -0.320 0.000
a 
2
nd 
3
rd
 Generation AED 0.089 -0.312 0.001 
Current Levetiracetam 0.079 -0.295 0.001 
4+ Seizures
b 0.053 -0.248 0.008 
Retired 0.041 0.221 0.017 
0 Seizures
b 0.039 0.217 0.020 
Depression 0.038 -0.215 0.021 
Neoplasm 0.033 -0.204 0.029 
Employed 0.022 0.169 0.032 
Current Pregablin 0.030 -0.195 0.036 
Epidermoid Tumour 0.027 -0.188 0.044 
Note: Table organised by magnitude of  Beta 
 a
p < 0.001 
b
Prior 6 Months 
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On the basis of the results from the Univariate regression analysis and Pearson correlation 
tables, independent variables were chosen for input into the multiple regression analysis. 
The variables were arranged into four blocks on the basis of a theoretical hierarchy. The 
chosen variables are shown in tables 47 and 48. The independent variables within each 
regression are unique to each group, but not the dependent variables.  
Table 47: Independent Variables for Regression - Meningioma Groups 
 
 
 
 
 
 
 
 
 
 
Table 48: Independent Variables for Regression - Epilepsy Groups 
 
 
 
Meningioma without Epilepsy and Meningioma with Epilepsy Groups  
(n = 165) 
Block Independent Variables 
1: Demographics 
Age 
Female
a 
Unemployed
a 
2: Comorbidities 
Number of Comorbidities 
Arthritis
a 
Depression
a 
Diabetes Mellitus
a 
Neoplasm
a 
3: Meningioma 
Number of Meningioma Symptoms 
Motor/Sensory
a 
Cranial Nerve
a 
Recurrence (of meningioma)
a 
4: Epilepsy 
Meningioma with Epilepsy
a 
Any Seizure Prior 6 Months
a 
Current AED Use
a 
a
Binary Variables 
Meningioma with Epilepsy and Epilepsy without Meningioma (n = 120) 
Block Independent Variable 
1: Demographics 
Age 
Unemployed
a 
Female
a 
2: Comorbidities 
Number of Comorbidities 
Depression
a 
Diabetes Mellitus
a 
Neoplasm
a 
Stroke
a 
4: Meningioma  
Cranial Nerve
a 
Cognitive Emotional
a 
3: Epilepsy 
Epilepsy without meningioma
a 
 
 1-3 Seizures prior 6 Months
a 
> 4 Seizures prior 6 months
a 
Levetiracetam
a 
Number of AEDS 
a
Binary Variables 
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Each block was inserted separately into a hierarchical model, so that model 1 would consist 
of block 1, model 2 would consist of block 1 and block 2, model 3 would consist of blocks 1 
to 3 and model 4 would consist of blocks 1 to 4.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
104 
 
6.3.3. Multiple Regression Results: Meningioma with Epilepsy and 
Meningioma without Epilepsy 
6.3.3.1. Regression Overview 
All regression analyses created models that accounted for variance in the four dependent 
variables. The models with the greatest explained variance for each regression analysis and 
the independent variables that significantly contributed to predicting the dependent 
variable are summarised below. For all regression equations, the block 1 was significant in 
explaining variance (F (p = < 0.05) and F change (p = < 0.05).  
 
6.3.3.2. SF-36: Physical Component Summary 
For PCS, model 3 accounted for 32.9% of the variance in PCS (adjusted R2 = 0.329, F (12,149) 
= 7.589, p < 0.001). The addition of blocks 2 (R2 change = 0.09, p = 0.003) and 3 (R2 change 
0.10, p < 0.001) were significant. The insertion of block 4 into the model did not explain any 
further variance in PCS (R2 change = 0.003, p =0.866). It reduced the adjusted R2 value 
(adjusted R2 = 0.319, F (15,146) = 6.027, p < 0.001).  
Numerous variables significantly and negatively predicted PCS in model 3. They are as 
follows: increasing age (β = -0.203, p = 0.004), unemployment (β = -0.289, p < 0.001), 
arthritis (β = -0.142, p = 0.036), diabetes mellitus (β = -0.147, p = 0.029), the presence of a 
neoplasm (β = -0.172, p = 0.010), increasing number of meningioma symptoms (β = -0.231, p 
= 0.003) and meningioma recurrence (β = -0.141, p = 0.044). 
The full regression model is shown in Table 49. 
 
 
 
105 
 
Table 49: Hierarchical Regression model SF-36 PCS Meningioma with Epilepsy and Meningioma without Epilepsy 
  Model 1 Model 2 Model 3 Model 4 
  R
2
 R
2 
Change R
2
 R
2 
Change R
2
 R
2 
Change R
2
 R
2 
Change 
  0.175*** 0.191*** 0.241*** 0.088* 0.329*** 0.101*** .319*** .003 
              
Block Variables B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta 
1 
(Constant) 64.507 4.684 
 
65.217 4.592 
 
67.835 4.419 
 
68.106 4.558 
 
Age -0.237 0.070 -0.248** -0.191 0.069 -0.200* -0.194 0.066 -0.203** -0.193 0.067 -0.202** 
Female -1.578 2.031 -0.056 -1.766 1.972 -0.062 -1.883 1.854 -0.066 -2.011 1.907 -0.071 
Unemployed -12.725 2.268 -0.412** -11.810 2.269 -0.382*** -8.917 2.237 -0.289*** -8.845 2.286 -0.286*** 
2 
# Comorbidities 
   
-0.774 0.437 -0.123 -0.602 0.426 -0.096 -0.558 0.437 -0.089 
Arthritis 
   
-4.594 2.564 -0.126 -5.151 2.436 -0.142* -5.145 2.468 -0.141* 
Depression 
   
-4.005 2.764 -0.104 -2.403 2.641 -0.062 -2.342 2.669 -0.061 
Diabetes Mellitis 
   
-5.528 2.980 -0.130 -6.247 2.834 -0.147* -5.834 2.934 -0.137* 
Neoplasm 
   
-5.000 1.932 -0.181* -4.759 1.829 -0.172* -4.735 1.854 -0.171* 
3 
# Menin. Symptoms 
      
-2.826 0.943 -0.231** -2.888 0.957 -0.236** 
Motor/Sensory 
      
-4.397 2.777 -0.111 -3.952 2.882 -0.100 
Cranial Nerve 
      
-1.616 3.402 -0.035 -1.910 3.466 -0.041 
Recurrence 
      
-5.772 2.838 -0.141 -5.583 2.876 -0.136 
4 
 
Meningioma with Epilepsy 
         
-1.886 2.243 -0.080 
Any Seizure Prior 6 Months 
         
-0.452 4.152 -0.008 
Current AED 
         
1.446 2.780 0.052 
* p <0.05          
**p<0.01          
***p<0.001          
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6.3.3.3. SF-36: Mental Component Summary 
Model two accounted for 25.4% of the variance in MCS (adjusted R2 = 0.254, F(8,153) = 
7.867, p = 0.000). Only the insertion of block 2 was significant (R2 change = 0.055, p = 0.043).  
Independent variables that significantly predicted MCS in model 2 were age (β = 0.214, p = 
0.003), unemployment (β = -0.348, p = 0.000) and depression (β = -0.166, p = 0.021). As a 
whole, model 3 and model 4 did not significantly add to the amount of variance in MCS, but 
the number of meningioma symptoms (β = -0.171, p = 0.035) and the use of AEDs (β = -
0.202, p = 0.048) significantly contributed to MCS in these models. 
The full regression model is shown in Table 50. 
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Table 50: Hierarchical Regression Model SF-36 MCS Meningioma with Epilepsy and Meningioma without Epilepsy 
  Model 1 Model 2 Model 3 Model 4 
  R
2
 R
2 
Change R
2
 R
2 
Change R
2
 R
2 
Change R
2
 R
2 
Change 
  0.222*** 0.237*** 0.254*** 0.055* 0.279*** 0.042 0.279*** 0.042 
              
Block Variables B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta 
1 
(Constant) 35.266 4.679  37.335 4.682  39.871 4.712  41.599 4.793  
Age 0.214 0.070 0.218** 0.210 0.070 0.214** 0.193 0.071 0.194** 0.182 0.071 0.185* 
Female 2.231 2.029 0.076 2.242 2.011 0.077 2.172 1.977 0.074 1.464 2.006 0.050 
Unemployed -12.220 2.266 -0.385*** -11.060 2.314 -0.348*** -9.559 2.386 -0.301*** -9.091 2.405 -0.286*** 
2 
Number of Comorbidities    -0.604 0.446 -0.094 -0.413 0.454 -0.064 -0.438 0.459 -0.068 
Arthritis    1.345 2.614 0.036 1.345 2.598 0.036 1.686 2.596 0.045 
Depression    -6.570 2.818 -0.166* -6.350 2.816 -0.160* -6.797 2.807 -0.172* 
Diabetes Mellitis    -5.740 3.039 -0.131 -6.024 3.022 -0.137* -6.519 3.086 -0.149 
Neoplasm    1.049 1.970 0.037 1.235 1.951 0.043 0.922 1.950 0.032 
3 
# Menin. Symptoms       -2.144 1.005 -0.171* -2.087 1.007 -0.166* 
Motor/Sensory       -0.552 2.962 -0.014 -1.071 3.031 -0.026 
Cranial Nerve       -3.519 3.628 -0.074 -3.983 3.645 -0.084 
Recurrence       0.719 3.026 0.017 0.133 3.025 0.003 
4 
 
Meningioma with Epilepsy          1.653 2.359 0.068 
Any Seizure Prior 6 Months          1.970 4.366 0.035 
Current AED          -5.827 2.924 -0.202* 
* p <0.05          
**p<0.01          
***p<0.001          
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6.3.3.4. FACT-BR 
Model 4 accounted for 40.6% of variance on the FACT-BR Total scores (adjusted R2 = 0.406, 
F(15,145) = 8.296, p = 0.000). The addition of each block was significant: block 2 (R2 change 
= 0.063, p = 0.021), block 3 (R2 change = 0.101, p = 0.000) and block 4 (R2 change = 0.064, p = 
0.001). 
In model four, the β scores for independent variables that significantly predicted FACT-BR 
Total were as follows: unemployment (β = -0.312, p = 0.000), depression (β = -0.152, p = 
0.019), diabetes mellitus (β = -0.147, p = 0.024) number of meningioma symptoms (β = -
0.234, p = 0.001) and current AED  (β = -0.218,  p = 0.020). 
The full regression model is shown in Table 51.
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Table 51: Hierarchical Regression Model FACT-BR Meningioma with Epilepsy and Meningioma without Epilepsy 
  Model 1 Model 2 Model 3 Model 4 
  R
2
 R
2 
Change R
2
 R
2 
Change R
2
 R
2 
Change R
2
 R
2 
Change 
  0.219*** 0.233*** 0.260*** 0.063* 0.349*** 0.101*** 0.406*** 0.064** 
              
Block Variables B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta 
1 
(Constant) 0.061 0.198 0.022 141.876 13.203   150.287 12.748   156.192 12.440   
Age 8.008 5.679 0.099 0.095 0.198 0.034 0.092 0.191 0.033 0.097 0.183 0.035 
Female -43.585 6.621 -0.470 7.983 5.595 0.098 7.642 5.249 0.094 4.748 5.111 0.058 
Unemployed 0.061 0.198 0.022*** -40.298 6.697 -0.435*** -33.244 6.576 -0.359*** -28.881 6.381 -0.312*** 
2 
Number of Comorbidities    -1.619 1.302 -0.086 -1.475 1.250 -0.079 -1.745 1.215 -0.093 
Arthritis    -1.082 7.579 -0.010 -2.872 7.204 -0.026 -1.019 6.917 -0.009 
Depression    -19.796 7.860 -0.177* -15.719 7.500 -0.141* -16.983 7.185 -0.152* 
Diabetes Mellitis    -18.956 8.563 -0.154* -20.193 8.117 -0.164* -18.191 7.965 -0.147* 
Neoplasm    -3.582 5.554 -0.045 -2.823 5.244 -0.035 -4.955 5.040 -0.062 
3 
# Menin. Symptoms       -8.981 2.739 -0.243** -8.636 2.638 -0.234** 
Motor/Sensory       -13.707 7.712 -0.123 -15.498 7.595 -0.139* 
Cranial Nerve       -7.717 9.958 -0.055 -11.740 9.601 -0.083 
Recurrence       -7.303 8.178 -0.061 -9.000 7.854 -0.076 
4 
 
Meningioma with Epilepsy          1.686 6.080 0.025 
Any Seizure Prior 6 Months          -16.623 11.333 -0.105 
Current AED          -17.705 7.501 -0.218* 
* p <0.05          
**p<0.01          
***p<0.001          
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6.3.3.5. AEP 
Model 4 accounted for 31.2% of the variance on AEP scores (adjusted R2 = 0.312, F(5,149) = 
5.954, p = 0.000). The addition of block 2 did not significantly explain more variance on AEP 
(R2 change = 0.036, p = 0.218). The addition of blocks 3 and four were significant (R2 change 
= 0.074, p = 0.004 and R2 change = 0.078, p = 0.001). 
The independent variables that significantly predicted AEP scores in model four were as 
follows: unemployment (β = 0.246, p = 0.001),  diabetes mellitus (β = 0.147, p = 0.034), 
recurrence of meningioma (β = 0.160, p = 0.023),  any seizure in prior 6 months (β = 0.187, p 
= 0.014) and current AED (β = 0.220, p = 0.027). 
The full model is shown in Table 52.
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Table 52: Hierarchical Regression Model AEP Meningioma with Epilepsy and Meningioma without Epilepsy 
  Model 1 Model 2 Model 3 Model 4 
  R
2
 R
2 
Change R
2
 R
2 
Change R
2
 R
2 
Change R
2
 R
2 
Change 
  0.173*** 0.188*** 0.183*** 0.036 0.242*** 0.074** 0.312*** 0.078*** 
              
Block Variables B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta 
1 
(Constant) 38.755 5.273   38.273 5.361   35.566 5.289   34.305 5.149   
Age -0.067 0.079 -0.062 -0.066 0.080 -0.061 -0.056 0.079 -0.052 -0.065 0.076 -0.060 
Female -0.435 2.263 -0.014 -0.212 2.275 -0.007 -0.128 2.192 -0.004 0.640 2.125 0.020 
Unemployed 14.589 2.559 0.416*** 13.494 2.639 0.384*** 10.369 2.675 0.295*** 8.643 2.584 0.246*** 
2 
Number of Comorbidities    -0.145 0.512 -0.020 -0.346 0.510 -0.048 -0.111 0.495 -0.016 
Arthritis    -2.261 2.997 -0.055 -2.041 2.920 -0.049 -3.261 2.797 -0.079 
Depression    4.639 3.130 0.109 3.436 3.058 0.081 3.931 2.923 0.092 
Diabetes Mellitus    7.433 3.484 0.153* 8.150 3.394 0.168* 7.135 3.326 0.147* 
Neoplasm    -0.371 2.259 -0.012 -0.397 2.191 -0.013 0.602 2.101 0.019 
3 
# Menin. Symptoms       2.279 1.126 0.164* 1.925 1.081 0.139 
Motor/Sensory       3.535 3.223 0.081 5.234 3.165 0.120 
Cranial Nerve       4.650 4.080 0.088 6.310 3.929 0.120 
Recurrence       6.831 3.399 0.146* 7.476 3.257 0.160* 
4 
 
Meningioma with Epilepsy          -2.777 2.537 -0.104 
Any Seizure Prior 6 Months          11.654 4.701 0.187* 
Current AED          6.932 3.108 0.220* 
* p <0.05          
**p<0.01          
***p<0.001          
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6.3.4. Multiple Regression Results: Meningioma with Epilepsy and 
Epilepsy without Meningioma 
 
6.3.4.1. Regression Overview 
Each hierarchical regression analyses produced a model that significantly accounted for a 
proportion of variance in the dependent variables. A summary of the main findings is 
included below. For all regression equations, block 1 was significant in explaining variance (F 
and F change p = < 0.05). 
 
6.3.4.2. SF-36: Physical Component Summary 
Model 2 significantly accounted for 33.2% of the variance in PCS (adjusted R2 = 0.332, F 
(8,077) = 7.0, p = 0.000). The addition of block 3 (R2 change = 0.025, p = 0.123) and block 4 
(R2 change = 0.023, p = 0.556) were not statistically significant.  
Two variables significantly and negatively predicted a lower PCS score in model 2. These 
were unemployment (β = -0.415, p < 0.001) and the number of comorbidities (β = -0.357, p < 
0.001). These variables remained significant in the other models. Cognitive/emotional 
symptoms due to the meningioma became a significant predictor of reduced PCS when the 
epilepsy block was added (β = -0.172, p = 0.043). No other variables were significant.  
The full model is presented in Table 53.
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Table 53: Hierarchical Regression model SF-36 PCS Meningioma with Epilepsy and Epilepsy without Meningioma 
 
  Model 1 Model 2 Model 3 Model 4 
  R
2
 R
2 
Change R
2
 R
2 
Change R
2
 R
2 
Change R
2
 R
2 
Change 
  0.229*** 0.250*** 0.332*** 0.129** 0.346*** 0.025 0.359*** 0.023 
              
Block Variables B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta 
1 
(Constant) 67.110 5.216  61.249 5.074  60.411 5.043  60.285 5.409  
Age -0.309 0.079 -0.333*** -0.132 0.085 -0.142 -0.109 0.085 -0.118 -0.126 0.087 -0.136 
Female -0.535 2.246 -0.020 0.508 2.117 0.019 0.387 2.098 0.014 0.861 2.152 0.032 
Unemployed -13.178 2.450 -0.459*** -11.935 2.355 -0.415*** -11.747 2.369 -0.409*** -11.075 2.610 -0.386*** 
2 
# Comorbidities    -2.243 0.618 -0.357*** -2.307 0.613 -0.368*** -2.083 0.652 -0.332** 
Depression    -1.604 2.769 -0.047 -1.734 2.741 -0.051 -1.550 2.787 -0.045 
Diabetes Mellitus    -5.750 3.459 -0.134 -3.443 3.679 -0.080 -2.071 3.916 -0.048 
Neoplasm    0.652 3.350 0.017 1.817 3.382 0.048 1.760 3.594 0.047 
Stroke    -0.228 2.911 -0.006 -0.782 2.900 -0.022 -0.769 3.028 -0.021 
3 
Cognitive/Emotional       -7.443 3.864 -0.155 -8.248 4.029 -0.172* 
Cranial Nerve       -8.984 10.146 -0.073 -13.157 10.504 -0.106 
4 
Epilepsy without Meningioma          -0.551 2.128 -0.024 
Levetiracetam          -3.903 2.818 -0.138 
1-3 Seizures Prior 6 Months          -1.960 3.034 -0.061 
4+ Seizures Prior 6 months          -3.409 3.450 -0.097 
# AEDS          2.000 1.762 0.121 
* p <0.05          
**p<0.01           
***p<0.001          
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6.3.4.3. SF-36: Mental Component Summary 
Model 2 accounted for 24.1% of the variance in MCS (adjusted R2 = 0.241, F (8,106) = 5.532, 
p < 0.001).  The addition of block 3 was insignificant (R2 change = 0.009, p = 0.531), as was 
the addition of block 4 (R2 change = 0.056, p = 0.134). 
Numerous variables significantly predicted impairment in MCS scores. These were 
unemployment (β = -0.303, p = 0.001), depression (β = -0.202, p = 0.021), diabetes mellitus 
(β = -0.178, p = 0.042) and stroke (β = -0.236, p = 0.007). MCS scores were significantly and 
positively predicted by increasing age (β = 0.262, p = 0.008).  
The full regression model is included in Table 54. 
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Table 54: Hierarchial Regression SF-36 MCS Meningioma with Epilepsy and Epilepsy without Meningioma 
 
  Model 1 Model 2 Model 3 Model 4 
  R
2
 R
2 
Change R
2
 R
2 
Change R
2
 R
2 
Change R
2
 R
2 
Change 
  0.127*** 0.150*** 0.241*** 0.145** 0.236*** 0.009 0.262*** 0.056 
              
Block Variables B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta 
1 
(Constant) 40.924 5.951  34.644 5.794  35.213 5.841  39.154 6.126  
Age 0.091 0.090 0.092 0.261 0.097 0.262** 0.243 0.098 0.245* 0.233 0.098 0.234* 
Female 0.724 2.563 0.025 1.516 2.418 0.052 1.663 2.430 0.057 1.363 2.437 0.047 
Unemployed -10.990 2.795 -0.357*** -9.324 2.690 -0.303*** -8.920 2.743 -0.290** -7.295 2.956 -0.237* 
2 
# Comorbidities    -0.790 0.706 -0.118 -0.744 0.709 -0.111 -0.862 0.738 -0.128 
Depression    -7.402 3.162 -0.202* -7.374 3.174 -0.202* -7.315 3.157 -0.200* 
Diabetes Mellitus    -8.141 3.950 -0.178* -8.025 4.261 -0.175 -5.986 4.435 -0.131 
Neoplasm    -3.051 3.826 -0.076 -3.832 3.916 -0.095 -3.396 4.071 -0.084 
Stroke    -9.197 3.325 -0.236* -8.788 3.359 -0.226** -7.880 3.429 -0.203* 
3 
Cognitive/Emotional          1.237 4.564 0.024 
Cranial Nerve          -10.839 11.897 -0.082 
4 
Epilepsy without Meningioma          0.282 2.410 0.011 
Levetiracetam          -3.644 3.192 -0.120 
1-3 Seizures Prior 6 Months          1.493 3.436 0.043 
4+ Seizures Prior 6 Months          -0.209 3.907 -0.006 
# AEDS          -2.970 1.996 -0.168 
* p <0.05          
**p<0.01           
***p<0.001          
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6.3.4.4. FACT-BR: General 
Model 4 accounted for 35.8% of the variance on FACT-G (adjusted R2 = 0.358, F (15,103) = 
5.391, p < 0.001). The addition of block’s 2 (R2 change = 0.118, p = 0.003) and 4 (R2 change = 
0.105, p = 0.003) were significant.  
Being unemployed (β = -0.293, p = 0.000), a past history of stroke (β = -0.234, p = 0.005) and 
current use of levetiracetam (β = -0.230, p = 0.017) all significantly and negatively predicted 
FACT-G.  
The full regression model is included below (Table 55).
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Table 55: : Hierarchical Regression FACT-G Meningioma with Epilepsy and Epilepsy without Meningioma 
 
  Model 1 Model 2 Model 3 Model 4 
  R
2
 R
2 
Change R
2
 R
2 
Change R
2
 R
2 
Change R
2
 R
2 
Change 
  0.183*** 0.204*** 0.273*** 0.118** 0.273*** 0.012 0.358 0.105** 
              
Block Variables B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta 
1 
(Constant) 90.402 10.536  79.411 10.387  78.101 10.455  84.215 10.518  
Age -0.138 0.159 -0.074 0.182 0.173 0.098 0.213 0.176 0.115 0.179 0.168 0.097 
Female 0.644 4.503 0.012 1.792 4.298 0.033 1.831 4.302 0.034 1.970 4.115 0.037 
Unemployed -26.521 4.917 -0.465*** -25.059 4.794 -0.440*** -24.622 4.870 -0.432*** -16.706 5.071 -0.293*** 
2 
# Comorbidities    -2.543 1.269 -0.204* -2.615 1.271 -0.210* -2.046 1.258 -0.164 
Depression    -6.793 5.744 -0.099 -7.096 5.747 -0.103 -7.261 5.457 -0.105 
Diabetes Mellitus    -14.536 7.191 -0.168* -11.115 7.685 -0.128 -5.407 7.638 -0.062 
Neoplasm    1.363 6.950 0.018 2.632 7.060 0.035 -0.574 7.008 -0.008 
Stroke    -14.652 5.872 -0.206* -15.363 5.917 -0.216* -16.614 5.794 -0.234** 
3 
Cognitive/Emotional       -9.125 7.579 -0.100 -14.716 7.397 -0.161 
Cranial Nerve       -17.685 21.266 -0.071 -33.351 20.584 -0.133 
4 
Epilepsy without Meningioma          4.750 4.120 0.104 
Levetiracetam          -12.894 5.338 -0.230* 
1-3 Seizures Prior 6 Months          -11.316 5.870 -0.177 
4+ Seizures Prior 6 Months          -5.357 6.722 -0.075 
# AEDS          -4.136 3.415 -0.124 
* p <0.05          
**p<0.01           
***p<0.001          
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6.3.4.5. AEP 
Model 4 accounted for 31.9% of the variance on AEP score (adjusted R2 = 0.319, F (15,103) = 
4.691 p < 0.001). The addition of block 2 (R2 change = 0.128, p = 0.003) and block 4 (R2 
change = 0.124, p = 0.001) were significant. The addition of block 3 reduced the accounted 
for variance in the model (Table 56).  
Variables that significantly predicted increased AEP scores were increasing number of 
comorbidities (β = 0.295, p = 0.006) and levetiracetam (β = 0.194, p = 0.051). 
Unemployment was significant in all models, but only marginally significant in model 4 (β = 
0.182, p = 0.051). 
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Table 56: Hierarchical Regression AEP Meningioma with Epilepsy and Epilepsy without Meningioma 
          
  Model 1 Model 2 Model 3 Model 4 
  R
2
 R
2 
Change R
2
 R
2 
Change R
2
 R
2 
Change R
2
 R
2 
Change 
  0.122*** 0.144*** 0.220*** 0.128** 0.216*** 0.009 0.319*** 0.124*** 
              
Block Variables B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta B 
Std. 
Error 
Beta 
1 
(Constant) 35.064 5.977   42.189 5.896   42.607 5.950   37.981 5.986   
Age 0.039 0.090 0.038 -0.163 0.098 -0.161 -0.171 0.100 -0.169 -0.150 0.095 -0.148 
Female 0.463 2.530 0.016 -0.594 2.413 -0.020 -0.651 2.422 -0.022 -0.574 2.297 -0.020 
Unemployed 11.941 2.771 .386*** 10.511 2.699 0.340*** 10.139 2.749 0.328*** 5.589 2.832 0.181 
2 
# Comorbidities    2.141 0.709 0.318** 2.162 0.713 0.321** 1.948 0.699 0.290** 
Depression    4.707 3.220 0.126 4.829 3.231 0.129 4.846 3.043 0.130 
Diabetes Mellitus    7.551 4.028 0.161 5.750 4.319 0.123 2.445 4.255 0.052 
Neoplasm    -2.012 3.894 -0.049 -2.391 3.969 -0.058 -0.731 3.903 -0.018 
Stroke    1.845 3.290 0.048 2.043 3.323 0.053 2.427 3.230 0.063 
3 
Cognitive/Emotional       3.188 4.265 0.064 6.551 4.124 0.132 
Cranial Nerve       11.635 11.971 0.086 20.008 11.488 0.147 
4 
Epilepsy without Meningioma          -2.762 2.305 -0.111 
Levetiracetam          6.293 2.979 0.207* 
1-3 Seizures Prior 6 Months          5.555 3.274 0.161 
4+ Seizures Prior 6 Months          2.665 3.752 0.069 
# AEDS          3.537 1.908 0.195 
* p <0.05          
**p<0.01           
***p<0.001          
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6.3.5. Post Hoc Analysis: AED Subgroup 
In the univariate and multivariate analysis of QoL in the meningioma groups, AEDs 
consistently predicted impaired QoL scores except for the physical summary score of the SF-
36. This raised the question, should meningioma patients receiving AEDs be treated as a 
separate group with specific QoL issues? 
Independent samples t-tests were used to compare scores between AED treated and non 
AED treated meningioma patients. All tests, except for PCS, suggested that QoL was 
significantly more impaired in AED treated populations. The differences in MCS and FACT-BR 
are clinically meaningful (Table 57).  
These results should be interpreted with caution however as post hoc analyses inflate the 
risk of type one error.  
 
Table 57: Post Hoc QoL Comparisons by AED use in the Meningioma Groups 
 
No AED AED 
 
 Mean Std. 
Deviation 
Mean Std. 
Deviation 
Difference In 
Mean 
PCS 46.88 11.17 46.94 11.45 +0.06 
MCS 49.11 10.98 44.19 12.98 -4.92* 
TOTAL 145.5 29.19 123.71 39.36 -21.79*** 
AEP 36.03 10.57 42.06 14.72 -6.03** 
*p < 0.05 
** p < 0.01 
***p < 0.001  
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Chapter 7: Discussion 
7.1. Introduction  
Quality of life (QoL) is increasingly being recognised as an important outcome measure that 
influences clinical decisions and policy making265,266. This is especially true for benign 
meningioma, as life expectancy is not impaired in the majority of these cases and disease 
burden can be high80.  
The relationships between meningioma and QoL, and between epilepsy and QoL, are well 
understood and there is a substantial literature base for these topics94,188. The relationship 
between meningioma patients with epilepsy and quality of life however, is not well 
understood and there is a lack of literature on this subject245.  
This study aimed to evaluate the impact that epilepsy would have on the quality of life of 
patients with benign meningioma. The QoL scores of meningioma patients with epilepsy 
were compared to the scores of meningioma patients without epilepsy and epilepsy 
patients without meningioma. Factors that were predictive of QoL were also identified.  
The main hypothesis was that meningioma patients with epilepsy would have a worse QoL 
than meningioma patients without epilepsy. The secondary hypothesis was that patients 
with meningioma and epilepsy would also have a worse QoL than patients with epilepsy but 
no meningioma.  
7.2. Sample Population 
In total 229 patients participated in this study: 109 had a meningioma but no epilepsy; 56 
had meningioma and epilepsy; and 64 had epilepsy without a meningioma. The mean age of 
participants was 60 (±12), the majority were female (81%) and many were retired (43%).  
Meningioma patients without epilepsy were most likely to respond to invitation and take 
part in this study (51.7%), followed by meningioma patients with epilepsy (40.3%) and 
epilepsy patients without meningioma (18.4%).   
The characteristics of all meningioma patients (with or without epilepsy) were 
representative of a post-resection meningioma population. Both groups were comparable, 
with exceptions to the significantly increased proportion of patients with tentorial 
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meningiomas and visual complications in the meningioma without epilepsy group. Patients 
with varying lengths of follow up were included in the study.   
Due to the matching process, the demographics of the epilepsy without meningioma group 
are not entirely representative of an epilepsy population.  Furthermore, the severity of 
epilepsy in this group is less than would be expected from patients attending a tertiary 
centre and more closely resembles a sample of patients from general practice267. Despite 
this, epilepsy in the epilepsy without meningioma group is significantly more burdensome 
than epilepsy in meningioma with epilepsy patients, with an increased number of seizures 
and anti-epileptic drugs (AEDs) and an increased proportion of dyscognitive seizures. In both 
groups, patients with seizures were also medicated with at least 1 AED.  
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7.3. Primary Outcome: The impact of epilepsy on the quality 
of life of meningioma. 
 When comparing the mean QoL scores of the meningioma with epilepsy and meningioma 
without epilepsy groups, the meningioma with epilepsy group had consistently reduced QoL 
scores. These differences however, are only statistically significant when measured by the 
FACT-BR. On the SF-36 and the AEP, these differences were not statistically or clinically 
significant. A discussion of the main findings from each QoL measure is included below. 
With exception to bodily pain, all subscale and summary scores of the SF-36 were reduced 
in the meningioma with epilepsy group, particularly in the subscales of general health, social 
functioning and emotional role. This resulted in a particularly reduced mental component 
summary (MCS) score. However, none of these differences in subscale or summary score 
were statistically significant. In addition to this, the differences in summary scores were not 
clinically significant.  
Disease specific QoL measures are more sensitive than general QoL measures at detecting 
differences of QoL within the same populations of patients. Since the SF-36 is a general QoL 
measure, this could have accounted for the statistically and clinically insignificant 
differences observed. It has been highlighted by previous research that scores on the SF-36 
are not particularly sensitive in detecting QoL differences between milder severities of 
epilepsy91. As mentioned earlier, the severity of epilepsy secondary to the meningioma in 
this study was very mild with the vast majority of patients in seizure remission.  
Other studies using the SF-36 have found mean QoL scores to be significantly impaired in 
brain tumour patients with epilepsy. In these studies however, comparisons were made 
with a healthy control group. While in the present study, all meningioma patients regardless 
of epilepsy status had lower SF-36 scores than would be expected in a normal population 
and indeed, the SF-36 scores of meningioma patients with epilepsy were lower again, it is 
not appropriate to attach any significance to this.   
Meningioma patients with epilepsy were impaired in all of the subscale and summated 
scores of the FACT-BR when compared to the meningioma without epilepsy group.  The 
biggest differences were seen in the domains of physical wellbeing, social wellbeing and 
brain tumour related wellbeing. Only the differences in the brain tumour related wellbeing 
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were significant, the other scores narrowly escaped significance. This resulted in a total 
score that was statistically different between groups. 
The brain tumour subscale contains two seizure related questions, namely “I have seizures” 
and “I am worried about seizures”. The possibility of the FACT-BR being over-sensitive to 
epilepsy on account of these two questions was entertained, but since they account for only 
10% of the subscale score, this was felt to be highly unlikely. Furthermore, seizure worry 
and the presence of seizures are reasonable determinants of QoL268.  No studies have used 
the FACT-BR to assess the impact of epilepsy on quality of life and so the epilepsy sensitivity 
of the FACT-BR in other studies cannot be commented upon.  
The brain tumour subscale mostly contains questions related to cognition and mood, which 
can be impaired in patients with epilepsy269. On the SF-36, mental health was almost 
significantly impaired. Both of these findings may imply that cognitive and emotional 
wellbeing is mostly impaired in meningioma patients with epilepsy.  
The AEP is intended to identify adverse drug reactions and despite the use of AEDs in the 
meningioma with epilepsy sample, the AEP also failed to detect a statistically or clinically 
significant difference in total score257. There was no strong evidence of the occurrence of 
adverse drug reactions. Scores above 45 are normally associated with AED toxicity and the 
proportion of patients in this range did not differ significantly between groups270. The mean 
of most individual items of the AEP were lower in the meningioma with epilepsy group but 
the only the difference in “shaky hands” was significant. 
Assuming that AEP scores should be more impaired in the meningioma with epilepsy group, 
the explanation for an insignificant difference on AEP could be the low AED burden in the 
epilepsy with meningioma group. Alternatively, meningioma symptoms could be accounting 
for impaired AEP scores. However, since only the proportion of visual symptoms secondary 
to the meningioma are significant, and AEP scores are worse in the meningioma with 
epilepsy group, this seems unlikely.  
The regression analysis provides a more conclusive explanation for the small difference on 
SF-36 scores. AEDs were consistently found to significantly predict impaired QoL scores both 
in the univariate and multiple regression analysis for all questionnaires except for the 
physical component summary (PCS) of the SF-36. When considered as a group in the 
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multiple regression analysis, epilepsy related variables accounted for significant increases in 
variance for the FACT-BR and the AEP, but individually, only AEDs were consistently 
significant. This suggests that QoL is more impaired in patients that take AEDs.  Since there 
is a substantial proportion of patients in the meningioma with epilepsy group that are not 
taking AEDs, it is likely that the effect of AEDs in this study has been diluted when comparing 
means.  
As a proof of concept and to guide further research, the meningioma with epilepsy and 
meningioma without epilepsy groups were re-categorised by current AED use. In doing this, 
all the total scores except PCS and the majority of subscale scores were significantly 
impaired in the meningioma group receiving AEDs. These differences were statistically and 
clinically significant. However, the dangers of attaching too much importance to a post-hoc 
subgroup analysis is understood and these findings will be interpreted solely as a point of 
interest.  
Multiple regression cannot determine whether AEDs are the causal factor of impaired QoL 
or whether they represent similar, related underlying constructs, such as seizure frequency, 
which is significantly correlated to the use of AEDs in this sample and known to reduce QoL 
in epilepsy patients.   
The regression analysis has also highlighted the importance of demographics, comorbidities 
and the effect of meningioma on QoL. These factors were more influential than the epilepsy 
variables in accounting for variance in QoL scores. This is not surprising as these groups 
represent numerous constructs that are known to impair QoL. Unemployment, diabetes 
mellitus and the number of meningioma symptoms were all consistently predictive of 
impaired QoL in all multiple regression analyses.  
Depression is an important factor that is repeatedly shown to be associated with impaired 
QoL scores188. This is not surprising as the presence of depression can reduce QoL as an 
independent factor and also by enhancing the subjective perception of poor QoL188.  In this 
study, depression was consistently predictive of reduced QoL in all univariate analysis but 
was not found to be predictive in the multiple regression analysis. This indicates that in this 
sample of meningioma patients, depression was complimentary to other factors in reducing 
QoL. In epilepsy and meningioma studies, depression is usually found to be associated with 
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various epilepsy and meningioma related factors, but in the present study only 
unemployment and the number of comorbidities were significantly correlated with 
depression85,188. This is probably because clinical depression was identified from the notes, 
while in other studies, the level of depression in each participant has been considered by 
the use of a scale188. It is assumed that the latter method is more sensitive at detecting 
current mood disequilibrium.   
Few studies have focused on the individual factors that influence QoL in meningioma 
patients. One study found that extent of resection and tumour size was predictive of 
impaired QoL in a multivariate analysis, but the effects of individual meningioma attributed 
symptoms were not.  While this latter point contrasts the findings of the present study, it is 
reasonable to assume that individual meningioma symptoms are not as powerful in 
predicting QoL as the combined effect of such symptoms, which is evident in this study.  
QoL has been tested numerous times between patient groups in this study increasing the 
risk of family-wise type I error. This has implications for the significant FACT-BR result as it 
resulted in the only significant difference in mean QoL score. There are other findings from 
this study that argue against this result being a type I error. Despite not reaching 
significance, the SF-36, AEP and remaining FACT scores consistently demonstrated a trend 
similar to the FACT-BR and the regression analysis showed that epilepsy factors are 
important determinants of QoL. In addition and as discussed previously, there are potential 
reasons for the lack of significance on the SF-36 and AEP.  
7.3.1. Comparisons with other Research 
The findings in this study are supported somewhat by the limited literature surrounding 
meningioma, epilepsy and QoL. A similar study concluded that QoL scores were reduced in a 
meningioma with epilepsy population as a result of AED and their effects on cognition245. 
This study used the SF-36, but the mean scores of their populations were compared to the 
scores of a healthy control group and so no comment can be made as to whether the small 
difference in QoL score due to epilepsy in meningioma in the present study is a common 
finding.  
Another study using the SF-36 but in a glioma population, also concluded that AED use 
impaired cognitive function but increased seizure frequency reduced QoL. This latter point 
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was not supported by the present study or the previous study mentioned. In the glioma 
study, QoL comparisons were made with a healthy control group. 
In epilepsy populations, AEDs are repeatedly shown to impair the QoL of study 
participants188. This finding is also evident in patients with a relatively low epilepsy burden, 
such as in patients with remission but who prefer to remain in receipt of an AED188. 
Increased seizure frequency and severity of seizure is also known to impair QoL in epilepsy, 
but in the present study these variables were not strong enough to be significant.  
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7.4. Secondary Outcome: The Influence of meningioma on 
the quality of life of epilepsy 
When comparing the QoL scores of the epilepsy without meningioma and the meningioma 
with epilepsy group, subscale and summary scores were consistently, but not significantly, 
worse in the epilepsy without meningioma group. On the SF-36, QoL was reduced in the 
epilepsy without meningioma  group for all summary and subscale scores, but only the 
difference in mental health subscale was significant. The differences in summary scores 
were statistically and clinically non-significant.  
A shortened version of the FACT-BR was used to compare quality of life in the meningioma 
with epilepsy and epilepsy without meningioma groups. All subscale and summary scores 
were lower in the epilepsy without meningioma group compared to the meningioma with 
epilepsy group, but none of these differences were statistically significant. Of the four 
subscales, emotional wellbeing had the biggest difference in score.   
The total AEP scores in the epilepsy without meningioma  group were larger than the total 
scores observed in the meningioma with epilepsy group and similarly to the above, these 
differences were not statistically or clinically significant. When interpreting the individual 
item scores, the majority of item means had higher scores in the epilepsy without 
meningioma group, but there was no statistically significant differences in individual item 
score.  
These findings suggest that patients with meningioma and epilepsy have QoL that is 
equivalent patients with epilepsy but no meningioma. This is despite the severity of epilepsy 
being mild in the epilepsy without meningioma group. If QoL was more impaired in the 
meningioma with epilepsy group, this should have been reflected on the FACT-BR scores. 
Instead this measure also demonstrated that QoL is slightly impaired in the epilepsy without 
meningioma group.  
Both groups differ significantly in terms of epilepsy severity and it may be hypothesised that 
differences in QoL should have significantly impaired QoL in the control group. One 
explanation for this not being shown, could be a lack of sensitivity to milder differences in 
epilepsy severity, particularly on the SF-36 and FACT-BR, both of which are not epilepsy 
specific measures. This explanation is supported by another study using the SF-36 in an 
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epilepsy population. It was found that when comparing patients with and without seizures, 
patients that experienced at least one seizure a month had significantly impaired scores271. 
In the present study, less than 20% of patients in the epilepsy without meningioma group 
experienced 6 or more seizures in 6 months.  
On the AEP, seizure frequency alone cannot explain the insignificant findings. Instead the 
mild severity of epilepsy in the control group and an overall lack of adverse drug reactions 
could have explained this. 
The effect of the meningioma could be reducing the difference in QoL. In other words, 
assuming that epilepsy severity is important in determining QoL differences in these groups, 
the difference in QoL due to epilepsy severity in the epilepsy without meningioma  group 
could be reduced by the effect of meningioma in the meningioma with epilepsy group.  
The findings from the regression analysis help to interpret the above findings. Increased 
seizure frequency, increased number of AEDs and the use of levetiracetam were found to 
significantly predict impaired QoL scores in the univariate analysis for all QoL measures. 
However in the multiple regression analysis only levetiracetam remained significant and this 
was only shown on FACT-G and AEP. The role of levetiracetam in predicting impaired QoL 
could be explained by its association with increased epilepsy severity260. Grouped epilepsy 
variables in a multiple regression analysis significantly add to the amount of accounted 
variance on the FACT-BR and the AEP, but this is not the case for the SF-36 confirming that 
this measure is not particularly sensitive at detecting differences in QoL due to epilepsy.  
When considering meningioma related variables in the QoL of the meningioma with 
epilepsy and epilepsy without meningioma groups, two variables were significant in the 
univariate analysis: cognitive/emotional symptoms in PCS and cranial nerve symptoms on 
FACT-G and AEP. In the univariate analysis, these factors were the least significant identified 
predictors of their respective questionnaire. In the multiple regression analysis, only 
cognitive/emotional symptoms were predictive. Furthermore, this variable only became 
predictive after the epilepsy block of variables were entered into the regression model, 
indicating that the presence of cognitive/emotional symptoms is only significant in the 
context of epilepsy related factors in this model. Furthermore, the addition of the 
meningioma block of variables was insignificant for all models. This regression model could 
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be criticised for only containing two meningioma related variables, but these were the only 
variables that significantly predicted any dependent variable. All other variables were found 
to be poor predictors. Epilepsy related variables were more powerful in predicting the 
dependent variable as individual and grouped independent variables in the multiple 
regression analyses.  
Overall, demographics and comorbidities were more consistent and superior in predicting 
impaired QoL than epilepsy or meningioma variables. Unemployment was consistently a 
predictive factor of impaired Qol in both the univariate and multiple regression analysis. 
Increased numbers of comorbidities, depression, diabetes mellitus and stroke were also 
found to be influential in the multiple regression. Number of comorbidities and 
unemployment have been shown in previous studies to impair QoL188.  
In the multiple regression analysis of the meningioma patients, depression was found to be 
predictive in the univariate but not the multiple regression analysis. In the multiple 
regression analyses of the epilepsy populations in this study, depression has a more 
significant role. This cannot be attributed to epilepsy related variables, such as AED use, as 
the correlation between them is not strong. Depression is significantly correlated with 
unemployment and the number of comorbidities in this sample, a finding similar in the 
meningioma regression analysis.  
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7.5. Conclusion 
The primary hypothesis of this study was that meningioma patients with epilepsy have 
impaired quality of life when compared to meningioma patients without epilepsy. There is 
sufficient evidence to accept this hypothesis. QoL is consistently impaired in all summary 
measures and most subscales, and on the FACT-BR the difference in QoL was statistically 
significant and clinically meaningful. It is important to note however that this impairment in 
QoL is mild, and this is evident in the lack of a statistical or clinically significance difference 
on the SF-36 or the AEP. This mild impairment in QoL may reflect the mild severity of 
epilepsy in meningioma patients.  
There is strong evidence that AEDs are strongly associated with impaired QoL in 
meningioma patients. Furthermore, there is limited evidence that subjective cognitive 
wellbeing is most impaired by epilepsy in meningioma. 
To summarise the main points of the secondary outcome, the QoL of meningioma with 
epilepsy and epilepsy without meningioma patients is roughly equivalent. There is some 
evidence to suggest that epilepsy patients overall have more impaired QoL than do 
meningioma patients with epilepsy. However, in this sample, the influence of other 
underlying patient characterisitcs, such as employment and disease status, were far more 
powerful predictors of impaired QoL. The secondary hypothesis for this research was that 
the QoL of meningioma patients with epilepsy would be worse than the QoL of epilepsy 
patients without meningioma.  This has not been shown in this study and this hypothesis 
can be confidently rejected.  
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7.6. Limitations of the present study 
The main challenge of this research was in successfully identifying and recruiting a sufficient 
number of meningioma patients with epilepsy. In the sample population, meningioma 
patients with epilepsy were a minority subgroup and furthermore these patients were less 
likely than meningioma patients without epilepsy to respond to invitation. Compounding 
this issue further is the relatively small proportion of meningioma patients with epilepsy 
that are medicated with AEDs or experience frequent seizures. Only 7 meningioma patients 
with epilepsy experienced seizures within the previous 6 months in the current study. This 
limited the ability of the regression analysis to predict QoL on the basis of seizure frequency. 
The poor response rate of the epilepsy without meningioma group was a limitation in this 
study with the potential of producing selection bias and reducing the external validity of the 
study.   
Another limitation lies in the use of the AEP as an epilepsy related questionnaire. In this 
study, the AEP was found to be insensitive in detecting a difference in epilepsy severities, 
even when the FACT-BR identified a significant difference. Perhaps a questionnaire more 
specific to the overall effects of epilepsy and QoL such as the QOLIE-31 would have provided 
more meaningful results272.  
The reliance upon paper notes and clinic letters in identifying recent comorbidities and 
patient characteristics is another limitation of this study. There is the potential that 
important QoL determining variables were not represented in the notes as a result of 
focused specialist consultations. It may be expected that this issue is more significant for the 
epilepsy without meningioma group, due to a lesser degree of regular follow up and 
inpatient care, but many patients were referred to clinics by their general practitioner, who 
usually provides an up to date summary of the patient’s current and significant past medical 
history. For all groups this non representation of current medical status is probably equally 
as important and more variance could have been explained in the regression models if the 
most up to date clinical information was obtained.  
The last limitation is the time period in which to conduct the study. Since there was a year 
to complete all research activities the analysis of QoL at numerous time points was not 
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feasible. Furthermore, the evaluation of cognitive dysfunction would have been a valuable 
addition to the study had there been enough time to administer cognitive assessments.   
7.7. Recommendations for Future Research 
Future studies have the opportunity to build upon the strengths and limitations of previous 
studies and the present study so that the quality of life of meningioma patients and 
meningioma patients with epilepsy can be better understood.  
If obtainable, larger samples of meningioma patients with epilepsy will allow for a better 
consideration of the effect of seizures and individual AEDs. This potentially has substantial 
implications for clinical recommendations on drug choice and the aim of AED treatment. 
The direct comparisons of meningioma patients with and without epilepsy were of great 
value in this study, as were the comparisons with an epilepsy without meningioma group, 
and these comparisons should be repeated. However, subgroups of epilepsy severity should 
be created, as QoL is not equivalent across all severities of epilepsy. In this study, patients 
on AEDs were particularly found to have reduced QoL. The addition of a matched healthy 
control group will also provide insight in how QoL differs between meningioma patients 
with epilepsy and the general population.  
Furthermore, the use of a measure more sensitive than the AEP is highly recommended for 
any future projects in this area aiming to stratify by epilepsy severity.  
Since QoL measures rely on a patient’s subjective interpretation of their own quality of life 
the influence of personality on QoL scores needs clarification in epilepsy and meningioma 
patients. Furthermore, the impact of cognitive functioning on QoL and the accuracy of QoL 
reporting also needs clarification.  
In addition to the variables considered in this study, comorbidity severity, marital status, 
race and tumour size should also be included in future studies.   
The use of medical records from tertiary centres is essential and should be supplemented by 
data from the patients themselves and their general practitioner.  
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7.8. What this study adds 
This is the largest focussed analysis of quality of life in epilepsy and meningioma performed 
so far. It is also the first study to have directly compared QoL in meningioma patients with 
and without epilepsy directly.  
The results of this study add to the existing knowledge base that epilepsy impairs QoL in 
meningioma patients. This study also agrees with the evidence that AEDs are a significant 
factor in the reduction of QoL.  
Most importantly, this study has found that the QoL of meningioma patients with epilepsy is 
reduced to a small extent when directly comparing meningioma patients with and without 
epilepsy. This is a novel finding that has not been reported elsewhere and may be a result of 
the mild epilepsy severity in meningioma patients.    
In this study the comparison of QoL between meningioma patients with epilepsy and 
epilepsy patients without meningioma was novel. This comparison has suggested that QoL is 
comparable in these groups.   
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7.9. Concluding remarks and clinical context 
The underlying aim for most clinicians is to maximise the quality of life of their patients. 
Given the comparatively mild severity of epilepsy in meningioma and the significant 
negative effect of AEDs on QoL, AEDs should not be prescribed too readily or aggressively in 
these patients. Even monotherapy in the meningioma patients was enough to reduce QoL 
and there was not much evidence of adverse drug reactions from the AEP. Furthermore, the 
detrimental effect of unemployment and comorbidities was large for all patient groups in 
this study. Careful consideration of these patient circumstances in addition to their primary 
health complaint will help the clinician to identify areas of improvement that will result in a 
meaningful benefit to the lives of their patients.  
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Appendix I 
NICE Guidelines for the Management of Epilepsy: 
 
 
I.I.  NICE guidance for treatment of focal, generalised and absence 
seizures 
I.II.  NICE guidance for treatment of myoclonic and tonic/atonic 
seizures 
 
 
   
I.l. NICE guidance for treatment of focal, generalised and absence seizures106 
  
Treatment of focal seizures in children, young people and adults. 
 
First line treatment: 
 carbamazepine, lamotrigine  
 
Alternative first line treatment: 
 levetiracetam, oxcarbazepine, sodium valproate  
 
Adjunctive treatment (if first line treatment is not effective or tolerated): 
 carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium 
valproate, topiramate. 
 
Action if adjunctive treatment is not effective or tolerated: 
 consider referral to tertiary services (where other AEDs may be tried)  
 
Treatment of generalised tonic clonic seizures in children, young people and adults. 
 
First line treatment:  
 sodium valproate, lamotrigine (if sodium valproate is not suitable) 
 
Alternative first line treatment: 
 carbamazepine, oxcarbazepine 
 
Adjunctive treatment (if first line treatment is not effective or tolerated): 
 clobazam, lamotrigine, levetiracetam, sodium valproate, topiramate 
 
(If the person also has absences or myoclonic seizures, or may have juvenile myoclonic epilepsy do 
not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine or vigabatrin)  
 
Treatment of absence seizures in children, young people and adults. 
 
First line treatment: 
 ethosuximide, sodium valproate (offer first if additional tonic clonicseizures are likely)  
 
Alternative first line treatment: 
 lamotrigine  
 
Adjunctive treatment (if first line treatment is not effective or tolerated): 
 Try a combination of ethosuximide, lamotrigine or sodium valproate.  
 
Action if adjunctive treatment is not effective or tolerated: 
 consider referral to tertiary services (where other AEDs may be tried)  
 
(Cautions: do not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine 
or vigabatrin) 
I.Il.  NICE guidance for treatment of myoclonic and tonic/atonic 
seizures106  
 
 
Treatment of myoclonic seizures in children, young people and adults. 
First line treatment: 
 sodium valproate  
 
Alternative first line treatment: 
  levetiracetam, topiramate  
 
Adjunctive treatment (if first line treatment is not effective or tolerated): 
 levetiracetam, sodium valproate, topiramate  
Action if adjunctive treatment is not effective or tolerated: 
 consider referral to tertiary services (where other AEDs may be tried)  
 
(Do not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine or 
vigabatrin) 
 
Treatment of tonic and atonic seizures in children, young people and adults. 
 
First line treatment: 
 sodium valproate 
 
Adjunctive treatment (if first line treatment is not effective or tolerated): 
 lamotrigine 
 
Action if adjunctive treatment is not effective or tolerated: 
 consider referral to tertiary services (where other AEDs may be tried) 
 
(Cautions: do not offer carbamazepine, gabapentin, oxcarbazepine, pregabalin, tiagabine or 
vigabatrin) 
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II.II.   R+D Project Approval Letter: The Walton Centre  
 
 
 
A Research Ethics Committee established by the Health Research Authority 
 
NRES Committee North West - Cheshire 
 
HRA NRES Centre North West 
Barlow House 
3rd Floor 
4 Minshull Street 
Manchester 
M1 3DZ 
 
Tel: 0161 625 7816 
Fax: 0161 625 7299 
 
12 November 2012 
 
Mr Matthew Tanti (md0u842e@student.liv.ac.uk) 
The Clinical Sciences Centre 
Longmoor Lane 
Liverpool 
L9 7AL 
 
 
Dear Mr Tanti 
 
Study title: The impact of epilepsy on the quality of life of patients 
with benign meningioma 
IRAS project number: 
REC reference: 
113165 
12/NW/0747 
 
Thank you for your letter of 06 November 2012, responding to the Committee’s request for further 
information on the above research and submitting revised documentation including additional 
changes as listed below: 
 
 Supplementary Questions form will only be sent to epileptic patients 
 Supplementary Questions form has removed seizure type descriptions and thus will not ask 
about seizure type 
 Supplementary Questions form has altered its question about seizure frequency for ease of 
use  
 A question eliciting employment status has been added to the bottom of the LEAP 
questionnaire 
 Participant’s details and their research data will be archived for 15 years after study 
completion in accordance with recommendations from the R&D department of the Walton 
Centre 
 General formatting and language improvements to documents 
 
The further information and additional changes as above were considered in correspondence by a 
sub-committee of the REC.  A list of the sub-committee members is attached.   
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation as 
revised, subject to the conditions specified below. 
 
 
 
 
A Research Ethics Committee established by the Health Research Authority 
 
Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
"Conditions of the favourable opinion" below). 
 
Non-NHS sites 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations involved in 
the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.   
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought from 
the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
  
Document    Version    Date    
Covering Letter    01 October 2012  
Investigator CV  Mr Michael 
Jenkinson - 1  
25 September 2012  
Investigator CV  Mr Anthony 
Marson - 1  
25 September 2012  
Investigator CV  Mr Matthew 
Tanti - 1  
19 September 2012  
Other: Cover sheet  5  24 September 2012  
Other: Patients Results Breakdown  3  24 September 2012  
Other: Summary of protocol in non-technical language  6  06 November 2012  
Other: Supplementary questions  10  06 November 2012  
Participant Consent Form  4  25 September 2012  
Participant Information Sheet: Epilepsy without Meningioma  5  05 November 2012  
Participant Information Sheet: Meningioma without Epilepsy   5  05 November 2012  
Participant Information Sheet: Meningioma with Epilepsy  5  05 November 2012  
Protocol  15  05 November 2012  
Questionnaire: Professor Anthony Marson    25 September 2012  
A Research Ethics Committee established by the Health Research Authority 
Questionnaire: FACT-Br    4  16 November 2007  
Questionnaire: Liverpool Adverse Events Profile (LEAP) and 
Employment Questionnaire  
1  01 November 2012  
Questionnaire: SF-36 Your Health and Well-Being    06 November 2012  
REC application  3.4  29 September 2012  
Response to Request for Further Information    06 November 2012  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed guidance 
on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the National Research 
Ethics Service and the application procedure.  If you wish to make your views known please use 
the feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After Review  
 
12/NW/0747 Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project 
 
Yours sincerely 
 
 
Mr Jonathan Deans 
Chair 
 
Email: nrescommittee.northwest-cheshire@nhs.net 
 
Enclosures:  “After ethical review – guidance for researchers”  
 
Copy to: Dr Mike Morris mike.morris@thewaltoncentre.nhs.uk) 
Mr Michael Jenkinson, The Walton Centre NHS Foundation Trust 
jenkinmd@liverpool.ac.uk 
Miss Rebecca McDonald, Research Governance offices 
(Rebecca.mcdonald@thewaltoncentre.nhs.uk) 
 
 
  
A Research Ethics Committee established by the Health Research Authority 
NRES Committee North West - Cheshire 
 
Attendance at Sub-Committee of the REC meeting held by correspondence 
 
  
Committee Members:  
 
Name   Profession   Present    Notes    
Mr Jonathan Deans  Consultant ENT Surgeon  Yes    
Dr Sue Elves  Consultant Clinical 
Psychologist  
Yes    
 
 
 
 
 


  
 
 
 
 
Appendix III 
Postal Invitation Pack: 
 
 
III.I.  Cover Letter 
III.II.   Information Leaflet for Meningioma Patients 
III.III.  Information leaflet for Meningioma Patients with Epilepsy 
III.IV.  Information Leaflet for Epilepsy Patients without 
Meningioma  
III.V.   Consent Form  
 
  
Appendix III.I.  
 
  Lower Lane 
  Fazakerley 
  Liverpool  
L9 7LJ 
   
Meningioma Epilepsy and QoL 
Cover Sheet Version 5 Dated 24/09/2012 
 
The impact of epilepsy on the quality of 
life of patients with benign meningioma  
Cover Sheet Version 5 Dated 24/09/2012 
 
Date:  
  
Dear  
 
We are writing to you today in the hope that you will agree to be part of a study establishing the 
quality of life of meningioma and epilepsy patients. Willing participants will complete a series of 
questionnaires in the comfort of their own home, and will only be inconvenienced for half an hour. 
Participation is completely voluntary and will not affect the treatment you are currently receiving in 
any way.  
 
If you are interested, could I direct your attention to the patient information leaflet inserted as part 
of this postal pack. It is essential that you read all the details on this form. If you decide that you 
would like to take part, all you have to do is fill in the consent form attached in this pack and post it 
via the pre-paid envelope provided. You have three weeks in which to do this.  
 
If you do not want to participate, all you need to do is ignore this letter. You will be contacted at a 
later date by phone. This will be to ensure we have sent these forms to the right address.  
 
If you have any queries, you can contact the research team using the details on page 3 of the patient 
information leaflet.  
 
 
 
Thank you for your time.  
We hope to hear from you soon.  
 
 
 
 
 
 
 
 
 
 
 
Mr Michael Jenkinson   Professor Anthony Marson  Matthew Tanti 
Consultant Neurosurgeon  Professor of Neurology   Postgraduate Researcher 
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The impact of epilepsy on the quality of life 
of patients with benign meningioma 
Patient Information Leaflet; Meningioma without Epilepsy Version 5 Dated 
05/11/2012 
 
Why is this study needed? 
Quality of Life (QoL) is a term that encompasses a person’s wellbeing and happiness. Epilepsy is known to 
impair QoL but for people with meningioma, QoL is less well understood, particularly if they also have 
epilepsy. Understanding QoL is important when deciding between the best treatment options for patients. 
How will the study answer its question? 
QoL is influenced by the physical, mental and emotional health of a person. The best way of ascertaining QoL 
is to take such influences into account and this is effectively done with questionnaires that can be filled out in 
the convenience of one’s home. 
We will be sending participants 3 questionnaires; one which focusses on brain cancer (FACT-BR), another 
focussing on epilepsy and employment (LAEP and Employment) and another focussing on QoL more generally 
(SF-36).We will be sending these questionnaires to three groups of people. You are in the meningioma without 
epilepsy group. The other groups are: 
 Meningioma with epilepsy. 
 Epilepsy without meningioma. 
 
The comparison of questionnaire results between the three groups will help us to understand what factors 
influence quality of life.  
Why have I been asked to take part?  
You have been asked to take part in this study because you are a patient who has previously had surgery for 
meningioma and has not suffered from epilepsy. Many meningioma patients do not suffer from epilepsy and 
their QoL scores are needed for comparisons with the epilepsy groups. Your QoL scores are very important to 
this study. 
What will happen to me during the study? 
If you would like to take part in this study, we ask that you complete and send the attached consent form back 
to the research group within 3 weeks. When the research group has received your consent form, you will then 
be sent the three questionnaires: 
 FACT-BR 
 LAEP and Employment 
 SF-36 
 
In total, the questionnaires will take between 10 and 30 minutes to complete and should be filled out on the 
same day. Participants are only required to complete one round of questionnaires.  
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Epilepsy and Meningioma QoL  
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You will have 3 weeks to return the completed questionnaires from the date you received them. You will not 
have to pay for postage as a prepaid envelope will be provided.  
When the questionnaires have been returned, you will have completed the study and there is nothing more 
you need to do.   
What are the risks or disadvantages of taking part? 
If you take part, your only inconvenience will be in answering our questions and posting completed forms. As 
mentioned before, all postage will be prepaid and the questionnaires will only take around 30 minutes to 
complete.  
There are no major risks associated with taking part in the study. The biggest risk is in the use of your 
identifiable personal information, i.e. your name and address. These details will be held securely and access to 
this information is strictly limited to members of the research team.   
Some questionnaires will ask sensitive questions regarding your work, emotions and relationships with other 
people. There is a slight risk that some people may find these questions upsetting. If this is a problem, you are 
able to withdraw yourself from the study and stop answering questions. This is not anticipated to be a major 
problem for the majority of participants.  
What are the benefits of taking part? 
There is no direct benefit to you as a result of your participation in this study. Indirectly some may learn of the 
influences on QoL, and some may be pleased in knowing that their participation may help doctors and future 
patients. 
What if there is a problem? 
It is not anticipated that there will be problems for you if you participate in this study. If there are any 
concerns you can contact the research team directly or consider withdrawing yourself from the study.  
Will my taking part in this study be kept confidential? 
Your confidentiality is a priority in this study. Only the research team will be aware of your participation. 
Questionnaire results will be anonymised, so your name and address is not shown and a patient study number 
will be assigned to your questionnaire. A conversion table with your name, address and study number will be 
secured in a locked cupboard and office. 
Electronic data will be stored on password protected and encrypted computers. This study will act in 
accordance with the data protection act 1998.  
When the study has been fully completed, identifiable information (names and addresses) and study data will 
be archived. This is to allow for future use of the data in scientific articles and conferences and to comply with 
local research policies. 
Do I have to take part, and can I change my mind? 
Your participation in this study is completely voluntary. It is recommended that you participate only if you 
wish to. You can change your mind and withdraw from the study at any point without giving a reason. 
Withdrawal from the study will not affect the care you receive at present or in the future.  
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What will happen to the results of the study? 
We aim to report the findings of this study through conferences and scientific journals. No identifiable 
information will be used when presenting results. 
If you would like an explanation of our findings to be sent to you, please initial the relevant “YES” box on the 
consent form. We will then arrange for a results breakdown sheet to be sent to you.  
Who is doing this research study? 
This study is based at the Education Centre of Aintree University Hospital, which is next door to the Walton 
Centre NHS Foundation Trust for Neurology and Neurosurgery. It will be completed as part of a research 
degree project under the close supervision of senior professionals from the University of Liverpool and the 
Walton Centre.  
Who has reviewed this research study? 
This study has been approved by the North West Greater Manchester Cheshire REC and the Walton Centre 
internal research committee.  
Contact details 
If you would like to gain independent advice about participation in research, you can contact the Walton 
Centre Research and Development department: 
 
 Telephone: 0151 529 5446 
 Email: researchdevelopment@thewaltoncentre.nhs.uk 
 
 
If you would like to speak to the research team, please do not hesitate to contact us via the following: 
 
 Telephone: 0151 529 5468    
 Email: matthew.tanti@thewaltoncentre.nhs.uk 
 Post:  Matthew Tanti 
Department of Neurological Science 
Clinical Sciences Centre for Research and Education 
Longmoor Lane 
Liverpool 
L7 9LJ   
 
 
 
Thanks for your time.  
 
 
 
 
 
 
 
Mr Michael Jenkinson   Professor Anthony Marson  Matthew Tanti 
Consultant Neurosurgeon  Professor of Neurology   Postgraduate Researcher 
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The impact of epilepsy on the quality of life 
of patients with benign meningioma 
Patient Information Leaflet; Meningioma with Epilepsy Version 5 Dated 
05/11/2012 
 
Why is this study needed? 
Quality of Life (QoL) is a term that encompasses a person’s wellbeing and happiness. Epilepsy is known to 
impair QoL but for people with meningioma, QoL is less well understood, particularly if they also have 
epilepsy. Understanding QoL is important when deciding between the best treatment options for patients.  
How will the study answer its question? 
QoL is influenced by the physical, mental and emotional health of a person. The best way of ascertaining QoL 
is to take such influences into account and this is effectively done with questionnaires that can be filled out in 
the convenience of one’s home. 
We will be sending participants 3 questionnaires; one which focusses on brain cancer (FACT-BR), another 
focussing on epilepsy and employment (LAEP and Employment) and another focussing on QoL more generally 
(SF-36). In addition, a set of supplementary questions will be sent to participants to establish how many 
seizures they have and what anti-epileptic medication they use.  
We will be sending these questionnaires to three groups of people. You are in the meningioma with epilepsy 
group. The other groups are: 
 Meningioma without epilepsy. 
 Epilepsy without meningioma. 
 
The comparison of questionnaire results between the three groups will help us to understand what factors 
influence quality of life.  
Why have I been asked to take part?  
You have been asked to take part in this study because you are a patient who has previously had surgery for 
meningioma and has suffered from epilepsy. Meningioma patients that suffer from epilepsy are very 
important to this study.  
What will happen to me during the study? 
If you would like to take part in this study, we ask that you complete and send the attached consent form back 
to the research group within 3 weeks. When the research group has received your consent form, you will then 
be sent the three questionnaires: 
 FACT-BR 
 LAEP and Employment 
 SF-36 
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You will also be sent a set of supplementary epilepsy questions. In total, the questionnaires and 
supplementary questions will take between 10 and 30 minutes to complete and should be filled out on the 
same day. Participants are only required to complete one round of questionnaires.  
You will have 3 weeks to return the completed questionnaires and supplementary question sheet from the 
date you received them. You will not have to pay for postage as a prepaid envelope will be provided.  
When the questionnaires have been returned, you will have completed the study and there is nothing more 
you need to do.   
What are the risks or disadvantages of taking part? 
If you take part, your only inconvenience will be in answering our questions and posting completed forms. As 
mentioned before, all postage will be prepaid and the questionnaires will only take around 30 minutes to 
complete.  
There are no major risks associated with taking part in the study. The biggest risk is in the use of your 
identifiable personal information, i.e. your name and address. These details will be held securely and access to 
this information is strictly limited to members of the research team.   
Some questionnaires will ask sensitive questions regarding your work, emotions and relationships with other 
people. There is a slight risk that some people may find these questions upsetting. If this is a problem, you are 
able to withdraw yourself from the study and stop answering questions. This is not anticipated to be a major 
problem for the majority of participants.  
What are the benefits of taking part? 
There is no direct benefit to you as a result of your participation in this study. Indirectly some may learn of the 
influences on QoL, and some may be pleased in knowing that their participation may help doctors and future 
patients. 
What if there is a problem? 
It is not anticipated that there will be problems for you if you participate in this study. If there are any 
concerns you can contact the research team directly or consider withdrawing yourself from the study.  
Will my taking part in this study be kept confidential? 
Your confidentiality is a priority in this study. Only the research team will be aware of your participation. 
Questionnaire results will be anonymised, so your name and address is not shown and a patient study number 
will be assigned to your questionnaire. A conversion table with your name, address and study number will be 
secured in a locked cupboard and office. 
Electronic data will be stored on password protected and encrypted computers. This study will act in 
accordance with the data protection act 1998.  
When the study has been fully completed, identifiable information (names and addresses) and study data will 
be archived. This is to allow for future use of the data in scientific articles and conferences and to comply with 
local research policies.   
 
Do I have to take part, and can I change my mind? 
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Your participation in this study is completely voluntary. It is recommended that you participate only if you 
wish to. You can change your mind and withdraw from the study at any point without giving a reason. 
Withdrawal from the study will not affect the care you receive at present or in the future.  
What will happen to the results of the study? 
We aim to report the findings of this study through conferences and scientific journals. No identifiable 
information will be used when presenting results. 
If you would like an explanation of our findings to be sent to you, please initial the relevant “YES” box on the 
consent form. We will then arrange for a results breakdown sheet to be sent to you.  
Who is doing this research study? 
This study is based at the Education Centre of Aintree University Hospital, which is next door to the Walton 
Centre NHS Foundation Trust for Neurology and Neurosurgery. It will be completed as part of a research 
degree project under the close supervision of senior professionals from the University of Liverpool and the 
Walton Centre.  
Who has reviewed this research study? 
This study has been approved by the North West Greater Manchester Cheshire REC and the Walton Centre 
internal research committee.  
Contact details 
If you would like to gain independent advice about participation in research, you can contact the Walton 
Centre Research and Development department: 
 
 Telephone: 0151 529 5446 
 Email: researchdevelopment@thewaltoncentre.nhs.uk 
 
If you would like to speak to the research team, please do not hesitate to contact us via the following: 
 
 Telephone: 0151 529 5468   
 Email: matthew.tanti@thewaltoncentre.nhs.uk 
 Post: Matthew Tanti 
Department of Neurological Science 
Clinical Sciences Centre for Research and Education 
Longmoor Lane 
Liverpool 
L7 9LJ   
 
Thanks for your time.  
 
 
 
 
 
Mr Michael Jenkinson   Professor Anthony Marson  Matthew Tanti 
Consultant Neurosurgeon  Professor of Neurology   Postgraduate Researcher 
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The impact of epilepsy on the quality of life 
of patients with benign meningioma 
Patient Information Leaflet; Epilepsy without Meningioma Version 5 Dated 
05/11/2012 
 
Why is this study needed? 
Quality of Life (QoL) is a term that encompasses a person’s wellbeing and happiness. Epilepsy is known to 
impair QoL but for people with meningioma, QoL is less well understood, particularly if they also have 
epilepsy. Understanding QoL is important when deciding between the best treatment options for patients. 
How will the study answer its question? 
QoL is influenced by the physical, mental and emotional health of a person. The best way of ascertaining QoL 
is to take such influences into account and this is effectively done with questionnaires that can be filled out in 
the convenience of one’s home. 
We will be sending you 3 questionnaires; one which focusses on the brain (FACT-BR), another focussing on 
epilepsy and employment (LAEP and Employment) and another focussing on QoL more generally (SF-36). In 
addition, a set of supplementary questions will be sent to participants to establish how many seizures they 
have and what anti-epileptic medication they use.  
We will be sending these questionnaires to three groups of people. You are in the epilepsy without 
meningioma group. The other groups are: 
 Meningioma with epilepsy. 
 Meningioma without epilepsy.  
 
The comparison of questionnaire results between the three groups will help us to understand what factors 
influence quality of life.  
Why have I been asked to take part?  
You have been asked to take part in this study because you are a patient who attends the epilepsy clinic and 
does not suffer from meningioma. Epilepsy patients are needed to provide comparative QoL scores, and so are 
very important to this study. 
What will happen to me during the study? 
If you would like to take part in this study, we ask that you complete and send the attached consent form back 
to the research group within 3 weeks. When the research group has received your consent form, you will then 
be sent the three questionnaires: 
 FACT-BR 
 LAEP and Employment 
 SF-36 
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You will also be sent a set of supplementary epilepsy questions. In total, the questionnaires and 
supplementary questions will take between 10 and 30 minutes to complete and should be filled out on the 
same day. Participants are only required to complete one round of questionnaires.  
You will have 3 weeks to return the completed questionnaires and supplementary question sheet from the 
date you received them. You will not have to pay for postage as a prepaid envelope will be provided.  
When the questionnaires have been returned, you will have completed the study and there is nothing more 
you need to do.   
What are the risks or disadvantages of taking part? 
If you take part, your only inconvenience will be in answering our questions and posting completed forms. As 
mentioned before, all postage will be prepaid and the questionnaires will only take around 30 minutes to 
complete.  
There are no major risks associated with taking part in the study. The biggest risk is in the use of your 
identifiable personal information, i.e. your name and address. These details will be held securely and access to 
this information is strictly limited to members of the research team.   
Some questionnaires will ask sensitive questions regarding your work, emotions and relationships with other 
people. There is a slight risk that some people may find these questions upsetting. If this is a problem, you are 
able to withdraw yourself from the study and stop answering questions. This is not anticipated to be a major 
problem for the majority of participants.  
What are the benefits of taking part? 
There is no direct benefit to you as a result of your participation in this study. Indirectly some may learn of the 
influences on QoL, and some may be pleased in knowing that their participation may help doctors and future 
patients. 
What if there is a problem? 
It is not anticipated that there will be problems for you if you participate in this study. If there are any 
concerns you can contact the research team directly or consider withdrawing yourself from the study.  
Will my taking part in this study be kept confidential? 
Your confidentiality is a priority in this study. Only the research team will be aware of your participation. 
Questionnaire results will be anonymised, so your name and address is not shown and a patient study number 
will be assigned to your questionnaire. A conversion table with your name, address and study number will be 
secured in a locked cupboard and office. 
Electronic data will be stored on password protected and encrypted computers. This study will act in 
accordance with the data protection act 1998.  
When the study has been fully completed, identifiable information (names and addresses) and study data will 
be archived. This is to allow for future use of the data in scientific articles and conferences and to comply with 
local research policies.  
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Do I have to take part, and can I change my mind? 
Your participation in this study is completely voluntary. It is recommended that you participate only if you 
wish to. You can change your mind and withdraw from the study at any point without giving a reason. 
Withdrawal from the study will not affect the care you receive at present or in the future.  
What will happen to the results of the study? 
We aim to report the findings of this study through conferences and scientific journals. No identifiable 
information will be used when presenting results. 
If you would like an explanation of our findings to be sent to you, please initial the relevant “YES” box on the 
consent form. We will then arrange for a results breakdown sheet to be sent to you.  
Who is doing this research study? 
This study is based at the Education Centre of Aintree University Hospital, which is next door to the Walton 
Centre NHS Foundation Trust for Neurology and Neurosurgery. It will be completed as part of a research 
degree project under the close supervision of senior professionals from the University of Liverpool and the 
Walton Centre.  
Who has reviewed this research study? 
This study has been approved by the North West Greater Manchester Cheshire REC and the Walton Centre 
internal research committee.  
Contact details 
If you would like to gain independent advice about participation in research, you can contact the Walton 
Centre Research and Development department: 
 
 Telephone: 0151 529 5446 
 Email: researchdevelopment@thewaltoncentre.nhs.uk 
 
If you would like to speak to the research team, please do not hesitate to contact us via the following: 
 
 Telephone: 0151 529 5468   
 Email: matthew.tanti@thewaltoncentre.nhs.uk 
 Post: Matthew Tanti 
Department of Neurological Science 
Clinical Sciences Centre for Research and Education 
Longmoor Lane 
Liverpool 
L7 9LJ   
 
Thanks for your time.  
 
 
 
 
 
Mr Michael Jenkinson   Professor Anthony Marson  Matthew Tanti 
Consultant Neurosurgeon  Professor of Neurology   Postgraduate Researcher 
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Centre Name:                 The Walton Centre 
Name of Investigator:        Matthew Tanti 
Patient’s Name: 
Patient’s Date of Birth:|__|__|/|__|__|/|__|__|__|__| 
Please initial 
boxes 
1. I confirm I have read and understood the information leaflet (version 5 dated 
(05/11/2012) for the above study, and have had the opportunity to ask questions and 
have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw from 
the study at any time without giving a reason and without my care or legal rights 
being affected. 
 
3. I understand that relevant sections of my medical notes and any data collected 
during the study may be looked at by authorised individuals from the research team, 
Regulatory Authorities, co-sponsors (Walton Centre NHS Foundation Trust and 
University of Liverpool), or from the NHS trust, where it is relevant to my taking part 
in this research. I give permission for these individuals to have access to my records 
for this purpose. 
 
4. I agree to take part in the above study. 
 
5. I would like to be informed of the results of the study (initial one box only). 
YES  
NO  
 
 
 
 
   
 
Name of Participant  Signature  Date (dd-mm-yyyy) 
 
 
Matthew Tanti 
   
 
           
Researcher   Signature  Date (dd-mm-yyyy) 
 
  
 
 
 
 
Appendix IV 
Questionnaires: 
 
 
IV.I.  Sf-36 
IV.II.   Fact-Br (For Fact-G discount “Additional Concerns”) 
IV.III.  AEP with additional employment question 
IV.IV.  Supplementary Questions (Only for patients with epilepsy) 
 
 SF-36v2® Health Survey © 1992, 2002, 2009 Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved. 
SF-36® is a registered trademark of Medical Outcomes Trust.  
(SF-36v2® Health Survey Standard, United Kingdom (English)) 
 
 
Your Health and Well-Being 
 
 
This survey asks for your views about your health.  This information will help 
keep track of how you feel and how well you are able to do your usual activities. 
Thank you for completing this survey! 
 
For each of the following questions, please tick the one box that best describes 
your answer. 
 
1. In general, would you say your health is: 
Excellent Very good Good Fair Poor      
   1    2    3    4    5 
 
 
 
2. Compared to one year ago, how would you rate your health in general 
now? 
Much better 
now than one 
year ago 
Somewhat 
better 
now than one 
year ago 
About the 
same as 
one year ago 
Somewhat 
worse 
now than one 
year ago 
Much worse 
now than one 
year ago 
     
   1    2    3    4    5 
 
 SF-36v2® Health Survey © 1992, 2002, 2009 Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved. 
SF-36® is a registered trademark of Medical Outcomes Trust.  
(SF-36v2® Health Survey Standard, United Kingdom (English)) 
3. The following questions are about activities you might do during a typical 
day.  Does your health now limit you in these activities?  If so, how much?  
 
 
 Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
   
 a Vigorous activities, such as running, lifting  
heavy objects, participating in strenuous sports ......................  1 .............  2 .............  3 
 b Moderate activities, such as moving a table, pushing  
a vacuum cleaner, bowling, or playing golf ............................ 1 .............  2 ............. 3
 c Lifting or carrying groceries ....................................................  1 .............  2 .............  3 
 d Climbing several flights of stairs .............................................  1 .............  2 .............  3 
 e Climbing one flight of stairs ....................................................  1 .............  2 .............  3 
 f Bending, kneeling, or stooping ................................................  1 .............  2 .............  3 
 g Walking more than a mile ........................................................  1 .............  2 .............  3 
 h Walking several hundred yards ...............................................  1 .............  2 .............  3 
 i Walking one hundred yards .....................................................  1 .............  2 .............  3 
 j Bathing or dressing yourself ....................................................  1 .............  2 .............  3 
 SF-36v2® Health Survey © 1992, 2002, 2009 Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved. 
SF-36® is a registered trademark of Medical Outcomes Trust.  
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4. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a 
result of your physical health? 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a Cut down on the amount of  
  time you spent on work or  
  other activities .................................  1 ..............  2 ..............  3 ..............  4 .............  5
 b Accomplished less than you  
  would like ........................................  1 ..............  2 ..............  3 ..............  4 .............  5
 c Were limited in the kind of  
  work or other activities ....................  1 ..............  2 ..............  3 ..............  4 .............  5
 d Had difficulty performing the 
  work or other activities (for  
  example, it took extra effort) ...........  1 ..............  2 ..............  3 ..............  4 .............  5 
 
 
5. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a 
result of any emotional problems (such as feeling depressed or anxious)? 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a Cut down on the amount of  
  time you spent on work or  
  other activities .................................  1 ..............  2 ..............  3 ..............  4 .............  5
 b Accomplished less than you  
  would like ........................................  1 ..............  2 ..............  3 ..............  4 .............  5
 c Did work or other activities 
  less carefully than usual ...................  1 ..............  2 ..............  3 ..............  4 .............  5
 
 
 SF-36v2® Health Survey © 1992, 2002, 2009 Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved. 
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6. During the past 4 weeks, to what extent has your physical health or 
emotional problems interfered with your normal social activities with 
family, friends, neighbours, or groups? 
Not at all Slightly Moderately Quite a bit Extremely      
   1    2  3  4    5 
 
 
 
 
 
7. How much bodily pain have you had during the past 4 weeks? 
None Very mild Mild Moderate Severe Very severe       
   1    2  3  4  5    6 
 
 
 
 
 
8. During the past 4 weeks, how much did pain interfere with your normal 
work (including both work outside the home and housework)? 
Not at all A little bit Moderately Quite a bit Extremely      
   1    2  3  4    5 
 
 
 
 SF-36v2® Health Survey © 1992, 2002, 2009 Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved. 
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9. These questions are about how you feel and how things have been with you 
during the past 4 weeks.  For each question, please give the one answer that 
comes closest to the way you have been feeling.  How much of the time 
during the past 4 weeks… 
 
 
10. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with 
friends, relatives, etc.)? 
All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time      
   1    2  3  4    5 
 
 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a Did you feel full of life? ..................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 b Have you been very nervous? ..........  1 ..............  2 ..............  3 ..............  4 ..............  5 
 c Have you felt so down in the  
dumps that nothing could  
cheer you up? ...................................  1 ..............  2 ..............  3 ..............  4 ..............  5
 d Have you felt calm and   
peaceful? ..........................................  1 ..............  2 ..............  3 ..............  4 ..............  5
 e Did you have a lot of energy? ..........  1 ..............  2 ..............  3 ..............  4 ..............  5 
 f Have you felt downhearted   
and low? ...........................................  1 ..............  2 ..............  3 ..............  4 ..............  5
 g Did you feel worn out? ....................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 h Have you been happy? .....................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 i Did you feel tired? ...........................  1 ..............  2 ..............  3 ..............  4 ..............  5 
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11. How TRUE or FALSE is each of the following statements for you? 
 Definitely 
true 
Mostly 
true 
Don’t 
know 
Mostly 
false 
Definitely
false      
 a I seem to get ill more 
easily than other people ..................  1 ..............  2 .............  3 ..............  4 ..............  5
 b I am as healthy as  
anybody I know ..............................  1 ..............  2 .............  3 ..............  4 ..............  5
 c I expect my health to  
get worse .........................................  1 ..............  2 .............  3 ..............  4 ..............  5 
 d My health is excellent .....................  1 ..............  2 .............  3 ..............  4 ..............  5
 
 
 
 
 
 
 
Thank you for completing these questions! 
FACT-Br (Version 4) 
English (Universal)  16 November 2007 
Copyright 1987, 1997  Page 1 of 3 
 
 
Below is a list of statements that other people with your illness have said are important. Please circle 
or mark one number per line to indicate your response as it applies to the past 7 days. 
 
 
 
 
 
PHYSICAL WELL-BEING 
 
Not 
at all 
A little 
bit 
Some-
what 
Quite
a bit 
Very 
much 
GP1 I have a lack of energy ....................................................... 0 1 2 3 4 
GP2 I have nausea ...................................................................... 0 1 2 3 4 
GP3 Because of my physical condition, I have trouble 
meeting the needs of my family .........................................
 
0 
 
1 
 
2 
 
3 
 
4 
GP4 I have pain .......................................................................... 0 1 2 3 4 
GP5 I am bothered by side effects of treatment ......................... 0 1 2 3 4 
GP6 I feel ill ............................................................................... 0 1 2 3 4 
GP7 I am forced to spend time in bed ........................................ 0 1 2 3 4 
 
 
 
SOCIAL/FAMILY WELL-BEING 
 
Not 
at all 
A little 
bit 
Some-
what 
Quite
a bit 
Very 
much 
GS1 I feel close to my friends.................................................... 0 1 2 3 4 
GS2 I get emotional support from my family ............................ 0 1 2 3 4 
GS3 I get support from my friends............................................. 0 1 2 3 4 
GS4 My family has accepted my illness .................................... 0 1 2 3 4 
GS5 I am satisfied with family communication about my 
illness..................................................................................
 
0 
 
1 
 
2 
 
3 
 
4 
GS6 I feel close to my partner (or the person who is my main 
support) ..............................................................................
 
0 
 
1 
 
2 
 
3 
 
4 
Q1 Regardless of your current level of sexual activity, please 
answer the following question. If you prefer not to answer it, 
please mark this box           and go to the next section. 
     
GS7 I am satisfied with my sex life ............................................ 0 1 2 3 4 
FACT-Br (Version 4) 
English (Universal)  16 November 2007 
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Please circle or mark one number per line to indicate your response as it applies to the past 7 
days. 
 
 
 
 
EMOTIONAL WELL-BEING Not 
at all 
A little 
bit 
Some-
what 
Quite
a bit 
Very 
much 
GE1 I feel sad .............................................................................. 0 1 2 3 4 
GE2 I am satisfied with how I am coping with my illness.......... 0 1 2 3 4 
GE3 I am losing hope in the fight against my illness.................. 0 1 2 3 4 
GE4 I feel nervous....................................................................... 0 1 2 3 4 
GE5 I worry about dying ............................................................. 0 1 2 3 4 
GE6 I worry that my condition will get worse ............................ 0 1 2 3 4 
 
 
 
 
 
FUNCTIONAL WELL-BEING 
 
Not 
at all 
A little 
bit 
Some-
what 
Quite
a bit 
Very 
much 
GF1 I am able to work (include work at home) .......................... 0 1 2 3 4 
GF2 My work (include work at home) is fulfilling..................... 0 1 2 3 4 
GF3 I am able to enjoy life.......................................................... 0 1 2 3 4 
GF4 I have accepted my illness................................................... 0 1 2 3 4 
GF5 I am sleeping well ............................................................... 0 1 2 3 4 
GF6 I am enjoying the things I usually do for fun ...................... 0 1 2 3 4 
GF7 I am content with the quality of my life right now.............. 0 1 2 3 4 
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Please circle or mark one number per line to indicate your response as it applies to the past 7 
days. 
 
 
ADDITIONAL CONCERNS Not at 
all 
A little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
Br1 I am able to concentrate ...................................................... 0 1 2 3 4 
Br2 I have had seizures (convulsions) ....................................... 0 1 2 3 4 
Br3 I can remember new things ................................................. 0 1 2 3 4 
Br4 I get frustrated that I cannot do things I used to.................. 0 1 2 3 4 
Br5 I am afraid of having a seizure (convulsion)....................... 0 1 2 3 4 
Br6 I have trouble with my eyesight .......................................... 0 1 2 3 4 
Br7 I feel independent ................................................................ 0 1 2 3 4 
NTX6 I have trouble hearing.......................................................... 0 1 2 3 4 
Br8 I am able to find the right word(s) to say what I mean ....... 0 1 2 3 4 
Br9 I have difficulty expressing my thoughts ........................... 0 1 2 3 4 
Br10 I am bothered by the change in my personality .................. 0 1 2 3 4 
Br11 I am able to make decisions and take responsibility .......... 0 1 2 3 4 
Br12 I am bothered by the drop in my contribution to the 
family .................................................................................
 
0 
 
1 
 
2 
 
3 
 
4 
Br13 I am able to put my thoughts together................................. 0 1 2 3 4 
Br14 I need help in caring for myself (bathing, dressing, 
eating, etc.) .........................................................................
 
0 
 
1 
 
2 
 
3 
 
4 
Br15 I am able to put my thoughts into action............................. 0 1 2 3 4 
Br16 I am able to read like I used to ............................................ 0 1 2 3 4 
Br17 I am able to write like I used to........................................... 0 1 2 3 4 
Br18 I am able to drive a vehicle (my car, truck, etc.)................. 0 1 2 3 4 
Br19 I have trouble feeling sensations in my arms, hands, or 
legs ......................................................................................
 
0 
 
1 
 
2 
 
3 
 
4 
Br20 I have weakness in my arms or legs.................................... 0 1 2 3 4 
Br21 I have trouble with coordination ......................................... 0 1 2 3 4 
An10 I get headaches ................................................................... 0 1 2 3 4 
 
 
Appendix IV.III.  
Epilepsy Meningioma and QoL 
LAEP and Employment questionnaire Version 1 Dated 01/11/2012 
 
Liverpool Adverse Events Profile (LAEP) and Employment 
Questionnaire 
 
During the last four weeks, have you had any of the problems listed below? For each item, if it has 
always or often been a problem, ring 4; if it has sometimes been a problem, ring 3; and so on. 
 
Please be sure to answer every item. 
 
 Never a Rarely Sometimes Always or 
 problem a problem a problem often a 
    problem 
Unsteadiness ..................................................... 1 .................... 2 ....................3.................... 4 
Tiredness............................................................ 1 .................... 2 ....................3.................... 4 
Restlessness ...................................................... 1 .................... 2 ....................3.................... 4 
Feelings of aggression ....................................... 1 .................... 2 ....................3.................... 4 
Nervousness and/or agitation ............................ 1 .................... 2 ....................3.................... 4 
Headache ........................................................... 1 .................... 2 ....................3.................... 4 
Hair loss ............................................................. 1 .................... 2 ....................3.................... 4 
Problems with skin, e.g. acne, rash ................... 1 .................... 2 ....................3.................... 4 
Double or blurred vision ..................................... 1 .................... 2 ....................3.................... 4 
Upset stomach ................................................... 1 .................... 2 ....................3.................... 4 
Difficulty in concentrating ................................... 1 .................... 2 ....................3.................... 4 
Trouble with mouth or gums............................... 1 .................... 2 ....................3.................... 4 
Shaky hands ...................................................... 1 .................... 2 ....................3.................... 4 
Weight gain ........................................................ 1 .................... 2 ....................3.................... 4 
Dizziness ............................................................ 1 .................... 2 ....................3.................... 4 
Sleepiness .......................................................... 1 .................... 2 ....................3.................... 4 
Depression ......................................................... 1 .................... 2 ....................3.................... 4 
Memory problems .............................................. 1 .................... 2 ....................3.................... 4 
Disturbed sleep .................................................. 1 .................... 2 ....................3.................... 4 
 
Employment  
Which statement best describes your current employment status? Please ring one answer. 
Employed Full Time A  Unable to Work due to Disability E 
Employed Part Time B  Looking after Family F 
Unemployed, Looking for Work C  Retired G 
Unemployed, not Looking for Work D  Student H 
Appendix IV.IV.  
Epilepsy Meningioma and QoL 
Supplementary Questions Version 10 Dated 06/11/2012 
 
Supplementary Questions 
Version 10 Dated 06/11/2012 
 
 
 
Seizure Frequency 
Over the past 6 months how many epileptic attacks have you had?  
Please tick the appropriate box: 
 
 
 
 
 
 
 
 
Anti-epileptic medication 
What anti-epileptic drugs (AEDs) do you currently take? If you are not prescribed AEDs just insert NA.   
 
Drug Name of Drug Strength (e.g. 200mg) Frequency (e.g. once a day) 
1    
2    
3    
4    
 
Number of Seizures in Past 
6 Months 
Tick  
None   
One    
2-3    
4-5    
6-9    
10+    
  
 
 
Appendix V 
Simple Linear Regression: 
V.I.   Simple Linear Regression: Meningioma without Epilepsy and 
Meningioma with Epilepsy - Demographic and Comorbidity Variables 
V.II.   Simple Linear Regression: Meningioma without Epilepsy and 
Meningioma with Epilepsy - Meningioma Variables 
V.III.   Simple Linear Regression: Meningioma without Epilepsy and 
Meningioma with Epilepsy - Epilepsy Variables 
V.IV.   Simple Linear Regression: Meningioma with Epilepsy and Epilepsy 
without Meningioma - Demographic and Comorbidity Variables 
V.V.  Simple Linear Regression: Meningioma with Epilepsy and Epilepsy 
without Meningioma – Meningioma Variables 
V.VI.   Simple Linear Regression: Meningioma with Epilepsy and Epilepsy 
without Meningioma – Epilepsy Variables 1 of 2 
V.VII.  Simple Linear Regression: Meningioma with Epilepsy and Epilepsy without 
Meningioma – Epilepsy Variables 2 of 2 
V.I. Simple Linear Regression: Meningioma without Epilepsy and Meningioma with Epilepsy - Demographic 
and Comorbidity Variables 
 
 
 
 
 
  
SF-36 PCS SF-36 MCS FACT-BR AEP 
 
Independent Variables 
Adjusted R 
Squared (R2) 
Beta 
(β) 
Significance 
(p) 
Adjusted R 
Squared (R2) 
Beta 
(β) 
Significance 
(p) 
Adjusted R 
Squared (R2) 
Beta 
(β) 
Significance 
(p) 
Adjusted R 
Squared (R2) 
Beta 
(β) 
Significance 
(p) 
D
e
m
o
g
ra
p
h
ic
s 
Age 0.019 -0.157 0.046 0.087 0.304 0.000 0.008 0.119 0.133 0.038 -0.209 0.008 
Female  -0.001 -0.071 0.370 -0.002 0.064 0.415 0.001 0.086 0.275 -0.005 0.031 0.698 
Employed Full Time 0.064 0.265 0.001 0.025 0.177 0.025 0.027 0.182 0.021 0.026 -0.179 0.022 
Employed Part Time 0.014 0.142 0.071 -0.006 0.026 0.739 0.007 0.116 0.142 -0.006 -0.003 0.968 
Employed 0.101 0.327 0.000 0.022 0.169 0.032 0.051 0.239 0.002 0.017 -0.153 0.052 
Unemployed Looking -0.006 -0.015 0.849 -0.006 -0.018 0.821 -0.005 0.028 0.720 -0.006 -0.010 0.895 
Unemployed not looking -0.004 0.050 0.525 -0.002 0.068 0.393 -0.004 0.050 0.526 0.001 -0.083 0.296 
Unemployed due Disability 0.148 -0.392 0.000 0.218 -0.472 0.000 0.284 -0.537 0.000 0.245 0.500 0.000 
Unemployed 0.123 -.359 0.000 .180 -.431 0.000 0.218 -0.472 0.000 0.191 0.443 0.000 
Caring for Family 0.006 0.112 0.155 0.000 -0.082 0.301 -0.006 0.022 0.782 -0.006 -0.018 0.817 
Retired 0.008 -0.119 0.132 0.049 0.234 0.003 0.010 0.127 0.109 0.021 -0.165 0.036 
Student 0.014 0.141 0.074 0.028 -0.186 0.018 -0.001 -0.076 0.339 -0.006 -0.014 0.856 
Blank -0.006 0.008 0.918 -0.006 -0.024 0.758 -0.006 -0.020 0.799 -0.006 -0.007 0.934 
C
o
m
o
r
b
id
it
ie
s 
Arthritis 0.023 -0.170 0.031 -0.004 0.049 0.532 -0.006 0.004 0.956 -0.004 -0.045 0.572 
Asthma -0.006 -0.016 0.841 -0.001 0.070 0.376 -0.003 0.055 0.484 -0.006 0.016 0.836 
Cardio (electric) -0.004 -0.049 0.537 -0.002 0.066 0.403 -0.005 -0.036 0.649 -0.006 0.025 0.750 
Depression 0.031 -0.193 0.014 0.072 -0.279 0.000 0.041 0.217 0.006 0.072 -0.280 0.000 
Diabetes M 0.019 -0.160 0.042 0.008 -0.117 0.138 0.013 0.140 0.076 0.022 -0.168 0.033 
Hypertension 0.025 -0.175 0.026 -0.001 0.073 0.357 -0.003 -0.058 0.466 -0.004 -0.049 0.537 
IHD 0.000 -0.078 0.324 0.001 -0.082 0.300 0.001 0.085 0.281 -0.003 -0.057 0.475 
Migraine -0.006 0.009 0.907 -0.006 -0.010 0.896 -0.006 0.024 0.759 -0.006 -0.023 0.774 
Neoplasm 0.032 -0.195 0.013 -0.001 0.073 0.357 -0.006 0.007 0.926 -0.005 -0.033 0.682 
Neuropathy 0.038 -0.210 0.007 -0.003 -0.055 0.485 -0.003 0.060 0.448 -0.003 -0.060 0.450 
Stroke 0.019 -0.159 0.043 -0.005 -0.037 0.640 -0.006 -0.006 0.935 0.006 -0.109 0.167 
Thyroid 0.013 -0.137 0.081 -0.005 0.032 0.687 -0.004 0.042 0.597 -0.006 -0.012 0.881 
# Comorbidities 0.122 -0.357 0.000 0.003 -0.097 0.221 0.011 0.133 0.092 0.041 -0.217 0.006 
V.II. Simple Linear Regression: Meningioma without Epilepsy and Meningioma with Epilepsy - Meningioma 
Variables 
 
 
 SF-36 PCS SF-36 MCS FACT-BR AEP 
Independent Variables 
Adjusted 
R 
Squared 
(R2) 
Beta 
(β) 
Significance 
(p) 
Adjusted 
R 
Squared 
(R2) 
Beta 
(β) 
Significance 
(p) 
Adjusted 
R 
Squared 
(R2) 
Beta 
(β) 
Significance 
(p) 
Adjusted 
R 
Squared 
(R2) 
Beta 
(β) 
Significance 
(p) 
M
e
n
in
g
io
m
a
 V
a
r
ia
b
le
s 
Years since Surgery -0.006 0.027 0.731 -0.006 0.014 0.857 -0.005 0.033 0.677 -0.003 -0.053 0.501 
Simpsons Grade -0.006 -0.004 0.957 -0.001 0.071 0.372 0.001 0.088 0.271 0.005 -0.104 0.190 
Recurrence 0.043 -0.221 0.005 0.008 -0.117 0.138 0.036 -0.205 0.009 0.055 0.247 0.001 
Radiotherapy 0.023 -0.171 0.030 -0.004 -0.051 0.516 0.011 -0.132 0.096 0.007 0.114 0.147 
Visual -0.006 -0.021 0.794 0.008 -0.117 0.138 0.000 -0.079 0.319 -0.006 0.015 0.847 
Cognitive/Emotional 0.029 -0.186 0.018 0.013 -0.138 0.079 0.017 -0.152 0.054 0.019 0.158 0.044 
Headache -0.002 -0.067 0.394 0.009 -0.122 0.123 0.011 -0.130 0.100 0.023 0.169 0.031 
Motor Sensory 0.040 -0.216 0.006 -0.003 -0.058 0.463 0.038 -0.209 0.008 0.015 0.145 0.065 
Infection 0.015 -0.145 0.066 -0.003 -0.057 0.468 0.011 -0.129 0.102 0.011 0.129 0.101 
Cranial Nerve 0.013 -0.140 0.076 0.051 -0.238 0.002 0.032 -0.196 0.013 0.036 0.204 0.009 
CSF -0.002 -0.068 0.392 0.003 -0.097 0.217 0.009 -0.124 0.118 0.015 0.145 0.065 
Dizzy/Balance/Coordination 0.012 -0.133 0.092 -0.004 -0.043 0.589 0.004 -0.100 0.206 0.008 0.119 0.130 
Cosmetic 0.003 -0.094 0.233 -0.002 -0.068 0.391 -0.005 -0.040 0.615 -0.005 -0.037 0.639 
Neuroendocrine 0.005 -0.105 0.182 0.016 -0.150 0.057 0.004 -0.099 0.211 0.003 0.095 0.227 
Resus 0.013 -0.139 0.077 0.033 -0.196 0.012 0.046 -0.228 0.004 0.008 0.118 0.136 
Scar Pain -0.006 0.016 0.838 -0.006 0.013 0.870 -0.003 0.060 0.450 -0.006 0.003 0.973 
PE -0.002 -0.063 0.427 -0.003 0.061 0.443 -0.006 -0.002 0.977 0.002 -0.089 0.259 
Haemorrhage 0.006 -0.112 0.155 -0.006 -0.022 0.784 0.000 -0.081 0.308 0.014 0.140 0.075 
Tinnitus -0.006 -0.013 0.866 -0.003 0.061 0.443 0.001 -0.085 0.282 0.022 0.167 0.033 
# Complications 0.114 -0.345 0.000 0.094 -0.316 0.000 0.153 -0.398 0.000 0.119 0.353 0.000 
Convexity -0.006 -0.002 0.978 -0.003 0.061 0.440 -0.003 0.057 0.473 -0.006 -0.027 0.735 
Ventricular -0.003 -0.056 0.481 0.006 -0.111 0.160 -0.001 -0.075 0.346 0.004 0.100 0.206 
Parasagital/Parafalcine -0.004 0.051 0.518 0.000 0.078 0.325 -0.002 0.068 0.395 0.007 -0.117 0.139 
SkullBase -0.006 -0.019 0.813 -0.006 -0.014 0.860 -0.005 -0.037 0.646 -0.006 0.008 0.921 
Skullbase postfossa 0.001 -0.086 0.277 0.007 -0.114 0.149 0.000 -0.082 0.304 0.008 0.119 0.130 
skullbase total -0.003 -0.056 0.480 -0.002 -0.064 0.419 -0.002 -0.068 0.391 -0.003 0.061 0.444 
Sphenoid Wing -0.006 0.022 0.784 -0.006 -0.017 0.834 -0.006 -0.015 0.852 -0.005 0.035 0.657 
Tentorial -0.006 -0.009 0.910 -0.001 -0.075 0.341 -0.003 -0.057 0.474 -0.002 0.065 0.408 
Frontal Lobe 0.001 -0.084 0.288 -0.006 0.023 0.770 0.000 -0.078 0.324 -0.003 -0.054 0.497 
Occipital Lobe -0.005 0.036 0.654 0.012 0.134 0.088 0.008 0.119 0.134 0.000 -0.080 0.311 
Parietal Lobe 0.008 0.121 0.126 -0.003 0.055 0.485 0.022 0.169 0.032 0.016 -0.149 0.058 
Temporal Lobe -0.004 0.044 0.578 -0.006 -0.022 0.779 -0.004 -0.044 0.583 -0.006 0.018 0.823 
Lobe Unknown 0.002 -0.088 0.265 0.008 -0.118 0.134 0.005 -0.104 0.189 0.024 0.174 0.027 
 
Significant Results are Highlighted. 
V.III. Simple Linear Regression: Meningioma without Epilepsy and Meningioma with Epilepsy - Epilepsy 
Variables 
 
 
 SF-36 PCS SF-36 MCS FACT-BR AEP 
Independent Variables 
Adjusted 
R 
Squared 
(R2) 
Beta 
(β) 
Significance 
(p) 
Adjusted 
R 
Squared 
(R2) 
Beta 
(β) 
Significance 
(p) 
Adjusted 
R 
Squared 
(R2) 
Beta 
(β) 
Significance 
(p) 
Adjusted 
R 
Squared 
(R2) 
Beta 
(β) 
Significance 
(p) 
E
p
il
e
p
sy
 V
a
r
ia
b
le
s 
Ep with Meng OR Meng -0.001 0.073 0.353 0.001 0.084 0.286 0.038 0.210 0.007 0.012 -0.134 0.090 
Years since Seizure 0.029 -0.216 0.104 0.002 -0.141 0.291 0.008 -0.159 0.233 -0.013 0.068 0.611 
Years on AED 0.024 -0.206 0.135 0.004 -0.150 0.278 0.012 -0.175 0.204 -0.011 0.091 0.513 
Current Carbamazepine -0.002 -0.065 0.408 0.008 -0.118 0.136 0.009 -0.125 0.114 -0.005 0.039 0.618 
Current Gabapentin -0.005 0.036 0.648 0.003 0.095 0.229 -0.003 0.061 0.445 0.007 -0.116 0.141 
Current Lamotrigine -0.004 0.051 0.521 -0.004 -0.048 0.544 0.003 -0.094 0.235 0.011 0.132 0.093 
Current Levetiracetam -0.006 -0.023 0.768 0.013 -0.138 0.081 0.016 -0.149 0.060 0.053 0.242 0.002 
Current Oxcarbazepine 0.010 -0.126 0.109 0.017 -0.152 0.053 0.014 -0.142 0.073 -0.001 0.073 0.357 
Current Phenytoin -0.005 0.033 0.678 0.016 -0.147 0.061 0.036 -0.206 0.009 0.019 0.157 0.046 
Current Sodium Valproate 0.000 0.081 0.307 -0.004 0.050 0.528 -0.003 -0.060 0.448 -0.006 0.024 0.765 
Current Clobazam -0.006 0.008 0.921 0.011 -0.132 0.095 0.013 -0.137 0.082 0.027 0.181 0.021 
First Carbamazepine -0.005 -0.037 0.637 -0.002 -0.064 0.421 0.007 -0.117 0.139 -0.003 0.057 0.470 
First Gabapentin -0.005 0.036 0.648 0.003 0.095 0.229 -0.003 0.061 0.445 0.007 -0.116 0.141 
First Lamotrigine 0.000 0.079 0.315 -0.001 0.074 0.351 0.002 0.091 0.251 0.007 -0.116 0.140 
First Levetiracetam -0.006 0.002 0.982 -0.006 0.001 0.995 -0.005 0.035 0.660 -0.003 0.061 0.442 
First Oxcarbazepine -0.006 0.008 0.921 -0.003 0.054 0.497 -0.006 0.002 0.980 -0.006 -0.002 0.985 
First Phenytoin -0.003 -0.053 0.504 0.002 -0.090 0.252 0.020 -0.160 0.042 0.012 0.133 0.091 
First Sodium Valproate -0.006 0.002 0.984 -0.006 -0.013 0.872 -0.002 -0.067 0.402 -0.005 -0.030 0.702 
First No Drug -0.005 0.033 0.675 -0.002 0.068 0.389 0.023 0.170 0.031 0.004 -0.101 0.200 
# AED -0.006 0.025 0.753 0.022 -0.168 0.032 0.069 -0.274 0.000 0.053 0.242 0.002 
Current AED Use -0.006 0.002 0.980 0.021 -0.164 0.037 0.066 -0.268 0.001 0.039 0.211 0.007 
First Generation -0.005 0.031 0.692 0.014 -0.141 0.074 0.054 -0.246 0.002 0.022 0.167 0.034 
Second/Third Generation -0.006 -0.004 0.965 0.007 -0.115 0.145 0.016 -0.150 0.058 0.029 0.186 0.018 
Seizure 0 0.001 0.085 0.282 0.001 0.088 0.267 0.060 0.257 0.001 0.093 -0.313 0.000 
Seizure 1 -0.006 -0.014 0.860 0.004 0.101 0.202 -0.005 -0.040 0.614 0.010 0.127 0.107 
Seizure 2-3 0.005 -0.105 0.182 0.008 -0.120 0.128 0.051 -0.239 0.002 0.046 0.229 0.003 
Seizure 10+ -0.006 0.008 0.921 0.011 -0.132 0.095 0.013 -0.137 0.082 0.027 0.181 0.021 
1-3 Seizures 0.003 -0.095 0.230 -0.005 -0.040 0.614 0.042 -0.219 0.005 0.063 0.262 0.001 
4+ Seizures -0.006 0.008 0.921 0.011 -0.132 0.095 0.013 -0.137 0.082 0.027 0.181 0.021 
Focal -0.002 -0.065 0.410 -0.001 -0.072 0.365 -0.003 -0.058 0.461 0.004 0.099 0.209 
Dyscognitive -0.006 -0.027 0.734 -0.006 -0.023 0.770 -0.006 -0.006 0.942 -0.006 -0.027 0.734 
Bilateral -0.005 0.041 0.607 -0.006 0.006 0.939 0.002 -0.089 0.262 -0.003 0.058 0.461 
 
Significant Results are Highlighted 
V.IV. Simple Linear Regression: Meningioma with Epilepsy and Epilepsy without Meningioma - Demographic 
and Comorbidity Variables 
 
 
 
SF-36 PCS SF-36 MCS FACT-G AEP 
Independent Variables 
Adjusted 
R 
Squared 
(R2) 
Beta (β) 
Significance 
(p) 
Adjusted 
R 
Squared 
(R2) 
Beta (β) 
Significance 
(p) 
Adjusted 
R 
Squared 
(R2) 
Beta (β) 
Significance 
(p) 
Adjusted 
R 
Squared 
(R2) 
Beta (β) 
Significance 
(p) 
D
e
m
o
g
ra
p
h
ic
s 
Age 0.041 -0.222 0.017 0.023 0.176 0.059 -0.007 0.043 0.645 -0.004 -0.063 0.493 
Female  -0.005 -0.059 0.530 -0.008 -0.024 0.802 -0.008 -0.023 0.800 -0.006 0.046 0.617 
Employed Full Time 0.134 0.376 0.000 0.011 0.140 0.136 0.066 0.271 0.003 0.071 -0.282 0.002 
Employed Part Time 0.016 0.157 0.094 -0.008 0.035 0.709 0.002 0.100 0.279 -0.008 -0.021 0.824 
Employed 0.182 0.434 0.000 0.013 0.148 0.115 0.085 0.305 0.000 0.063 -0.266 0.003 
Unemployed and looking -0.008 0.035 0.707 -0.001 -0.089 0.344 -0.005 -0.058 0.533 -0.007 0.036 0.697 
Unemployed not looking -0.004 0.068 0.470 0.001 0.101 0.282 0.001 0.098 0.287 0.004 -0.112 0.223 
Unemployed due Disability 0.168 -0.419 0.000 0.146 -0.392 0.000 0.214 -0.470 0.000 0.160 0.408 0.000 
Unemployed 0.137 -0.381 0.000 0.134 -0.376 0.000 0.209 -0.465 0.000 0.135 0.378 0.000 
Caring for Family 0.024 -0.180 0.054 0.021 -0.173 0.064 -0.006 -0.046 0.618 0.004 0.111 0.231 
Retired -0.002 -0.081 0.390 0.041 0.221 0.017 0.004 0.110 0.235 0.004 -0.111 0.228 
Student 0.009 0.131 0.162 0.018 -0.164 0.080 0.009 -0.133 0.148 -0.008 -0.028 0.763 
Blank -0.009 0.014 0.879 0.010 0.137 0.144 -0.005 0.057 0.535 -0.005 0.059 0.526 
C
o
m
o
r
b
id
it
ie
s 
Arthritis 0.058 -0.258 0.005 -0.007 0.044 0.640 0.002 -0.101 0.276 0.010 0.134 0.145 
Asthma -0.003 0.074 0.432 -0.009 0.000 0.997 -0.008 0.027 0.772 -0.002 0.081 0.383 
Cardio (electric) 0.010 -0.138 0.142 -0.007 0.037 0.692 -0.006 0.050 0.587 -0.008 0.027 0.773 
Depression 0.020 -0.168 0.072 0.038 -0.215 0.021 0.015 -0.153 0.096 0.021 0.171 0.063 
Diabetes M 0.036 -0.211 0.023 0.005 -0.119 0.205 0.020 -0.168 0.067 0.027 0.189 0.040 
Hypertension 0.026 -0.187 0.046 -0.008 -0.021 0.820 0.000 -0.094 0.309 -0.001 0.089 0.338 
IHD 0.006 -0.123 0.189 -0.003 -0.075 0.426 0.009 -0.133 0.151 0.010 0.135 0.144 
Migraine -0.007 0.038 0.688 -0.009 0.010 0.919 -0.006 -0.046 0.622 0.000 0.094 0.309 
Neoplasm 0.034 -0.205 0.028 0.033 -0.204 0.029 0.015 -0.153 0.096 0.014 0.149 0.105 
Neuropathy 0.039 -0.217 0.020 -0.009 -0.016 0.861 -0.004 -0.069 0.454 -0.006 0.053 0.566 
Stroke -0.006 -0.049 0.601 0.019 -0.165 0.078 0.019 -0.165 0.073 -0.008 0.029 0.751 
Thyroid -0.005 -0.065 0.492 0.000 0.091 0.332 0.003 0.106 0.252 -0.008 -0.014 0.884 
# Comorbidities 0.186 -0.440 0.000 0.011 -0.140 0.135 0.048 -0.237 0.009 0.070 0.279 0.002 
 
Significant Results Are Highlighted 
 
 
 
V.V. Simple Linear Regression: Meningioma with Epilepsy and Epilepsy without Meningioma – Meningioma 
Variables   
 
 
SF-36 PCS SF-36 MCS FACT-G AEP 
Independent Variables 
Adjusted 
R 
Squared 
(R2) 
Beta (β) 
Significance 
(p) 
Adjusted 
R 
Squared 
(R2) 
Beta 
(β) 
Significance 
(p) 
Adjusted 
R 
Squared 
(R2) 
Beta (β) 
Significance 
(p) 
Adjusted 
R 
Squared 
(R2) 
Beta (β) 
Significance 
(p) 
M
e
n
in
g
io
m
a
 
Years since Surgery 0.012 -0.175 0.200 -0.006 -0.114 0.409 -0.010 -0.092 0.506 -0.011 -0.087 0.529 
Simpsons Grade -0.014 -0.073 0.601 -0.011 0.090 0.520 -0.008 0.103 0.457 -0.012 -0.082 0.556 
Recurrence 0.062 -0.265 0.004 0.003 -0.109 0.246 0.026 -0.185 0.044 0.057 0.254 0.005 
Radiotherapy 0.013 -0.146 0.120 -0.009 0.016 0.868 0.001 -0.095 0.305 0.013 0.146 0.113 
Visual -0.004 0.069 0.461 -0.006 0.057 0.544 -0.007 0.039 0.675 0.020 -0.168 0.068 
Cognitive/Emotional -0.009 -0.010 0.917 -0.007 0.037 0.692 -0.006 0.051 0.580 -0.009 0.002 0.980 
Headache -0.002 0.081 0.391 -0.009 -0.018 0.848 -0.008 -0.026 0.779 -0.007 0.037 0.689 
Motor Sensory 0.032 -0.201 0.031 -0.001 0.086 0.361 -0.003 -0.072 0.435 -0.006 0.054 0.562 
Infection -0.001 -0.090 0.338 -0.009 0.012 0.897 0.004 -0.113 0.221 0.005 0.116 0.210 
Cranial Nerve 0.023 -0.177 0.059 0.019 -0.165 0.078 0.028 -0.191 0.037 0.032 0.199 0.030 
CSF  -0.007 -0.048 0.610 -0.001 0.086 0.363 -0.007 -0.033 0.718 -0.005 0.062 0.504 
Dizzy/Balance/Coordination -0.007 -0.046 0.624 -0.006 0.056 0.555 -0.006 0.055 0.553 -0.006 0.051 0.582 
Cosmetic -0.002 0.085 0.367 -0.009 -0.013 0.891 -0.007 -0.045 0.628 0.007 -0.123 0.183 
Resus 0.013 -0.147 0.118 0.024 -0.180 0.054 0.035 -0.209 0.023 0.001 0.099 0.286 
PE -0.005 -0.062 0.507 0.000 0.094 0.320 -0.007 0.045 0.628 0.006 -0.120 0.194 
Tinnitus -0.009 -0.005 0.954 0.000 0.094 0.320 -0.008 -0.013 0.890 0.018 0.162 0.078 
# Complications 0.008 -0.128 0.174 -0.005 0.058 0.539 0.004 -0.110 0.233 -0.004 0.066 0.474 
Convexity -0.008 -0.032 0.735 0.021 0.173 0.064 -0.006 0.050 0.593 -0.002 -0.078 0.399 
Parasagittal/Parafalcine -0.007 -0.041 0.663 -0.002 0.082 0.384 -0.005 0.058 0.529 -0.008 -0.032 0.731 
Skull base total -0.008 0.028 0.767 -0.006 -0.050 0.596 -0.006 -0.046 0.622 -0.001 0.087 0.347 
Sphenoid Wing -0.004 0.069 0.461 -0.008 0.025 0.794 -0.007 0.040 0.667 -0.006 -0.047 0.615 
Frontal Lobe 0.005 -0.117 0.214 -0.005 0.060 0.527 -0.007 -0.034 0.717 -0.006 0.054 0.558 
Occipital Lobe 0.002 0.102 0.276 -0.003 0.074 0.435 0.005 0.116 0.211 -0.001 -0.086 0.353 
Parietal Lobe 0.005 0.118 0.207 0.017 0.160 0.088 0.004 0.114 0.219 0.054 -0.249 0.006 
Temporal Lobe -0.009 0.010 0.913 -0.006 -0.055 0.563 -0.004 -0.069 0.453 -0.008 0.026 0.780 
Lobe Unknown -0.009 -0.003 0.972 -0.005 0.058 0.535 -0.007 0.042 0.649 -0.009 0.001 0.991 
 
Significant Result Are Highlighted 
V.VI. Simple Linear Regression: Meningioma with Epilepsy and Epilepsy without Meningioma – Epilepsy 
Variables 1 of 2 
 
 
 
SF-36 PCS SF-36 MCS FACT-G AEP 
 
Independent Variables 
Adjusted 
R 
Squared 
(R2) 
Beta (β) 
Significance 
(p) 
Adjusted 
R 
Squared 
(R2) 
Beta (β) 
Significance 
(p) 
Adjusted 
R 
Squared 
(R2) 
Beta (β) 
Significance 
(p) 
Adjusted 
R 
Squared 
(R2) 
Beta (β) 
Significance 
(p) 
E
p
il
e
p
sy
  
Ep with Meng OR Meng -0.009 -0.007 0.940 0.019 -0.165 0.078 -0.003 -0.071 0.441 -0.005 0.056 0.549 
Years since Seizure 0.004 -0.115 0.223 -0.009 -0.008 0.936 -0.008 -0.021 0.823 -0.009 0.002 0.982 
Years on AED -0.003 -0.081 0.405 -0.002 0.086 0.374 -0.008 0.030 0.756 -0.008 -0.030 0.755 
Remitted Epilepsy 0.008 -0.128 0.173 -0.007 -0.047 0.616 -0.007 0.041 0.658 -0.008 -0.028 0.766 
Stroke 0.014 -0.150 0.111 0.019 -0.165 0.078 0.015 -0.154 0.094 -0.005 0.057 0.539 
MTLS 0.000 0.092 0.326 -0.007 -0.043 0.646 -0.007 0.040 0.667 -0.002 0.078 0.402 
Hippocampal Sclerosis 0.006 -0.119 0.203 0.002 -0.104 0.268 0.019 -0.166 0.070 0.023 0.177 0.054 
AVM -0.007 -0.038 0.687 0.004 -0.112 0.234 -0.008 -0.030 0.749 0.001 0.095 0.302 
Cavernoma -0.007 0.044 0.644 0.007 -0.127 0.176 0.013 -0.146 0.112 0.001 0.095 0.302 
Epidermoid Tumour -0.008 0.019 0.840 0.027 -0.188 0.044 0.000 -0.090 0.331 -0.005 0.058 0.529 
Acoustic Neuroma 0.010 -0.136 0.148 -0.004 0.071 0.452 -0.004 0.069 0.453 -0.004 0.066 0.477 
Encephalitis 0.000 -0.095 0.312 0.016 -0.157 0.093 0.006 -0.118 0.201 0.002 0.103 0.265 
Not Stated -0.007 -0.037 0.698 -0.006 0.057 0.543 -0.007 -0.036 0.695 -0.006 -0.054 0.558 
# AED -0.008 -0.025 0.792 0.094 -0.320 0.000 0.101 -0.330 0.000 0.114 0.349 0.000 
Current AED Use -0.001 0.091 0.334 0.082 -0.300 0.001 0.078 -0.293 0.001 0.042 0.225 0.014 
Current Carbamazepine 0.002 0.101 0.281 0.082 -0.045 0.633 -0.004 0.070 0.447 -0.005 -0.061 0.511 
Current Gabapentin 0.002 -0.104 0.267 0.003 0.110 0.240 -0.005 -0.062 0.501 -0.009 -0.006 0.947 
Current Lamotrigine 0.000 0.092 0.328 0.000 -0.093 0.323 -0.008 -0.009 0.924 0.010 0.134 0.146 
Current Levetiracetam 0.020 -0.169 0.071 0.079 -0.295 0.001 0.090 -0.313 0.001 0.094 0.319 0.000 
Current Oxcarbazepine 0.010 -0.136 0.148 0.012 -0.142 0.130 0.012 -0.142 0.123 -0.005 0.058 0.529 
Current Phenytoin -0.005 0.061 0.519 -0.009 0.004 0.963 -0.001 -0.088 0.340 -0.007 0.040 0.666 
Current Sodium Valproate -0.006 0.050 0.594 -0.008 0.026 0.781 -0.003 -0.072 0.435 -0.007 -0.040 0.664 
Current Phenobrbitone -0.007 0.044 0.644 0.005 0.116 0.215 -0.002 0.079 0.393 -0.007 -0.038 0.680 
Current Lacosamide 0.006 -0.119 0.203 0.002 -0.104 0.268 0.019 -0.166 0.070 0.023 0.177 0.054 
Current Zonisamide -0.007 -0.048 0.609 0.020 -0.170 0.070 -0.003 -0.073 0.427 0.015 0.151 0.100 
Current Pregablin 0.020 -0.168 0.072 0.030 -0.195 0.036 0.028 -0.191 0.038 0.013 0.147 0.110 
Current Clobazam -0.008 0.019 0.840 0.006 -0.119 0.204 -0.002 -0.083 0.372 0.023 0.177 0.054 
First Generation 0.010 0.138 0.140 -0.009 -0.011 0.907 -0.005 -0.057 0.538 -0.007 -0.040 0.667 
Second/Third Generation -0.001 -0.091 0.334 0.089 -0.312 0.001 0.074 -0.287 0.002 0.088 0.309 0.001 
 
Significant Results are Highlighted 
 
 
V.VII. Simple Linear Regression: Meningioma with Epilepsy and Epilepsy without Meningioma – Epilepsy 
Variables 2 of 2 
 
 
 
 
 
 
 
 SF-36 PCS SF-36 MCS FACT-G AEP 
Independent Variables 
Adjusted 
R Squared 
(R2) 
Beta (β) 
Significance 
(p) 
Adjusted 
R Squared 
(R2) 
Beta (β) 
Significance 
(p) 
Adjusted 
R Squared 
(R2) 
Beta (β) 
Significance 
(p) 
Adjusted 
R Squared 
(R2) 
Beta (β) 
Significance 
(p) 
E
p
il
e
p
sy
 
Cryptogenic 0.014 0.149 0.111 -0.006 0.050 0.593 0.005 0.118 0.202 0.001 0.100 0.281 
Seizure 1 0.003 -0.106 0.258 -0.008 -0.020 0.830 0.018 -0.162 0.079 0.015 0.151 0.101 
Seizure 2-3 -0.004 -0.066 0.483 -0.007 -0.037 0.691 0.013 -0.147 0.110 0.017 0.160 0.082 
Seizure 4-5 -0.009 -0.011 0.903 0.019 -0.165 0.078 0.008 -0.127 0.170 0.002 0.104 0.262 
Seizure 6-9 0.002 -0.106 0.259 0.015 -0.153 0.102 0.025 -0.182 0.048 0.023 0.178 0.053 
Seizure 10+ 0.022 -0.176 0.061 0.002 -0.106 0.262 0.006 -0.118 0.200 0.016 0.156 0.089 
1-3 Seizures 0.007 -0.124 0.186 -0.007 -0.043 0.645 0.043 -0.227 0.013 0.045 0.230 0.012 
Seizure 0 0.039 0.217 0.020 0.039 0.217 0.020 0.120 0.357 0.000 0.124 -0.363 0.000 
4+ Seizures 0.017 -0.160 0.087 0.053 -0.248 0.008 0.049 -0.239 0.009 0.052 0.244 0.007 
Focal -0.008 0.025 0.791 -0.006 0.054 0.569 0.001 0.098 0.289 -0.008 -0.026 0.781 
Dyscognitive -0.009 0.012 0.903 0.005 -0.117 0.212 -0.008 -0.019 0.841 -0.004 0.066 0.477 
Bilateral -0.003 0.079 0.400 -0.006 0.055 0.557 -0.008 0.021 0.825 -0.007 -0.043 0.644 
First Carbamazepine -0.007 -0.038 0.690 -0.003 -0.078 0.409 -0.005 -0.058 0.533 -0.008 0.010 0.918 
First Gabapentin -0.006 0.052 0.583 0.009 0.132 0.161 -0.006 0.055 0.553 0.014 -0.150 0.104 
First Lamotrigine 0.030 0.195 0.037 -0.009 -0.009 0.927 0.010 0.135 0.144 -0.009 -0.006 0.948 
First Levetiracetam -0.007 -0.042 0.656 0.002 -0.103 0.275 -0.005 -0.059 0.525 -0.004 0.067 0.467 
First Oxcarbazepine -0.008 0.019 0.840 -0.001 0.086 0.361 -0.005 0.055 0.552 -0.008 -0.012 0.896 
First Phenytoin -0.009 -0.009 0.923 0.001 0.101 0.282 -0.009 0.006 0.946 -0.007 -0.036 0.699 
First Sodium Valproate 0.004 -0.114 0.226 0.000 -0.096 0.308 -0.007 -0.042 0.646 -0.004 0.067 0.467 
First No Drug -0.008 0.022 0.814 -0.007 0.039 0.676 -0.006 -0.050 0.586 -0.003 -0.077 0.403 
First Phenobarbitone -0.007 0.044 0.644 0.005 0.116 0.215 -0.002 0.079 0.393 -0.007 -0.038 0.680 
 
Significant Results are Highlighted 
